CN117800904A - 含有磺酰基结构的RORγ抑制剂 - Google Patents
含有磺酰基结构的RORγ抑制剂 Download PDFInfo
- Publication number
- CN117800904A CN117800904A CN202311636222.8A CN202311636222A CN117800904A CN 117800904 A CN117800904 A CN 117800904A CN 202311636222 A CN202311636222 A CN 202311636222A CN 117800904 A CN117800904 A CN 117800904A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- methyl
- optionally
- added
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 157
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- -1 hydroxy, amino Chemical group 0.000 claims description 196
- 229910052736 halogen Inorganic materials 0.000 claims description 44
- 150000002367 halogens Chemical class 0.000 claims description 44
- 238000006467 substitution reaction Methods 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 41
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 41
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 37
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 30
- 125000001424 substituent group Chemical group 0.000 claims description 30
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 27
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 27
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 26
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 23
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 19
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 14
- 125000004076 pyridyl group Chemical group 0.000 claims description 14
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 13
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 12
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 12
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims description 11
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims description 11
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 11
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 125000002883 imidazolyl group Chemical group 0.000 claims description 9
- 125000002971 oxazolyl group Chemical group 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000002541 furyl group Chemical group 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 8
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 8
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- 125000004306 triazinyl group Chemical group 0.000 claims description 8
- 229910052720 vanadium Inorganic materials 0.000 claims description 8
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 7
- 125000000335 thiazolyl group Chemical group 0.000 claims description 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 3
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 24
- 201000010099 disease Diseases 0.000 abstract description 21
- 241000124008 Mammalia Species 0.000 abstract description 6
- 230000001404 mediated effect Effects 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 159
- 230000002829 reductive effect Effects 0.000 description 97
- 239000000203 mixture Substances 0.000 description 95
- 238000006243 chemical reaction Methods 0.000 description 93
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 83
- 239000000243 solution Substances 0.000 description 81
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 79
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 59
- WVDDGKGOMKODPV-UHFFFAOYSA-N hydroxymethyl benzene Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 57
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 57
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 56
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 55
- 239000000047 product Substances 0.000 description 54
- 230000015572 biosynthetic process Effects 0.000 description 53
- 238000003786 synthesis reaction Methods 0.000 description 53
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 52
- 238000005481 NMR spectroscopy Methods 0.000 description 51
- 238000005070 sampling Methods 0.000 description 46
- 239000012074 organic phase Substances 0.000 description 44
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 44
- 239000000706 filtrate Substances 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 36
- 238000001514 detection method Methods 0.000 description 36
- 238000004809 thin layer chromatography Methods 0.000 description 36
- 239000011541 reaction mixture Substances 0.000 description 31
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 30
- 235000019445 benzyl alcohol Nutrition 0.000 description 28
- 239000007858 starting material Substances 0.000 description 25
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
- 238000010898 silica gel chromatography Methods 0.000 description 22
- 238000004128 high performance liquid chromatography Methods 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 20
- 239000012043 crude product Substances 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 238000003756 stirring Methods 0.000 description 18
- 238000002390 rotary evaporation Methods 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- 239000007788 liquid Substances 0.000 description 16
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 14
- 238000004440 column chromatography Methods 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 230000008034 disappearance Effects 0.000 description 13
- 238000001035 drying Methods 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 12
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 12
- 125000005843 halogen group Chemical group 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- 108060001084 Luciferase Proteins 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 238000010828 elution Methods 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 239000005089 Luciferase Substances 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 125000000392 cycloalkenyl group Chemical group 0.000 description 8
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 239000012280 lithium aluminium hydride Substances 0.000 description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 8
- 238000010791 quenching Methods 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 108050003558 Interleukin-17 Proteins 0.000 description 6
- 102000013691 Interleukin-17 Human genes 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- 229930182816 L-glutamine Natural products 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 6
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 6
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 6
- 235000005152 nicotinamide Nutrition 0.000 description 6
- 239000011570 nicotinamide Substances 0.000 description 6
- 229960003966 nicotinamide Drugs 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 6
- 239000012279 sodium borohydride Substances 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 6
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 5
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- SLXFZGMMNCYWJF-JTQLQIEISA-N (2R)-2-amino-2-(4-ethylsulfonylphenyl)ethanol Chemical compound N[C@@H](CO)C1=CC=C(C=C1)S(=O)(=O)CC SLXFZGMMNCYWJF-JTQLQIEISA-N 0.000 description 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 4
- BMGIBWXMJMGHAS-UHFFFAOYSA-N 1-(2-amino-5-ethylphenyl)pentan-3-ol Chemical compound C(CCC1=C(N)C=CC(CC)=C1)(O)CC BMGIBWXMJMGHAS-UHFFFAOYSA-N 0.000 description 4
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 229910052805 deuterium Inorganic materials 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 4
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 4
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- ICHQRFPYVZQXTC-GFCCVEGCSA-N (1S)-3-(2-amino-5-ethylpyridin-3-yl)-1-cyclopropylprop-2-yn-1-ol Chemical compound CCC1=CC(=C(N=C1)N)C#C[C@H](C2CC2)O ICHQRFPYVZQXTC-GFCCVEGCSA-N 0.000 description 3
- OTPVFZSTXFLWNJ-QMMMGPOBSA-N (3s)-1-trimethylsilylpent-1-yn-3-ol Chemical compound CC[C@H](O)C#C[Si](C)(C)C OTPVFZSTXFLWNJ-QMMMGPOBSA-N 0.000 description 3
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 3
- CKDDJLLDFFRJLV-UHFFFAOYSA-N 1-cyclopropyl-3-trimethylsilylprop-2-yn-1-ol Chemical compound C[Si](C)(C)C#CC(O)C1CC1 CKDDJLLDFFRJLV-UHFFFAOYSA-N 0.000 description 3
- OTPVFZSTXFLWNJ-UHFFFAOYSA-N 1-trimethylsilylpent-1-yn-3-ol Chemical compound CCC(O)C#C[Si](C)(C)C OTPVFZSTXFLWNJ-UHFFFAOYSA-N 0.000 description 3
- TUAHLJPPPYCDJR-UHFFFAOYSA-N 1-trimethylsilylpent-1-yn-3-one Chemical compound CCC(=O)C#C[Si](C)(C)C TUAHLJPPPYCDJR-UHFFFAOYSA-N 0.000 description 3
- GJJKOIYVMNOZSD-UHFFFAOYSA-N 3-fluoro-4-formylbenzoic acid Chemical compound OC(=O)C1=CC=C(C=O)C(F)=C1 GJJKOIYVMNOZSD-UHFFFAOYSA-N 0.000 description 3
- FLICZDVBYUMMAS-UHFFFAOYSA-N 4-(2-methylpropanoyl)benzoic acid Chemical compound CC(C)C(=O)C1=CC=C(C(O)=O)C=C1 FLICZDVBYUMMAS-UHFFFAOYSA-N 0.000 description 3
- VNNBKUDCKLANIV-UHFFFAOYSA-N 4-(dibromomethyl)-3-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(C(Br)Br)C(F)=C1 VNNBKUDCKLANIV-UHFFFAOYSA-N 0.000 description 3
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 3
- CDIVITZCXSLLQQ-UHFFFAOYSA-N 4-ethyl-2-iodoaniline Chemical compound CCC1=CC=C(N)C(I)=C1 CDIVITZCXSLLQQ-UHFFFAOYSA-N 0.000 description 3
- KBQZNXRFIQHVOT-UHFFFAOYSA-N 5-ethyl-3-iodopyridin-2-amine Chemical compound CCc1cnc(N)c(I)c1 KBQZNXRFIQHVOT-UHFFFAOYSA-N 0.000 description 3
- CFPYPZFHUWVKSY-UHFFFAOYSA-N C1C(CO1)C2=CC=C(C=C2)NC(=O)C(F)(F)F Chemical compound C1C(CO1)C2=CC=C(C=C2)NC(=O)C(F)(F)F CFPYPZFHUWVKSY-UHFFFAOYSA-N 0.000 description 3
- QZYKSEASODDWRW-UHFFFAOYSA-N CCC1=CC(=C(C=C1)N)C#CC(CC)O Chemical compound CCC1=CC(=C(C=C1)N)C#CC(CC)O QZYKSEASODDWRW-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- KKGLBDBARHKGEC-UHFFFAOYSA-N methyl 4-(1-hydroxy-2-methylpropyl)benzoate Chemical compound COC(=O)C1=CC=C(C(O)C(C)C)C=C1 KKGLBDBARHKGEC-UHFFFAOYSA-N 0.000 description 3
- FDFGUTZYPYEQNI-UHFFFAOYSA-N methyl 4-(2-methylpropanoyl)benzoate Chemical compound COC(=O)C1=CC=C(C(=O)C(C)C)C=C1 FDFGUTZYPYEQNI-UHFFFAOYSA-N 0.000 description 3
- QIMFXCTWULNQSG-UHFFFAOYSA-N methyl 5-[(2,6-diethyl-3,4-dihydro-2H-quinolin-1-yl)sulfonyl]-2-hydroxybenzoate Chemical compound C(C1N(C2=C(C=C(C=C2)CC)CC1)S(=O)(=O)C1=CC(=C(O)C=C1)C(=O)OC)C QIMFXCTWULNQSG-UHFFFAOYSA-N 0.000 description 3
- JCUQSWVHGVRETC-UHFFFAOYSA-N methyl 5-chlorosulfonyl-2-hydroxybenzoate Chemical compound COC(=O)C1=CC(S(Cl)(=O)=O)=CC=C1O JCUQSWVHGVRETC-UHFFFAOYSA-N 0.000 description 3
- LTQPTZCKCBJVET-UHFFFAOYSA-N methyl 6-(dibromomethyl)pyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(C(Br)Br)N=C1 LTQPTZCKCBJVET-UHFFFAOYSA-N 0.000 description 3
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 229910001961 silver nitrate Inorganic materials 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- LGHKHMSCVFCTRZ-UHFFFAOYSA-N tert-butyl 6-hydrazinylpyridine-3-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CC=C(NN)N=C1 LGHKHMSCVFCTRZ-UHFFFAOYSA-N 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- LYMAPHFPNDXZBZ-GFCCVEGCSA-N (1R)-1-cyclopropyl-3-(5-ethyl-2-iodopyridin-3-yl)propan-1-ol Chemical compound CCC1=CC(=C(N=C1)I)CC[C@H](C2CC2)O LYMAPHFPNDXZBZ-GFCCVEGCSA-N 0.000 description 2
- WQVFPSANBQZOIA-GFCCVEGCSA-N (1R)-3-(2-amino-5-ethylpyridin-3-yl)-1-cyclopropylpropan-1-ol Chemical compound CCC1=CC(=C(N=C1)N)CC[C@H](C2CC2)O WQVFPSANBQZOIA-GFCCVEGCSA-N 0.000 description 2
- BMGIBWXMJMGHAS-LBPRGKRZSA-N (3S)-1-(2-amino-5-ethylphenyl)pentan-3-ol Chemical compound CCC1=CC(=C(C=C1)N)CC[C@H](CC)O BMGIBWXMJMGHAS-LBPRGKRZSA-N 0.000 description 2
- LBSKEFWQPNVWTP-RXMQYKEDSA-N (3s)-pent-1-yn-3-ol Chemical compound CC[C@H](O)C#C LBSKEFWQPNVWTP-RXMQYKEDSA-N 0.000 description 2
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- ILQGRJDODBLFCW-UHFFFAOYSA-N 2,2,2-trifluoro-N-[4-(3-fluorooxetan-3-yl)phenyl]acetamide Chemical compound C1C(CO1)(C2=CC=C(C=C2)NC(=O)C(F)(F)F)F ILQGRJDODBLFCW-UHFFFAOYSA-N 0.000 description 2
- IWHOQYROAIQDLF-UHFFFAOYSA-N 2,2,2-trifluoro-N-[4-(3-hydroxyoxetan-3-yl)phenyl]acetamide Chemical compound C1C(CO1)(C2=CC=C(C=C2)NC(=O)C(F)(F)F)O IWHOQYROAIQDLF-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- FPKSWQFAXUXUJX-UHFFFAOYSA-N 4-(oxetan-3-yl)aniline Chemical class C1=CC(N)=CC=C1C1COC1 FPKSWQFAXUXUJX-UHFFFAOYSA-N 0.000 description 2
- HRXZRAXKKNUKRF-UHFFFAOYSA-N 4-ethylaniline Chemical compound CCC1=CC=C(N)C=C1 HRXZRAXKKNUKRF-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- BNMAEFDJMINDKB-UHFFFAOYSA-N CC(C)N(CC1=NC(=CC=C1)C(F)(F)F)C2=C(C=C(C=C2)C#N)F Chemical compound CC(C)N(CC1=NC(=CC=C1)C(F)(F)F)C2=C(C=C(C=C2)C#N)F BNMAEFDJMINDKB-UHFFFAOYSA-N 0.000 description 2
- QGYLSDDZIUWALY-UHFFFAOYSA-N CC(C)N(CC1=NC(=CC=C1)C(F)(F)F)C2=C(C=C(C=C2)C(=O)O)F Chemical compound CC(C)N(CC1=NC(=CC=C1)C(F)(F)F)C2=C(C=C(C=C2)C(=O)O)F QGYLSDDZIUWALY-UHFFFAOYSA-N 0.000 description 2
- LCORAYIEBAKFRT-UHFFFAOYSA-N CCC1=CC(=C(C=C1)NS(=O)(=O)C2=CC(=C(C=C2)O)C(=O)OC)CCC(CC)O Chemical compound CCC1=CC(=C(C=C1)NS(=O)(=O)C2=CC(=C(C=C2)O)C(=O)OC)CCC(CC)O LCORAYIEBAKFRT-UHFFFAOYSA-N 0.000 description 2
- XBDSDCMKHBAUPQ-KOMQPUFPSA-N CCN(C(C=C1)=NC=C1C(O)=O)N(C[C@H](CC1)CC[C@@H]1C(F)(F)F)C(OC(C)(C)C)=O Chemical compound CCN(C(C=C1)=NC=C1C(O)=O)N(C[C@H](CC1)CC[C@@H]1C(F)(F)F)C(OC(C)(C)C)=O XBDSDCMKHBAUPQ-KOMQPUFPSA-N 0.000 description 2
- ZJKBUVVVXZLMMS-UHFFFAOYSA-N COC(=O)C1=C(C=CC(=C1)S(=O)(=O)N2C(CCC3=C2C=CC(=C3)C4COC4)C5CC5)O Chemical compound COC(=O)C1=C(C=CC(=C1)S(=O)(=O)N2C(CCC3=C2C=CC(=C3)C4COC4)C5CC5)O ZJKBUVVVXZLMMS-UHFFFAOYSA-N 0.000 description 2
- RLIFXXOTEFSIRT-UHFFFAOYSA-N COC(=O)C1=C(C=CC(=C1)S(=O)(=O)N2C(CCC3=C2C=CC(=C3)I)C4CC4)OCC5CCOCC5 Chemical compound COC(=O)C1=C(C=CC(=C1)S(=O)(=O)N2C(CCC3=C2C=CC(=C3)I)C4CC4)OCC5CCOCC5 RLIFXXOTEFSIRT-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- TVGXOGYFENWJKW-IBGZPJMESA-N N-[(1R)-1-(4-ethylsulfonylphenyl)-2-hydroxyethyl]-4-(2-methylpropanoyl)benzamide Chemical compound CCS(=O)(=O)C1=CC=C(C=C1)[C@H](CO)NC(=O)C2=CC=C(C=C2)C(=O)C(C)C TVGXOGYFENWJKW-IBGZPJMESA-N 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 229910052770 Uranium Inorganic materials 0.000 description 2
- LDPSHXVZVLFJTP-UHFFFAOYSA-N [6-(trifluoromethyl)pyridin-2-yl]methanol Chemical compound OCC1=CC=CC(C(F)(F)F)=N1 LDPSHXVZVLFJTP-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 229910052740 iodine Chemical group 0.000 description 2
- 239000011630 iodine Chemical group 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
- LVKCSZQWLOVUGB-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].C[CH-]C LVKCSZQWLOVUGB-UHFFFAOYSA-M 0.000 description 2
- AARWZYFWYNJHOQ-UHFFFAOYSA-N methyl 2-chloro-5-fluoro-6-methylpyridine-3-carboxylate Chemical compound COC(=O)C1=CC(F)=C(C)N=C1Cl AARWZYFWYNJHOQ-UHFFFAOYSA-N 0.000 description 2
- GJYBURAJRAHKAW-UHFFFAOYSA-N methyl 3-fluoro-4-formylbenzoate Chemical compound COC(=O)C1=CC=C(C=O)C(F)=C1 GJYBURAJRAHKAW-UHFFFAOYSA-N 0.000 description 2
- KPWDHJLTZNGXQE-UHFFFAOYSA-N methyl 5-[(2-cyclopropyl-3,4-dihydro-2H-quinolin-1-yl)sulfonyl]-2-hydroxybenzoate Chemical compound COC(=O)C1=C(C=CC(=C1)S(=O)(=O)N2C(CCC3=CC=CC=C32)C4CC4)O KPWDHJLTZNGXQE-UHFFFAOYSA-N 0.000 description 2
- IBRSHRMZNOKFKS-UHFFFAOYSA-N methyl 5-[(2-cyclopropyl-6-ethyl-3,4-dihydro-2H-quinolin-1-yl)sulfonyl]-2-hydroxybenzoate Chemical compound CCc1ccc2N(C(CCc2c1)C1CC1)S(=O)(=O)c1ccc(O)c(c1)C(=O)OC IBRSHRMZNOKFKS-UHFFFAOYSA-N 0.000 description 2
- ZFIHBTMALUQXAL-UHFFFAOYSA-N methyl 5-fluoro-6-methylpyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C(C)C(F)=C1 ZFIHBTMALUQXAL-UHFFFAOYSA-N 0.000 description 2
- AYABEJGGSWJVPN-UHFFFAOYSA-N methyl 6-(trifluoromethyl)pyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(C(F)(F)F)=N1 AYABEJGGSWJVPN-UHFFFAOYSA-N 0.000 description 2
- CFRLXHMEAGBUCM-WWPIYYJJSA-N methyl 6-[(1S)-1-amino-2-methylpropyl]-5-fluoropyridine-3-carboxylate dihydrochloride Chemical compound CC(C)[C@@H](C1=C(C=C(C=N1)C(=O)OC)F)N.Cl.Cl CFRLXHMEAGBUCM-WWPIYYJJSA-N 0.000 description 2
- BZOWIADSJYMJJJ-UHFFFAOYSA-N methyl 6-formylpyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(C=O)N=C1 BZOWIADSJYMJJJ-UHFFFAOYSA-N 0.000 description 2
- GKVRWTJYBUJYEO-UHFFFAOYSA-N methyl [6-(trifluoromethyl)pyridin-2-yl]methanesulfonate Chemical compound COS(=O)(=O)CC1=NC(=CC=C1)C(F)(F)F GKVRWTJYBUJYEO-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- QXJIABOUHLYVHP-UHFFFAOYSA-N n-chloromethanamine Chemical compound CNCl QXJIABOUHLYVHP-UHFFFAOYSA-N 0.000 description 2
- FOAUSALTDRHMLA-UHFFFAOYSA-N n-methyl-6-(trifluoromethyl)pyridin-2-amine Chemical compound CNC1=CC=CC(C(F)(F)F)=N1 FOAUSALTDRHMLA-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- USFPINLPPFWTJW-UHFFFAOYSA-N tetraphenylphosphonium Chemical compound C1=CC=CC=C1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 USFPINLPPFWTJW-UHFFFAOYSA-N 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- ODMHKFPQZBIVAJ-CQSZACIVSA-N (1R)-3-(2-amino-5-ethylphenyl)-1-cyclopropylpropan-1-ol Chemical compound CCC1=CC(CC[C@@H](O)C2CC2)=C(N)C=C1 ODMHKFPQZBIVAJ-CQSZACIVSA-N 0.000 description 1
- NFQRIJRWUCDRPN-ZCFIWIBFSA-N (1S)-1-cyclopropylprop-2-yn-1-ol Chemical compound C#C[C@@H](O)C1CC1 NFQRIJRWUCDRPN-ZCFIWIBFSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- ILWJAOPQHOZXAN-UHFFFAOYSA-N 1,3-dithianyl Chemical group [CH]1SCCCS1 ILWJAOPQHOZXAN-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 description 1
- LNNXOEHOXSYWLD-UHFFFAOYSA-N 1-bromobut-2-yne Chemical compound CC#CCBr LNNXOEHOXSYWLD-UHFFFAOYSA-N 0.000 description 1
- NFQRIJRWUCDRPN-UHFFFAOYSA-N 1-cyclopropylprop-2-yn-1-ol Chemical compound C#CC(O)C1CC1 NFQRIJRWUCDRPN-UHFFFAOYSA-N 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 1
- CACZOIOUVVFGLV-UHFFFAOYSA-N 2,6-dichloro-5-fluoro-4-methylpyridine-3-carboxylic acid Chemical compound CC1=C(F)C(Cl)=NC(Cl)=C1C(O)=O CACZOIOUVVFGLV-UHFFFAOYSA-N 0.000 description 1
- PFOYYSGBGILOQZ-UHFFFAOYSA-N 2-(2-methylpropanoyl)cyclohexan-1-one Chemical compound CC(C)C(=O)C1CCCCC1=O PFOYYSGBGILOQZ-UHFFFAOYSA-N 0.000 description 1
- JFTZVYKESKQING-UHFFFAOYSA-N 2-(cyclopenten-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CCCC1 JFTZVYKESKQING-UHFFFAOYSA-N 0.000 description 1
- WFIFHOWQEJADPH-UHFFFAOYSA-N 2-chloro-4-(2-oxo-4-phenylpyrrolidin-1-yl)benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC=C1N1C(=O)CC(C=2C=CC=CC=2)C1 WFIFHOWQEJADPH-UHFFFAOYSA-N 0.000 description 1
- APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)-n-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- CESUXLKAADQNTB-ZETCQYMHSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](N)=O CESUXLKAADQNTB-ZETCQYMHSA-N 0.000 description 1
- WBBPRCNXBQTYLF-UHFFFAOYSA-N 2-methylthioethanol Chemical compound CSCCO WBBPRCNXBQTYLF-UHFFFAOYSA-N 0.000 description 1
- BTBFCBQZFMQBNT-UHFFFAOYSA-N 3,4-difluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1F BTBFCBQZFMQBNT-UHFFFAOYSA-N 0.000 description 1
- XUQCONCMPCVUDM-UHFFFAOYSA-N 3-fluoro-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C=C1F XUQCONCMPCVUDM-UHFFFAOYSA-N 0.000 description 1
- HRADVHZVMOMEPU-UHFFFAOYSA-N 3-iodopyrrolidine-2,5-dione Chemical compound IC1CC(=O)NC1=O HRADVHZVMOMEPU-UHFFFAOYSA-N 0.000 description 1
- CEAVPXDEPGAVDA-UHFFFAOYSA-N 3-methoxy-4-methylbenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1C CEAVPXDEPGAVDA-UHFFFAOYSA-N 0.000 description 1
- ROADCYAOHVSOLQ-UHFFFAOYSA-N 3-oxetanone Chemical compound O=C1COC1 ROADCYAOHVSOLQ-UHFFFAOYSA-N 0.000 description 1
- LMEAZIIFLVDISW-UHFFFAOYSA-N 4-(trifluoromethyl)cyclohexane-1-carboxylic acid Chemical compound OC(=O)C1CCC(C(F)(F)F)CC1 LMEAZIIFLVDISW-UHFFFAOYSA-N 0.000 description 1
- DZTGHHXWNCQUNM-VWLOTQADSA-N 4-[[2-(4-chlorophenyl)acetyl]-propan-2-ylamino]-N-[(1R)-1-(4-ethylsulfonylphenyl)-2-hydroxyethyl]-3-fluorobenzamide Chemical compound CCS(=O)(=O)C1=CC=C(C=C1)[C@H](CO)NC(=O)C2=CC(=C(C=C2)N(C(C)C)C(=O)CC3=CC=C(C=C3)Cl)F DZTGHHXWNCQUNM-VWLOTQADSA-N 0.000 description 1
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
- VLWRKVBQUANIGI-UHFFFAOYSA-N 4-fluoro-n-methylaniline Chemical compound CNC1=CC=C(F)C=C1 VLWRKVBQUANIGI-UHFFFAOYSA-N 0.000 description 1
- OQTNJLQWOVTCPV-UHFFFAOYSA-N 5-ethylpyridin-2-amine Chemical compound CCC1=CC=C(N)N=C1 OQTNJLQWOVTCPV-UHFFFAOYSA-N 0.000 description 1
- GXSBXAANKLORNW-UHFFFAOYSA-N 5-ethylsulfonyl-N-methylpyridin-2-amine hydrochloride Chemical compound CCS(=O)(=O)C1=CN=C(C=C1)NC.Cl GXSBXAANKLORNW-UHFFFAOYSA-N 0.000 description 1
- OKBHXGBLXDNJJD-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(C(F)(F)F)=N1 OKBHXGBLXDNJJD-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ODMHKFPQZBIVAJ-UHFFFAOYSA-N C1C(C(CCC2=C(N)C=CC(CC)=C2)O)C1 Chemical compound C1C(C(CCC2=C(N)C=CC(CC)=C2)O)C1 ODMHKFPQZBIVAJ-UHFFFAOYSA-N 0.000 description 1
- PPSCWDZSQCQRPY-UHFFFAOYSA-N C1CC(=O)N(C1)C2=CC3=C(C=C2)N(C(CC3)C4CC4)S(=O)(=O)C5=CC(=C(C=C5)OCC6CCOCC6)CO Chemical compound C1CC(=O)N(C1)C2=CC3=C(C=C2)N(C(CC3)C4CC4)S(=O)(=O)C5=CC(=C(C=C5)OCC6CCOCC6)CO PPSCWDZSQCQRPY-UHFFFAOYSA-N 0.000 description 1
- ALLMQFUEDCWALJ-UHFFFAOYSA-N C1CC1C2CCC3=C(N2S(=O)(=O)C4=CC(=C(C=C4)OCC5CCOCC5)CO)C=CC(=C3)N6CCOCC6 Chemical compound C1CC1C2CCC3=C(N2S(=O)(=O)C4=CC(=C(C=C4)OCC5CCOCC5)CO)C=CC(=C3)N6CCOCC6 ALLMQFUEDCWALJ-UHFFFAOYSA-N 0.000 description 1
- IBBDBZJDIILNNJ-HNNXBMFYSA-N CC(C)[C@@H](C1=C(C=C(C=N1)C(=O)OC)F)NC(=O)C2=CC=C(C=C2)Cl Chemical compound CC(C)[C@@H](C1=C(C=C(C=N1)C(=O)OC)F)NC(=O)C2=CC=C(C=C2)Cl IBBDBZJDIILNNJ-HNNXBMFYSA-N 0.000 description 1
- NEJYVTNJEZXGRT-UHFFFAOYSA-N CCC1=CC2=C(C=C1)N(C(CC2)C3CC3)S(=O)(=O)C4=CC(=C(C=C4)OCC5=CN=NC=C5)CO Chemical compound CCC1=CC2=C(C=C1)N(C(CC2)C3CC3)S(=O)(=O)C4=CC(=C(C=C4)OCC5=CN=NC=C5)CO NEJYVTNJEZXGRT-UHFFFAOYSA-N 0.000 description 1
- KUHNODMJEVEJJI-UHFFFAOYSA-N CCC1=CC2=C(C=C1)N(C(CC2)C3CC3)S(=O)(=O)C4=CC(=C(C=C4)OCC5=NN=C(O5)C)CO Chemical compound CCC1=CC2=C(C=C1)N(C(CC2)C3CC3)S(=O)(=O)C4=CC(=C(C=C4)OCC5=NN=C(O5)C)CO KUHNODMJEVEJJI-UHFFFAOYSA-N 0.000 description 1
- PPJFCMWZACTGRF-UHFFFAOYSA-N CCC1=CC2=C(C=C1)N(C(CC2)C3CC3)S(=O)(=O)C4=CC(=C(C=C4)OCC5CC(=O)N(C5)C)CO Chemical compound CCC1=CC2=C(C=C1)N(C(CC2)C3CC3)S(=O)(=O)C4=CC(=C(C=C4)OCC5CC(=O)N(C5)C)CO PPJFCMWZACTGRF-UHFFFAOYSA-N 0.000 description 1
- IOHDBSXXALQZPB-UHFFFAOYSA-N CCC1=CC2=C(C=C1)N(C(CC2)C3CC3)S(=O)(=O)C4=CC(=C(C=C4)OCC5CC(=O)OC5)CO Chemical compound CCC1=CC2=C(C=C1)N(C(CC2)C3CC3)S(=O)(=O)C4=CC(=C(C=C4)OCC5CC(=O)OC5)CO IOHDBSXXALQZPB-UHFFFAOYSA-N 0.000 description 1
- MCCIOLDULSNQSL-UHFFFAOYSA-N CCC1=CC2=C(C=C1)N(C(CC2)C3CC3)S(=O)(=O)C4=CC(=C(C=C4)OCC5CS(=O)(=O)C5)CO Chemical compound CCC1=CC2=C(C=C1)N(C(CC2)C3CC3)S(=O)(=O)C4=CC(=C(C=C4)OCC5CS(=O)(=O)C5)CO MCCIOLDULSNQSL-UHFFFAOYSA-N 0.000 description 1
- ZAYSHWNZHRYFAF-WIIYFNMSSA-N CCC1=CC2=C(C=C1)N([C@@H](CC2)C3CC3)S(=O)(=O)C4=CC(=C(C=C4)OCC5CCS(=O)(=O)C5)CO Chemical compound CCC1=CC2=C(C=C1)N([C@@H](CC2)C3CC3)S(=O)(=O)C4=CC(=C(C=C4)OCC5CCS(=O)(=O)C5)CO ZAYSHWNZHRYFAF-WIIYFNMSSA-N 0.000 description 1
- OIIATYLQGPQMET-UHFFFAOYSA-N CCC1CCC2=C(N1S(=O)(=O)C3=CC(=C(C=C3)OCCC4=NC=CN=C4)CO)C=CC(=C2)CC Chemical compound CCC1CCC2=C(N1S(=O)(=O)C3=CC(=C(C=C3)OCCC4=NC=CN=C4)CO)C=CC(=C2)CC OIIATYLQGPQMET-UHFFFAOYSA-N 0.000 description 1
- KPFXIKPEMZWBLR-UAPYVXQJSA-N CCN(C(C=C1)=NC=C1C(OC(C)(C)C)=O)N(C[C@H](CC1)CC[C@@H]1C(F)(F)F)C(OC(C)(C)C)=O Chemical compound CCN(C(C=C1)=NC=C1C(OC(C)(C)C)=O)N(C[C@H](CC1)CC[C@@H]1C(F)(F)F)C(OC(C)(C)C)=O KPFXIKPEMZWBLR-UAPYVXQJSA-N 0.000 description 1
- UMVJMHFLXALUII-AVKWCDSFSA-N CC[C@@H]1CCC2=C(N1S(=O)(=O)C3=CC(=C(C=C3)OCC4CCS(=O)(=O)C4)CO)C=CC(=C2)CC Chemical compound CC[C@@H]1CCC2=C(N1S(=O)(=O)C3=CC(=C(C=C3)OCC4CCS(=O)(=O)C4)CO)C=CC(=C2)CC UMVJMHFLXALUII-AVKWCDSFSA-N 0.000 description 1
- ZZPRHLPIRZZIML-UHFFFAOYSA-N COC(=O)C1=C(C=CC(=C1)S(=O)(=O)N2C(CCC3=C2C=CC(=C3)C(F)F)C4CC4)OCC5CCOCC5 Chemical compound COC(=O)C1=C(C=CC(=C1)S(=O)(=O)N2C(CCC3=C2C=CC(=C3)C(F)F)C4CC4)OCC5CCOCC5 ZZPRHLPIRZZIML-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 101100493713 Caenorhabditis elegans bath-45 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 244000188706 Eriosema chinense Species 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- VPTLBPSKJJAMGR-IBGZPJMESA-N N-[(1R)-1-(4-ethylsulfonylphenyl)-2-hydroxyethyl]-3-fluoro-4-(2-methylpropanoyl)benzamide Chemical compound CCS(=O)(=O)C1=CC=C(C=C1)[C@H](CO)NC(=O)C2=CC(=C(C=C2)C(=O)C(C)C)F VPTLBPSKJJAMGR-IBGZPJMESA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- JWIPGAFCGUDKEY-UHFFFAOYSA-L O[Cr](Cl)(=O)=O.C1=CC=NC=C1 Chemical compound O[Cr](Cl)(=O)=O.C1=CC=NC=C1 JWIPGAFCGUDKEY-UHFFFAOYSA-L 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- OEYVFRVNVPKHQQ-UHFFFAOYSA-N Pyrimidin-4-yl-Methanol Chemical compound OCC1=CC=NC=N1 OEYVFRVNVPKHQQ-UHFFFAOYSA-N 0.000 description 1
- 108091008680 RAR-related orphan receptors Proteins 0.000 description 1
- 108091008773 RAR-related orphan receptors γ Proteins 0.000 description 1
- 102000042839 ROR family Human genes 0.000 description 1
- 108091082331 ROR family Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 229910052789 astatine Inorganic materials 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- HGQULGDOROIPJN-UHFFFAOYSA-N azetidin-1-ium;chloride Chemical compound Cl.C1CNC1 HGQULGDOROIPJN-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- OSQPUMRCKZAIOZ-UHFFFAOYSA-N carbon dioxide;ethanol Chemical compound CCO.O=C=O OSQPUMRCKZAIOZ-UHFFFAOYSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- HKYGSMOFSFOEIP-UHFFFAOYSA-N dichloro(dichloromethoxy)methane Chemical compound ClC(Cl)OC(Cl)Cl HKYGSMOFSFOEIP-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- WADLLLSMEPLCNO-UHFFFAOYSA-N methyl 2,6-dichloro-5-fluoropyridine-3-carboxylate Chemical compound COC(=O)C1=CC(F)=C(Cl)N=C1Cl WADLLLSMEPLCNO-UHFFFAOYSA-N 0.000 description 1
- FEIOASZZURHTHB-UHFFFAOYSA-N methyl 4-formylbenzoate Chemical compound COC(=O)C1=CC=C(C=O)C=C1 FEIOASZZURHTHB-UHFFFAOYSA-N 0.000 description 1
- FMFHOANJVSFNEL-UHFFFAOYSA-N methyl 5-fluoro-6-formylpyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C(C=O)C(F)=C1 FMFHOANJVSFNEL-UHFFFAOYSA-N 0.000 description 1
- FHMDSXUNFMNNLU-UHFFFAOYSA-N methyl 6-(dibromomethyl)-5-fluoropyridine-3-carboxylate Chemical compound COC(=O)C1=CC(=C(N=C1)C(Br)Br)F FHMDSXUNFMNNLU-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 108091028154 miR-2170 stem-loop Proteins 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 108090000629 orphan nuclear receptors Proteins 0.000 description 1
- 102000004164 orphan nuclear receptors Human genes 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000003585 oxepinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- SEVSMVUOKAMPDO-UHFFFAOYSA-N para-Acetoxybenzaldehyde Natural products CC(=O)OC1=CC=C(C=O)C=C1 SEVSMVUOKAMPDO-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GCRNGPNGNJSZCC-UHFFFAOYSA-N tert-butyl 3-amino-3a,4,6,6a-tetrahydro-1h-pyrrolo[3,4-c]pyrazole-5-carboxylate Chemical compound N1N=C(N)C2CN(C(=O)OC(C)(C)C)CC21 GCRNGPNGNJSZCC-UHFFFAOYSA-N 0.000 description 1
- OFRLMTIBUAXBGV-UHFFFAOYSA-N tert-butyl 6-chloropyridine-3-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CC=C(Cl)N=C1 OFRLMTIBUAXBGV-UHFFFAOYSA-N 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- JHLVEBNWCCKSGY-UHFFFAOYSA-N tert-butyl n-methylcarbamate Chemical compound CNC(=O)OC(C)(C)C JHLVEBNWCCKSGY-UHFFFAOYSA-N 0.000 description 1
- JYEVUDXCQHLXNG-UHFFFAOYSA-N tert-butyl pyridine-3-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CC=CN=C1 JYEVUDXCQHLXNG-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 238000005533 tritiation Methods 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/26—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D331/00—Heterocyclic compounds containing rings of less than five members, having one sulfur atom as the only ring hetero atom
- C07D331/04—Four-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/46—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom
- C07D333/48—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本申请属于医药技术领域,涉及一类含有磺酰基结构的RORγ抑制剂类、其制备方法、含有这些化合物的药物组合物。本申请所提供的式(I)化合物和式(V)化合物具有良好的RORγ抑制活性,有望用于治疗哺乳动物由RORγ受体介导的疾病。
Description
本申请是基于申请日为2019年11月27日,申请号为201980076661.3,发明名称为“含有磺酰基结构的RORγ抑制剂”的申请的分案申请。
相关申请的交叉引用
本申请要求于2018年11月27日向中国国家知识产权局提交的第201811426060.4号中国专利申请、于2019年03月28日向中国国家知识产权局提交的第201910243555.1号中国专利申请、于2019年03月28日向中国国家知识产权局提交的第201910243579.9号中国专利申请的优先权和权益,所有申请公开的内容通过引用整体并入本文中。
技术领域
本申请涉及一类含有磺酰基结构的RORγ抑制剂、其制备方法、含有这些化合物的药物组合物、以及其在治疗RORγ受体介导的疾病中的用途。
背景技术
维甲酸相关孤儿核受体(ROR)是核受体家族的成员之一,它能够调控多种生理和生化过程。ROR家族包括三种类型,RORα、RORβ以及RORγ。三种不同的ROR可以在不同的组织中表达并且调控不同的生理过程。RORα主要分布在肝脏,骨骼肌,皮肤,肺,脂肪组织,肾脏,胸腺和大脑;RORβ主要作用于中枢神经系统;RORγ可以在许多组织中表达,包括肝脏,动物脂肪和骨骼肌。
RORγ有两种亚型:RORγ1和RORγt(RORγ2)。RORγ1在许多组织,如:胸腺,肌肉,肾脏和肝脏中表达,而RORγt则只在免疫细胞内表达。RORγt被认为能够调控T细胞辅助T细胞17((Th17)的分化。Th17是一类辅助T细胞的细胞,这种细胞可以产生白介素17(IL-17)和其他细胞激素。Th17细胞与众多自身免疫性和炎性疾病的病理学有关系,所述疾病包括但不限于银屑病、多发性硬化症、类风湿性关节炎、克罗恩病、哮喘、慢性阻塞性肺病、Behcet’sdisease和肠易激综合征等。
现有技术中Vitae Pharmaceuticals Inc的专利申请,如WO2014179564、WO2015116904、WO2016061160等;以及葛兰素史克公司的专利申请,如WO2013045431、WO2013160418、WO2013160419等;以及如WO2015116904、WO2016061160、US20160122318、WO2017024018、WO2017087608、WO2017132432均公开了一系列可作为RORγ抑制剂的化合物。鉴于RORγ抑制剂具有很大的潜在价值,进一步寻找具有RORγ抑制功能的化合物是十分必要的。
发明内容
一方面,本申请提供式(I)化合物、其立体异构体或其药学上可接受的盐,
其中,
U、V、W、Z各自独立地选自CH或N;
R1选自 或5-6元杂芳基,其中所述5-6元杂芳基任选地被m个R4取代;
R2独立地选自卤素、羟基、氨基、氰基、硝基、C1-C6烷基、C1-C6烷氧基或3-6元环烷基,其中所述C1-C6烷基、C1-C6烷氧基或3-6元环烷基任选地被一个或两个或三个选自卤素、羟基、氨基、氰基的取代基取代;
R3独立地选自卤素、羟基、氨基、氰基、硝基、C1-C6烷基、3-6元环烷基、3-6元杂环烷基、3-6元环烯基、3-6元杂环烯基或5-6元杂芳基,其中所述C1-C6烷基、3-6元环烷基、3-6元杂环烷基、3-6元环烯基、3-6元杂环烯基或5-6元杂芳基任选地被一个或两个或三个选自卤素、羟基、氨基、氰基、卤代C1-C3烷基的取代基取代;
R4独立地选自卤素、羟基、氨基、氰基、硝基或C1-C6烷基,其中所述C1-C6烷基任选地被一个或两个或三个选自卤素、羟基、氨基、氰基的取代基取代;
p选自1、2或3;
q选自1、2或3;
n选自0、1、2、3、4或5;
m选自0、1、2、3、4、5或6。
在一些实施方案中:当R1选自R3选自卤素、氰基、3-6元环烷基、C1-C6烷基,其中所述C1-C6烷基、3-6元环烷基任选地被一个或两个或三个选自卤素、羟基、氨基、氰基、/>卤代C1-C3烷基的取代基取代时,至少有一个R2选自3-6元环烷基;
同时不包括以下化合物:
在一些实施方案中:当R1选自R3选自氯、氰基、甲基、乙基、正丙基、异丙基、叔丁基、环丙基、环丁基、-CF3、-CH2CF3、-CF2CH3、-C(OH)(CH3)2时,至少有一个R2选自3-6元环烷基;
同时不包括以下化合物:
在一些实施方案中,当R1选自R3选自卤素、氰基、3-6元环烷基、C1-C6烷基,其中所述C1-C6烷基、3-6元环烷基任选地被一个或两个或三个选自卤素、羟基、氨基、氰基、/>卤代C1-C3烷基的取代基取代时,至少有一个R2选自3-6元环烷基;
同时,当q为1时,R3不为甲基、乙基、异丙基和环丁基。
在一些实施方案中:当R1选自R3选自氯、氰基、甲基、乙基、正丙基、异丙基、叔丁基、环丙基、环丁基、-CF3、-CH2CF3、-CF2CH3、-C(OH)(CH3)2时,至少有一个R2选自3-6元环烷基;同时,当q为1时,R3不为甲基、乙基、异丙基和环丁基。
在一些实施方案中,U、V、W、Z中至少有一个为CH。
在一些实施方案中,U、V、W、Z中至多有一个为N。
在一些典型的实施方案中,U、V、W、Z均为CH。
在一些典型的实施方案中,V、W、Z为CH,U为N。
在一些典型的实施方案中,U、V、Z为CH,W为C(R3)。
在一些实施方案中,R1选自
在一些实施方案中,R1选自 呋喃基、噻吩基、吡咯基、吡唑基、咪唑基、吡啶基、嘧啶基、哒嗪基、吡嗪基、噻唑基、异噻唑基、噁唑基、异噁唑基、1,2,4-三氮唑基、1,2,3-三氮唑基、1,3,4-噁二唑基、1,2,4-噁二唑基、1,2,5-噁二唑基、四唑基或三嗪基,其中呋喃基、噻吩基、吡咯基、吡唑基、咪唑基、吡啶基、嘧啶基、哒嗪基、吡嗪基、噻唑基、异噻唑基、噁唑基、异噁唑基、1,2,4-三氮唑基、1,2,3-三氮唑基、1,3,4-噁二唑基、1,2,4-噁二唑基、1,2,5-噁二唑基、四唑基或三嗪基任选地被m个R4取代。
在一些实施方案中,R1选自 异噁唑基、1,2,4-三氮唑基、1,2,3-三氮唑基、1,3,4-噁二唑基、嘧啶基、吡嗪基或哒嗪基,其中所述异噁唑基、1,2,4-三氮唑基、1,2,3-三氮唑基、1,3,4-噁二唑基、嘧啶基、吡嗪基或哒嗪基任选地被m个R4取代。
在一些实施方案中,R1选自 异噁唑基、1,2,4-三氮唑基、1,2,3-三氮唑基、1,3,4-噁二唑基、嘧啶基、吡嗪基或哒嗪基,其中所述异噁唑基、1,2,4-三氮唑基、1,2,3-三氮唑基、1,3,4-噁二唑基、嘧啶基、吡嗪基或哒嗪基任选地被m个R4取代。在一些典型的实施方案中,R1选自 其中所述/> 任选地被m个R4取代。
在一些典型的实施方案中,R1选自 其中所述/> 任选地被m个R4取代。
在一些实施方案中,R4独立地选自C1-C4烷基。
在一些实施方案中,R4独立地选自甲基、乙基、异丙基或叔丁基。
在一些典型的实施方案中,R4独立地选自甲基。
在一些更典型的实施方案中,R1选自
在一些更典型的实施方案中,R1选自
在一些实施方案中,R2独立地选自C1-C4烷基、或3-6元环烷基,其中所述C1-C4烷基或3-6元环烷基任选地被一个或两个或三个选自卤素、羟基、氨基、氰基的取代基取代;
在一些典型的实施方案中,R2独立地选自C1-C4烷基、或3-6元环烷基。
在一些典型的实施方案中,R2独立地选自乙基、或环丙基。
在一些典型的实施方案中,R2独立地选自乙基或环丙基。
在一些实施方案中,至少有一个R2选自3-6元环烷基。
在一些实施方案中,至少有一个R2选自环丙基。
在一些实施方案中,R3独立地选自C1-C4烷基、3-6元杂环烷基、3-6元环烯基、3-6元杂环烯基或5-6元杂芳基,其中所述C1-C4烷基、3-6元杂环烷基、3-6元环烯基、3-6元杂环烯基或5-6元杂芳基任选地被一个或两个或三个选自卤素、羟基、氨基、氰基、卤代C1-C3烷基的取代基取代;
在一些实施方案中,R3独立地选自C1-C4烷基。
在一些实施方案中,R3独立地选自甲基、乙基、任意位置失去一个氢原子的 所形成的基团、或噁唑基,其中所述R3任选地被一个或两个或三个选自卤素、羟基、氨基、氰基、/>的取代基取代。
在一些典型的实施方案中,R3独立地选自甲基、乙基、 其中R3任选地被一个或两个或三个选自卤素、羟基、氨基、氰基、/>的取代基取代。
在一些更典型的实施方案中,R3独立地选自-CHF2、-CF3、乙基、-C(O)CH3、
在一些实施方案中,p为1。
在一些实施方案中,q为1或2。
在一些实施方案中,n为0、1、2、或3。
在一些实施方案中,m为0、1或2。
在一些实施方案中,当R1选自时,R3独立地选自3-6元杂环烷基、3-6元环烯基、3-6元杂环烯基或5-6元杂芳基,其中所述3-6元杂环烷基、3-6元环烯基、3-6元杂环烯基或5-6元杂芳基任选地被一个或两个或三个选自卤素、羟基、氨基、氰基、/>卤代C1-C3烷基的取代基取代。
在一些典型的实施方案中,R1选自R3独立地选自 其中R3任选地被一个或两个或三个选自卤素、羟基、氨基、氰基、/>的取代基取代。
在一些实施方案中,当R1选自时,至少有一个R2选自3-6元环烷基。
在一些实施方案中,当R1选自时,R3选自被一个或两个或三个选自卤素、羟基、氨基、氰基、/>的取代基取代C1-C4烷基。
在一些实施方案中,R1选自V、W、Z均为C,U为N,R3选自未取代C1-C4烷基。
在一些实施方案中,当R1选自R3选自未取代C1-C4烷基时,q为2。
在一些实施方案中,上述式(I)化合物、其立体异构体或其药学上可接受的盐具有式(II)所示的结构,
其中,U、R1、R2、R3、n、p、q如前述式(I)化合物中所定义。
在一些实施方案中,上述式(I)化合物、其立体异构体或其药学上可接受的盐具有式(III)所示的结构,
其中,U、R1、R2、R3、n、q如前述式(I)化合物中所定义。
在一些实施方案中,上述式(I)化合物、其立体异构体或其药学上可接受的盐具有式(IV)所示的结构,
其中,U、R1、R2、R3、n如前述式(I)化合物中所定义。
在一些实施方案中,本申请涉及的化合物选自以下化合物、其立体异构体或其药学上可接受的盐:
/>
在一些典型的实施方案中,本申请涉及的化合物选自以下化合物或其药学上可接受的盐:
/>
/>
/>
/>
/>
另一方面,本申请还提供式(V)化合物、其立体异构体或其药学上可接受的盐,
其中,
X、Y、Q、P各自独立地选自CH或N,其中所述X、Y、Q、P可任选地被R6取代;
U'、V'、W'、Z'各自独立地选自CH或N,其中所述U'、V'、W'、Z'可任选地被R7取代;
L1、L2、L3各自独立地选自单键、CH2、NH、C(O)或S(O)2,其中所述L1、L2、L3可任选地被一个或两个选自R4'的基团取代,且L1、L2、L3各不相同;
R1'选自任选地被一个或两个或三个选自卤素、羟基或C3-C6环烷基的取代基取代的C1-C6烷基;
R2'选自H、卤素、羟基、C1-C6烷基、卤代C1-C6烷基或羟基C1-C6烷基;
R3'选自H、C1-C6烷基或C1-C6烷基C(O)-;
R4'独立地选自卤素、羟基、氨基或C1-C6烷基,其中所述C1-C6烷基可任选地被一个或两个或三个选自卤素、羟基、氰基或氨基的取代基取代;
R5选自3-6元环烷基、3-6元杂环烷基、苯基或5-6元杂芳基,其中所述3-6元环烷基、3-6元杂环烷基、苯基或5-6元杂芳基可任选地被一个或两个或三个选自卤素、羟基、氰基、硝基、氨基、C1-C3烷基或卤代C1-C3烷基的取代基取代;
R6选自卤素、羟基、氨基、硝基或C1-C6烷基,其中所述C1-C6烷基可任选地被一个或两个或三个选自卤素、羟基、氰基或氨基的取代基取代;
R7选自卤素、羟基、氨基、硝基、C1-C6烷基或C1-C6烷氧基,其中所述C1-C6烷基或C1-C6烷氧基可任选地被一个或两个或三个选自卤素、羟基、氰基或氨基的取代基取代。
在一些实施方案中,X、Y、Q、P中至少有一个为CH,其中所述X、Y、Q、P可任选地被R6取代。
在一些实施方案中,X、Y、Q、P中至多有一个为N,其中所述X、Y、Q、P可任选地被R6取代。
在一些典型的实施方案中,X、Q、P选自CH,Y选自CH或N,其中所述X、Y、Q、P可任选地被R6取代。
在一些实施方案中,U'、V'、W'、Z'中至少有一个为CH,其中所述U'、V'、W'、Z'可任选地被R7取代。
在一些实施方案中,U'、V'、W'、Z'中至多有一个为N,其中所述U'、V'、W'、Z'可任选地被R7取代。
在一些实施方案中,Z'、U'选自CH,V'、W'选自CH或N,其中所述U'、V'、W'、Z'可任选地被R7取代。
在一些实施方案中,U'、V'、W'、Z'均为CH,其中所述U'、V'、W'、Z'可任选地被R7取代。
在一些实施方案中,U'、W'、Z'为CH,V'为N,其中所述U'、W'、Z'可任选地被R7取代。
在一些实施方案中,U'、V'、Z'为CH,W'为N,其中所述U'、V'、Z'可任选地被R7取代。
在一些实施方案中,R7选自-F、-Cl、-Br、甲氧基、乙氧基、异丙基氧基或叔丁基氧基。
在一些典型的实施方案中,R7选自-F或甲氧基。
在一些典型的实施方案中,U'、V'、W'、Z'均为CH,其中U'、V'、W'、Z'未被R7取代。
在一些典型的实施方案中,U'、W'、Z'选自CH,V'选自C(F)或C(OCH3),其中U'、W'、Z'未被R7取代。
在一些典型的实施方案中,U'、W'、Z'选自CH,V'选自N,其中U'、W'、Z'未被R7取代。
在一些典型的实施方案中,U'、Z'选自CH,W'选自N,V'选自C(F),其中U'、Z'未被R7取代。
在一些实施方案中,R1'选自甲基、乙基、异丙基或叔丁基。
在一些典型的实施方案中,R1'选自乙基。
在一些实施方案中,R2'选自H、甲基、乙基、异丙基或叔丁基,其中所述甲基、乙基、异丙基或叔丁基可任选地被一个羟基取代。
在一些典型的实施方案中,R2'选自H或-CH2OH。
在一些典型的实施方案中,与R2'连接的C原子的手性构型为R型。
在一些更典型的实施方案中,R2'选自-CH2OH,且与R2'连接的C原子的手性构型为R型。
在一些实施方案中,R3'选自H、甲基、乙基、异丙基或叔丁基。
在一些典型的实施方案中,R3'选自H或甲基。
在一些实施方案中,R4'选自甲基、乙基、异丙基或叔丁基。
在一些典型的实施方案中,R4'选自乙基或异丙基。
在一些实施方案中,L1选自CH2或NH,其中所述L1可任选地被一个或两个选自R4'的基团取代。
在一些实施方案中,L1选自CH2,其中L1被异丙基取代。在一些实施方案中,L1选自NH,其中L1被异丙基或乙基取代。
在一些实施方案中,L2选自单键、NH或C(O),其中所述L2可任选地被一个或两个选自R4的基团取代。
在一些典型的实施方案中,L2选自单键、NH或C(O)。
在一些实施方案中,L3选自CH2或C(O),其中所述L3可任选地被一个或两个选自R4的基团取代。
在一些典型的实施方案中,L3选自CH2或C(O)。
在一些更典型的实施方案中,选自
在一些实施方案中,R5选自环丙基、环丁基、环戊基、环己基、苯基、呋喃基、噻吩基、吡咯基、吡唑基、咪唑基、吡啶基、嘧啶基、哒嗪基、吡嗪基、噻唑基、异噻唑基、噁唑基、异噁唑基、1,2,4-三氮唑基、1,2,3-三氮唑基、四唑基或三嗪基,其中所述环丙基、环丁基、环戊基、环己基、苯基、呋喃基、噻吩基、吡咯基、吡唑基、咪唑基、吡啶基、嘧啶基、哒嗪基、吡嗪基、噻唑基、异噻唑基、噁唑基、异噁唑基、1,2,4-三氮唑基、1,2,3-三氮唑基、四唑基或三嗪基可任选地被一个或两个或三个选自卤素、羟基、氰基、硝基、氨基、C1-C3烷基或卤代C1-C3烷基的取代基取代。
在一些实施方案中,R5选自环己基、苯基或吡啶基,其中所述环己基、苯基或吡啶基可任选地被一个或两个或三个选自卤素、羟基、氰基、硝基、氨基、C1-C3烷基或卤代C1-C3烷基的取代基取代。
在一些实施方案中,R5选自环己基、苯基或吡啶基,所述环己基、苯基或吡啶基可任选地被一个或两个或三个选自F、Cl、三氟甲基的取代基取代。
在一些典型的实施方案中,R5选自
在一些更典型的实施方案中,R5选自
在一些实施方案中,式(V)化合物、其立体异构体或其药学上可接受的盐具有式(VI)所示的结构,
其中,X、Y、Q、P、U'、V'、W'、Z'、L1、L2、L3、R2'、R3'和R5如前述式(V)化合物中所定义。
在一些实施方案中,式(V)化合物、其立体异构体或其药学上可接受的盐具有式(VII)所示的结构,
其中,U'、V'、W'、Z'、L1、L2、L3、R2'、R3'和R5如前述式(V)化合物中所定义。
在一些实施方案中,式(V)化合物、其立体异构体或其药学上可接受的盐具有式(VIII)所示的结构,
其中,U'、V'、W'、Z'、L1、L2、L3、R2'、R3'和R5如前述式(V)化合物中所定义。
在一些实施方案中,本申请优选下述化合物、其立体异构体或其药学上可接受的盐:
/>
在一些实施方案中,本申请优选下述化合物或其药学上可接受的盐:
/>
/>
在一些实施方案中,本申请所述C1-C6烷基选自C1-C4烷基或C1-C3烷基。在一些实施方案中,所述C1-C6烷基选自甲基、乙基、异丙基、叔丁基。
在一些实施方案中,本申请所述C1-C6烷氧基选自C1-C4烷氧基或C1-C3烷氧基。在一些实施方案中,所述C1-C6烷氧基选自甲氧基、乙氧基、异丙氧基、叔丁氧基。
在一些实施方案中,本申请所述卤代C1-C6烷基选自卤代C1-C4烷基或卤代C1-C3烷基。在一些实施方案中,所述卤代C1-C6烷基选自氟代C1-C4烷基或氟代C1-C3烷基。在一些实施方案中,所述卤代C1-C6烷基选自氟代甲基或氟代乙基。在一些实施方案中,所述卤代C1-C6烷基选自-CF3、-CF2、-CH2CF3、-CF2CH3、-CHFCH3、-CF2CF3。
在一些实施方案中,本申请所述卤代C1-C3烷基选自氟代C1-C3烷基。在一些实施方案中,所述卤代C1-C3烷基选自氟代甲基或氟代乙基。
在一些实施方案中,本申请所述卤素选自氟或氯。
在一些实施方案中,本申请所述羟基C1-C6烷基选自羟基C1-C4烷基或羟基C1-C3烷基。在一些实施方案中,所述羟基C1-C6烷基选自羟甲基、羟乙基。
在一些实施方案中,本申请所述3-6元环烷基选自环丙基、环丁基、环戊基、环己基。
在一些实施方案中,本申请所述3-6元杂环烷基选自任意位置失去一个氢原子的 />所形成的基团。
在一些实施方案中,本申请所述3-6元环烯基选自任意位置失去一个氢原子的 所形成的基团。
在一些实施方案中,本申请所述3-6元杂环烯基选自任意位置失去一个氢原子的 所形成的基团。
在一些实施方案中,本申请所述5-6元杂芳基中的杂原子选自O、S或N,杂原子数目为1、2或3。
在一些实施方案中,本申请所述5-6元杂芳基选自呋喃基、噻吩基、吡咯基、吡唑基、咪唑基、吡啶基、嘧啶基、哒嗪基、吡嗪基、噻唑基、异噻唑基、噁唑基、异噁唑基、1,2,4-三氮唑基、1,2,3-三氮唑基、1,3,4-噁二唑基、1,2,4-噁二唑基、1,2,5-噁二唑基、四唑基或三嗪基。
另一方面,本申请涉及药物组合物,其包含本申请的式(I)化合物或式(V)化合物、其立体异构体或其药学上可接受的盐。
在一些实施方案中,本申请涉及药物组合物,其包含治疗有效量的本申请的式(I)化合物或式(V)化合物、其立体异构体或其药学上可接受的盐。
在另一些实施方案中,本申请的药物组合物还包括药学上可接受的辅料。
本申请的药物组合物可通过将本申请的化合物与适宜的药学上可接受的辅料组合而制备,例如可配制成固态、半固态、液态或气态制剂,如片剂、丸剂、胶囊剂、粉剂、颗粒剂、膏剂、乳剂、悬浮剂、栓剂、注射剂、吸入剂、凝胶剂、微球及气溶胶等。
给予本申请化合物或其药学上可接受的盐或其药物组合物的典型途径包括但不限于口服、直肠、局部、吸入、肠胃外、舌下、阴道内、鼻内、眼内、腹膜内、肌内、皮下、静脉内给药。
本申请的药物组合物可以采用本领域众所周知的方法制造,如常规的混合法、溶解法、制粒法、制糖衣药丸法、磨细法、乳化法、冷冻干燥法等。
在一些实施方案中,药物组合物是口服形式。对于口服给药,可以通过将活性化合物与本领域熟知的药学上可接受的辅料混合,来配制该药物组合物。这些辅料能使本申请的化合物被配制成片剂、丸剂、锭剂、糖衣剂、胶囊剂、液体、凝胶剂、浆剂、悬浮剂等,用于对患者的口服给药。
可以通过常规的混合、填充或压片方法来制备固体口服组合物。例如,可通过下述方法获得:将所述的活性化合物与固体辅料混合,任选地碾磨所得的混合物,如果需要则加入其它合适的辅料,然后将该混合物加工成颗粒,得到了片剂或糖衣剂的核心。适合的辅料包括但不限于:粘合剂、稀释剂、崩解剂、润滑剂、助流剂、甜味剂或矫味剂等。
药物组合物还可适用于肠胃外给药,如合适的单位剂型的无菌溶液剂、混悬剂或冻干产品。
另一方面,本申请的式(I)化合物或式(V)化合物、其立体异构体或其药学上可接受的盐可用于医药用途。
另一方面,本申请涉及预防或者治疗哺乳动物由RORγ受体介导的疾病的方法,包括对需要该治疗的哺乳动物,优选人类,给予治疗有效量的本申请的式(I)化合物或式(V)化合物、其立体异构体或其药学上可接受的盐、或其药物组合物。在一些实施方案中,所述RORγ受体为RORγt受体。
本申请的式(I)化合物或式(V)化合物、其立体异构体或其药学上可接受的盐的所有施用方法中,每天给药的剂量为0.01到100mg/kg体重,优选为0.05到50mg/kg体重,更优选0.1到5mg/kg体重,以单独或分开剂量的形式。
另一方面,本申请涉及式(I)化合物或式(V)化合物、其立体异构体或其药学上可接受的盐、或其药物组合物在制备预防或者治疗RORγ受体介导的疾病的药物中的用途。在一些实施方案中,所述RORγ受体为RORγt受体。
另一方面,本申请涉及预防或者治疗RORγ受体介导的疾病的式(I)化合物或式(V)化合物、其立体异构体或其药学上可接受的盐。在一些实施方案中,所述RORγ受体为RORγt受体。
所述RORγ受体介导的疾病包括免疫相关性疾病,例如肿瘤和关节炎。
定义
除非另有说明,本申请中所用的下列术语具有下列含义。一个特定的术语在没有特别定义的情况下不应该被认为是不确定的或不清楚的,而应该按照本领域普通的含义去理解。当本文中出现商品名时,意在指代其对应的商品或其活性成分。
术语“被取代”是指特定原子上的任意一个或多个氢原子被取代基取代,只要特定原子的价态是正常的并且取代后的化合物是稳定的。当取代基为氧代(即=O)时,意味着两个氢原子被取代,氧代不会发生在芳香基上。
术语“任选”或“任选地”是指随后描述的事件或情况可以发生或不发生,该描述包括发生所述事件或情况和不发生所述事件或情况。例如,乙基“任选”被卤素取代,指乙基可以是未被取代的(CH2CH3)、单取代的(如CH2CH2F)、多取代的(如CHFCH2F、CH2CHF2等)或完全被取代的(CF2CF3)。本领域技术人员可理解,对于包含一个或多个取代基的任何基团,不会引入任何在空间上不可能存在和/或不能合成的取代或取代模式。
本文中的Cm-Cn,是该部分具有给定范围中的整数个碳原子。例如“C1-C6”是指该基团可具有1个碳原子、2个碳原子、3个碳原子、4个碳原子、5个碳原子或6个碳原子。
术语“卤”或“卤素”是指氟、氯、溴和碘。
术语“羟基”指-OH基团。
术语“氰基”指-CN基团。
术语“氨基”指-NH2基团、-NH(烷基)和-N(烷基)2,氨基的具体例子包括但不限于-NH2、-NHCH3、-NHCH(CH3)2、-N(CH3)2、-NHC2H5、-N(CH3)C2H5等。
术语“硝基”指-NO2基团。
术语“烷基”是指通式为CnH2n+1的烃基。该烷基可以是直链或支链的。例如,术语“C1-C6烷基”指含有1至6个碳原子的烷基(例如甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、正戊基、1-甲基丁基、2-甲基丁基、3-甲基丁基、新戊基、己基、2-甲基戊基等)。类似地,烷氧基、烷基氨基、二烷基氨基、烷基磺酰基和烷硫基的烷基部分(即烷基)具有上述相同定义。
术语“卤代烷基”意在包括单卤代烷基和多卤代烷基;例如,术语“卤代C1-C3烷基”意在包括但不仅限于三氟甲基、2,2,2-三氟乙基和3-溴丙基等等。卤代烷基的实例包括但不仅限于:三氟甲基、三氯甲基、五氟乙基和五氯乙基。
术语“烷氧基”指-O-烷基。
术语“环烷基”是指由碳原子和氢原子组成的全碳单环的饱和烃基团,如C3-C20环烷基,优选为C3-C6环烷基,例如环丙基、环丁基、环戊基、环己基等。所述环烷基可以是非取代的或是被取代的,所述的取代基包括但不限于烷基、烷基氧基、氰基、羧基、芳基、杂芳基、氨基、卤素、磺酰基、亚磺酰基、磷酰基和羟基。
术语“环烯基”是指由碳原子和氢原子组成的全碳单环的部分饱和烃基团,例如环丁烯基、环戊烯基、环己烯基等。
术语“杂环烷基”是指完全饱和的并且可以以单环、桥环或螺环存在的环状基团。除非另有指示,该杂环通常为含有1至3个独立地选自硫、氧和/或氮的杂原子(优选1或2个杂原子)的3至7元环。3元杂环烷基的实例包括但不限于环氧乙烷基、环硫乙烷基、环氮乙烷基,4元杂环烷基的非限制性实例包括但不限于吖丁啶基、噁丁环基、噻丁环基,5元杂环烷基的实例包括但不限于四氢呋喃基、四氢噻吩基、吡咯烷基、异噁唑烷基、噁唑烷基、异噻唑烷基、噻唑烷基、咪唑烷基、四氢吡唑基,6元杂环烷基的实例包括但不限于哌啶基、四氢吡喃基、四氢噻喃基、吗啉基、哌嗪基、1,4-噻噁烷基、1,4-二氧六环基、硫代吗啉基、1,3-二噻烷基、1,4-二噻烷基、,7元杂环烷基的实例包括但不限于氮杂环庚烷基、氧杂环庚烷基、硫杂环庚烷基。优选为具有5或6个环原子的单环杂环烷基。
术语“杂环烯基”是指部分饱和的杂环烷基,例如杂环烷基含有至少一个双键。
术语“杂芳基”是指“杂芳环”分子去掉1个氢原子后余下的基团,杂芳基可以是非取代的或取代的,所述的取代基包括但不限于烷基、烷基氧基、芳基、芳烷基、氨基、卤素、羟基、氰基、硝基、羰基和杂脂环基。非取代的杂芳基的非限制性实例包括但不限于吡咯基、呋喃基、噻吩基、咪唑基、噁唑基、吡唑基、吡啶基、嘧啶基、吡嗪基、喹啉基、异喹啉基、四唑基、三嗪基。
术语“治疗”意为将本申请所述化合物或制剂进行给药以预防、改善或消除疾病或与所述疾病相关的一个或多个症状,且包括:
(i)预防疾病或疾病状态在哺乳动物中出现,特别是当这类哺乳动物易患有该疾病状态,但尚未被诊断为已患有该疾病状态时;
(ii)抑制疾病或疾病状态,即遏制其发展;
(iii)缓解疾病或疾病状态,即使该疾病或疾病状态消退。
术语“治疗有效量”意指(i)治疗或预防特定疾病、病况或障碍,(ii)减轻、改善或消除特定疾病、病况或障碍的一种或多种症状,或(iii)预防或延迟本文中所述的特定疾病、病况或障碍的一种或多种症状发作的本申请化合物的用量。构成“治疗有效量”的本申请化合物的量取决于该化合物、疾病状态及其严重性、给药方式以及待被治疗的哺乳动物的年龄而改变,但可例行性地由本领域技术人员根据其自身的知识及本申请内容而确定。
术语“药学上可接受的”,是针对那些化合物、材料、组合物和/或剂型而言,它们在可靠的医学判断的范围之内,适用于与人类和动物的组织接触使用,而没有过多的毒性、刺激性、过敏性反应或其它问题或并发症,与合理的利益/风险比相称。
作为药学上可接受的盐,例如,可以提及金属盐、铵盐、与有机碱形成的盐、与无机酸形成的盐、与有机酸形成的盐、与碱性或者酸性氨基酸形成的盐等。
术语“药物组合物”是指一种或多种本申请的化合物或其盐与药学上可接受的辅料组成的混合物。药物组合物的目的是有利于对有机体给予本申请的化合物。
术语“药学上可接受的辅料”是指对有机体无明显刺激作用,而且不会损害该活性化合物的生物活性及性能的那些辅料。合适的辅料是本领域技术人员熟知的,例如碳水化合物、蜡、水溶性和/或水可膨胀的聚合物、亲水性或疏水性材料、明胶、油、溶剂、水等。
词语“包括(comprise)”或“包含(comprise)”及其英文变体例如comprises或comprising应理解为开放的、非排他性的意义,即“包括但不限于”。
在本申请中,除非特别定义,所采用的缩略语的含义如下所示:℃是指摄氏度;DCM是指二氯甲烷;MeOH是指甲醇;THF是指四氢呋喃;TEA是指三乙胺;DIAD是指偶氮二甲酸二异丙酯;PPh3是指三苯基膦;PdCl2(PPh3)2是指双(三苯基膦)氯化钯;NaBH4是指硼氢化钠;LC-MS是指液相色谱与质谱联用;PE是指石油醚;EA是指乙酸乙酯;CsF是指氟化铯;TLC是指薄层色谱;M是指摩尔浓度单位mol/L,例如2M是指2mol/L;mM是指摩尔浓度单位毫摩尔/升,例如2mM是指2mmol/L;N是指当量浓度,例如1N HCl是指浓度为1mol/L的盐酸;2N NaOH是指浓度为2mol/L的氢氧化钠;LAH或LiAlH4是指氢化铝锂;PCC是指吡啶氯铬酸盐;mCPBA是指间氯过氧苯甲酸;(S,S)-Noyori’s催化剂是指[(1S,2S)-N-(对甲苯磺酰基)-1,2-二苯基-1,2-乙二胺](对异丙基甲苯)钌;DMF是指N,N-二甲基甲酰胺;TMS是指四甲基硅烷基;TBAF是指四丁基氟化铵;rt是指室温;Py是指吡啶;NIS是指N-碘代琥珀酰亚胺;TFA或TFAA是指三氟乙酸酐;Pd(PPh3)4是指四三苯基膦钯;dioxane是指二氧六环;Pd(OAc)2是指醋酸钯;Bu4NBr是指四丁基溴化胺;BAST是指二乙胺基三氟化硫。
本申请的中间体和化合物还可以以不同的互变异构体形式存在,并且所有这样的形式包含于本申请的范围内。术语“互变异构体”或“互变异构体形式”是指可经由低能垒互变的不同能量的结构异构体。例如,质子互变异构体(也称为质子转移互变异构体)包括经由质子迁移的互变,如酮-烯醇及亚胺-烯胺异构化。质子互变异构体的具体实例是咪唑部分,其中质子可在两个环氮间迁移。价互变异构体包括通过一些成键电子的重组的互变。互变异构体的非限制性实例包括但不限于。
本申请还包括与本文中记载的那些相同的,但一个或多个原子被原子量或质量数不同于自然中通常发现的原子量或质量数的原子置换的同位素标记的本申请化合物。可结合到本申请化合物的同位素的实例包括氢、碳、氮、氧、磷、硫、氟、碘和氯的同位素,诸如分别为2H、3H、11C、13C、14C、13N、15N、15O、17O、18O、31P、32P、35S、18F、123I、125I和36Cl等。
某些同位素标记的本申请化合物(例如用3H及14C标记的那些)可用于化合物和/或底物组织分布分析中。氚化(即3H)和碳-14(即14C)同位素对于由于它们易于制备和可检测性是尤其优选的。正电子发射同位素,诸如15O、13N、11C和18F可用于正电子发射断层扫描(PET)研究以测定底物占有率。通常可以通过与公开于下文的方案和/或实施例中的那些类似的下列程序,通过同位素标记试剂取代未经同位素标记的试剂来制备同位素标记的本申请化合物。
此外,用较重同位素(诸如氘(即2H))取代可以提供某些由更高的代谢稳定性产生的治疗优点(例如增加的体内半衰期或降低的剂量需求),并且因此在某些情形下可能是优选的,其中氘取代可以是部分或完全的,部分氘取代是指至少一个氢被至少一个氘取代。
本申请化合物可以是不对称的,例如,具有一个或多个立体异构体。除非另有说明,所有立体异构体都包括,如对映异构体和非对映异构体。本申请的含有不对称碳原子的化合物可以以光学活性纯的形式或外消旋形式被分离出来。光学活性纯的形式可以从外消旋混合物拆分,或通过使用手性原料或手性试剂合成。
具体实施方式
下面通过实施例对本申请进行详细描述,但并不意味着对本申请任何不利限制。本文已经详细地描述了本申请,其中也公开了其具体实施例方式,对本领域的技术人员而言,在不脱离本申请精神和范围的情况下针对本申请具体实施方式进行各种变化和改进将是显而易见地。
中间体1:1-(2-氨基-5-乙基苯基)-3-戊醇的合成
1.1 4-乙基-2-碘苯胺
向250mL单口瓶中投入4-乙基苯胺(10.0g),加二氯甲烷(50ml)溶解,加入100ml水溶解的碳酸氢钠(10.4g)溶液,分批次加入碘(22.0g),室温搅拌过夜,TLC检测原料消失。后处理:加饱和亚硫酸钠水溶液,分液,水相用二氯甲烷萃取(50mL×2),合并有机相,用饱和食盐水(20mL×2)洗涤,无水硫酸钠干燥,减压旋蒸除去溶剂得油状物,过柱纯化,收集产物点减压浓缩得4-乙基-2-碘苯胺(12.7g)。
1.2 1-(2-氨基-5-乙基苯基)-戊-1-炔-3-醇
向单口瓶中投入4-乙基-2-碘苯胺(5.0g),加60ml三乙胺溶解,加入戊-1-炔-3醇(2.0g),加入碘化亚铜(183mg),双(三苯基膦)二氯化钯(673mg),氮气置换三次,室温搅拌过夜,取样,TLC检测,原料反应完全。后处理:加水100ml,用乙酸乙酯(30ml×3)萃取三次,合并有机相,用饱和氯化钠水溶液洗,无水硫酸钠干燥,过滤,滤液减压浓缩得油状物,过柱纯化,收集产物点减压浓缩,得1-(2-氨基-5-乙基苯基)-戊-1-炔-3-醇(1.3g)。
1.3 1-(2-氨基-5-乙基苯基)-3-戊醇
于单口瓶中加入1-(2-氨基-5-乙基苯基)-戊-1-炔-3-醇(1.3g),甲醇溶解,加入钯碳(260mg),氢气置换三次,加氢气,室温搅拌过夜。TLC检测反应完全。过滤减压浓缩得1-(2-氨基-5-乙基苯基)-3-戊醇(1.0g)。
中间体2:3-(2-氨基-5-乙基苯基)-1-环丙基丙烷-1-醇
2.1 1-环丙基-3-(三甲基硅基)丙-2-炔-1-醇
向50mL单口瓶中投入三甲基硅乙炔(1.0g),反应溶剂四氢呋喃(10mL),氮气保护,于-40℃条件下加入正丁基锂(2.5M,8mL),加毕,保持该温度反应0.5小时。滴加环丙烷甲醛(0.7g),加毕,该温度下反应1小时,取样,TLC检测,原料点消失,反应完全。后处理:用饱和氯化铵溶液(30mL)淬灭,向体系中加入甲基叔丁基醚(25mL×2),合并有机相,用饱和食盐水(20mL×1)洗涤一次,无水硫酸钠干燥,浓缩,得1-环丙基-3-(三甲基硅基)丙-2-炔-1-醇(1.2g,粗品),直接用于下一步反应。
2.2 1-环丙基丙-2-炔-1-醇
向50mL单口反应瓶中投入化合物1-环丙基-3-(三甲基硅基)丙-2-炔-1-醇(1.2g,粗品),加入甲醇(15mL),加入氟化铯(1.63g),室温反应16小时。取样,TLC检测,原料点消失,反应完全。后处理:向反应体系中加入甲基叔丁基醚(80mL)稀释,用饱和食盐水(30mL×2)洗涤两次,无水硫酸钠干燥,浓缩,得1-环丙基丙基-2-炔-1-醇(1.0g)。
2.3 3-(2-氨基-5-乙基苯基)-1-环丙基丙烷-1-醇
参照中间体1中步骤1.1-1.3的合成方式制得标题化合物。
中间体3:(S)-1-(2-氨基-5-乙基苯基)-3-戊醇的合成
3.1 1-(三甲基硅基)-1-戊炔-3-醇
向500mL三口瓶中依次投入三甲基硅乙炔(7.00g),无水四氢呋喃(100mL),氮气置换三次,乙醇-干冰浴降温至低于-70℃,滴加正丁基锂正己烷溶液(31.4mL,2.5M),滴加完毕,低温搅拌约30分钟,滴加正丙醛(5.7mL),滴加完毕,自然升温至室温。后处理:加入饱和氯化铵水溶液淬灭反应,乙酸乙酯萃取(50mL×3),饱和食盐水(20mL)润洗,无水硫酸钠干燥,浓缩,减压蒸馏得1-(三甲基硅基)-1-戊炔-3-醇(6.96g)。
1H NMR(400MHz,CDCl3)δ4.30(d,J=4.8Hz,1H),1.91(d,J=4.8Hz,1H),1.76–1.66(m,2H),1.00(t,J=7.4Hz,3H),0.23–0.03(m,9H)。
3.2 1-(三甲基硅基)-1-戊炔-3-酮
向250mL单口瓶中投入1-(三甲基硅基)-1-戊炔-3-醇(6.00g),100mL二氯甲烷稀释,冰浴冷却,加入硅胶(20g),分批加入氯铬酸吡啶(9.10g),滴加完毕,室温反应16小时。TLC检测,原料点消失,硅藻土过滤,减压蒸馏得1-(三甲基硅基)-1-戊炔-3-酮(5.00g)。
1H NMR(400MHz,CDCl3)δ2.57(q,J=7.4Hz,2H),1.12(t,J=7.4Hz,3H),0.22(s,9H)。
3.3(S)-1-(三甲基硅基)-1-戊炔-3-醇
向250mL单口瓶中投入1-(三甲基硅基)-1-戊炔-3-酮(2.00g)和无水异丙醇(12mL),加入溶于6mL无水异丙醇的(S,S)-Noyori’s催化剂(1.02g,参照文献Chem.Eur.J.21(32),11387-11392,2015制得)溶液,室温反应0.5小时。TLC检测,原料点消失,减压旋蒸除去溶剂,重复三批次,合并柱层析纯化得(S)-1-(三甲基硅基)-1-戊炔-3-醇(7.50g)。1H NMR(400MHz,CDCl3)δ4.29(t,J=6.4Hz,1H),2.16(s,1H),1.75–1.62(m,2H),0.98(t,J=7.4Hz,3H),0.15(s,9H)。
3.4(S)-1-戊炔-3-醇
向100mL单口瓶中投入(S)-1-(三甲基硅基)-1-戊炔-3-醇(7.50g)和甲醇(50mL),分批加入氟化铯(8.00g),加毕,室温反应16小时。TLC检测,原料点消失,减压旋蒸除去溶剂,柱层析得(S)-1-戊炔-3-醇(4.50g)。
3.5(S)-1-(2-氨基-5-乙基苯基)-3-戊醇的合成
参照中间体1中步骤1.1-1.3的合成方式制得标题化合物。
中间体4:(R)-3-(2-氨基-5-乙基苯基)-1-环丙基丙烷-1-醇
参照中间体3的合成方式制得标题化合物。
实施例1:5-((2,6-二乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((嘧啶-4-基)甲氧基)苯甲醇的合成
1.1 5-氯磺酰-2-羟基苯甲酸甲酯
将2mL氯化亚砜,6mL氯磺酸投入反应瓶中,用冰水浴将其冻至0-5℃。称取2g水杨酸甲酯并缓慢滴入反应瓶中,滴加完毕,继续于室温搅拌反应16小时。将反应液缓慢滴加至冰水中,析出白色固体,待冰完全融化后抽滤得产品,自然风干得到5-氯磺酰-2-羟基苯甲酸甲酯3.0克。
1.2 5-(N-(4-乙基-2-(3-羟基戊基)苯基)氨基磺酰基)-2-羟基苯甲酸甲酯
向25mL单口反应瓶中投入1-(2-氨基-5-乙基苯基)-3-戊醇(0.3g),加入反应溶剂吡啶(5mL),冰浴搅拌下,分批加入5-氯磺酰-2-羟基苯甲酸甲酯(0.47g),加毕,撤掉冰浴,室温反应16小时。取样,TLC监测,原料点消失,送检LC-MS,检测到产物峰420[M-H]-。反应液减压浓缩除去吡啶,残留物用乙酸乙酯(50mL)稀释,用水(20mL×2)洗涤两次,饱和食盐水(20mL×2)洗涤两次,无水硫酸钠干燥,浓缩,残留物柱层析纯化,得标题化合物360mg(MS(ESI)m/z:[M-H]-420.0)。
1.3 5-((2,6-二乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-羟基苯甲酸甲酯
向10mL三口瓶中投入三苯基磷(0.67g),加入四氢呋喃(4mL),氮气置换三次,冰浴条件下,滴加偶氮二甲酸二异丙酯(0.43g),加毕,该温度下搅拌0.5小时;滴加5-(N-(4-乙基-2-(3-羟基戊基)苯基)氨基磺酰基)-2-羟基苯甲酸甲酯(0.36g)的四氢呋喃溶液(4mL),加毕,自然升温反应16小时。取样,TLC检测,原料点消失,送检LC-MS,检测到产物峰402[M-H]-。向反应体系加入乙酸乙酯(60mL)稀释,用水(20mL×2)洗涤两次,饱和食盐水(20mL×3)洗涤三次,无水硫酸钠干燥,浓缩,残留物经柱层析纯化,得标题化合物0.25g(MS(ESI)m/z:402[M-H]-)。
1.4 5-((2,6-二乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((嘧啶-4-基)甲氧基)苯甲酸甲酯
向10mL三口瓶中投入5-((2,6-二乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-羟基苯甲酸甲酯(0.25g),4-羟甲基嘧啶(0.1g)和三苯基磷(0.49g),加入四氢呋喃(6mL),氮气置换三次,冰浴条件下,滴加偶氮二甲酸二异丙酯(0.31g),加毕,自然升温反应16小时。取样,TLC检测,原料点消失,送检LC-MS,检测到产物峰496[M+H]+。向反应体系加入乙酸乙酯(60mL)稀释,用水(20mL×2)洗涤两次,饱和食盐水(20mL×3)洗涤三次,无水硫酸钠干燥,浓缩,残留物经柱层析纯化,得标题化合物0.6g(MS(ESI)m/z:496[M+H]+),包含部分三苯基氧磷,直接用于下一步还原。
1.5 5-((2,6-二乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((嘧啶-4-基)甲氧基)苯甲醇
向25mL单口瓶中投入5-((2,6-二乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((嘧啶-4-基)甲氧基)苯甲酸甲酯(0.60g),无水甲醇(8mL),冰浴冷却至0℃;分批加入硼氢化钠(0.07g),加毕,自然升温反应16小时。取样,TLC监测,原料点消失。送检LC-MS,检测到产物峰468[M+H]+。冰浴条件下,用1N盐酸淬灭,用乙酸乙酯(20mL×3)萃取三次,合并有机相,饱和食盐水(20mL×2)洗涤两次,无水硫酸钠干燥,浓缩,得残留物300mg,直接送perp-HPLC制备,最终制得标题化合物24mg(MS(ESI)m/z:[M+H]+468)。
1H NMR(400MHz,CDCl3)δ9.21(s,1H),8.78(d,J=5.1Hz,1H),7.64(d,J=8.3Hz,1H),7.51(d,J=2.3Hz,1H),7.47(d,J=5.1Hz,1H),7.40(dd,J=8.6,2.3Hz,1H),7.06(dd,J=8.2,1.8Hz,1H),6.81(d,J=8.7Hz,1H),6.79(s,1H),5.23(s,2H),4.72(s,2H),4.20–4.12(m,1H),2.60(q,J=7.6Hz,2H),2.54(m,1H),2.42–2.34(m,1H),1.86–1.69(m,2H),1.65–1.61(m,1H),1.42(ddt,J=32.3,13.2,6.5Hz,2H),1.22(t,J=7.6Hz,3H),0.94(t,J=7.4Hz,3H)。
实施例2:5-((2,6-二乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-(2-(甲磺酰基)乙氧基)苯甲醇的合成
2.1 5-((2,6-二乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-(2-(甲硫基)乙氧基)苯甲酸甲酯
向10mL三口瓶中投入5-((2,6-二乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-羟基苯甲酸甲酯(0.25g),2-(甲硫基)-乙醇(0.068g)和三苯基磷(0.39g),加入四氢呋喃(5mL),氮气置换三次,冰浴条件下,滴加偶氮二甲酸二异丙酯(0.25g),加毕,自然升温反应16小时。取样,TLC检测,原料点消失,送检LC-MS,检测到产物峰478[M+H]+。向反应体系加入乙酸乙酯(60mL)稀释,用水(10mL×2)洗涤两次,饱和食盐水(15mL×2)洗涤三次,无水硫酸钠干燥,浓缩,残留物柱层析纯化,得标题化合物0.5g,(MS(ESI)m/z:478.0[M+H]+)。
2.2 5-((2,6-二乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-(2-(甲硫基)乙氧基)苯甲醇
向25mL单口瓶中投入5-((2,6-二乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-(2-(甲硫基)乙氧基)苯甲酸甲酯(0.5g),无水四氢呋喃(5mL),冰浴冷却至0℃;分批加入四氢铝锂(0.07g),加毕,该温度下反应1小时。取样,TLC监测,原料点消失。送检LC-MS,检测到产物峰449.8[M+H]+。冰浴条件下,用1N HCl淬灭,用乙酸乙酯(10mL×3)萃取三次,合并有机相,饱和食盐水(15mL×2)洗涤两次,无水硫酸钠干燥,浓缩,得标题化合物(500mg,粗品),直接用于下一步反应(MS(ESI)m/z:449.8[M+H]+)。
2.3 5-((2,6-二乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-(2-(甲磺酰基)乙氧基)苯甲醇
向25mL单口瓶中投入5-((2,6-二乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-(2-(甲硫基)乙氧基)苯甲醇(0.50g,粗品),二氯甲烷(5mL),冰浴冷却至0℃;分批加入间氯过氧苯甲酸(0.34g),加毕,自然升温反应16小时。取样,TLC监测,原料点消失。送检LC-MS,检测到产物峰481.9[M+H]+。向反应体系中加入乙酸乙酯(60mL),用水(20mL×2)洗涤两次,饱和碳酸氢钠溶液(20mL×2)洗涤两次,饱和食盐水(20mL×2)洗涤两次,无水硫酸钠干燥,浓缩,得粗品固体600mg,直接送perp-HPLC制备,最终制得标题化合物96mg(MS(ESI)m/z:482.0[M+H]+)。
1H NMR(400MHz,CDCl3):δ7.59(d,J=8.3Hz,1H),7.42(d,J=1.9Hz,1H),7.30–7.26(m,1H),7.08–7.00(m,1H),6.80(s,1H),6.72(d,J=8.7Hz,1H),4.50(d,J=2.0Hz,2H),4.46(t,J=5.2Hz,2H),4.17–4.07(m,1H),3.59–3.44(m,2H),3.06(s,3H),2.93(m,1H),2.59(q,J=7.6Hz,2H),2.43–2.32(m,1H),1.88–1.79(m,1H),1.70(td,J=13.7,6.0Hz,1H),1.57(td,J=14.4,7.4Hz,1H),1.42(dtt,J=19.4,13.0,6.7Hz,2H),1.21(t,J=7.6Hz,3H),0.92(t,J=7.4Hz,3H)。
实施例3:5-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-(3-(甲磺酰基)丙氧基)苯甲醇的合成
3.1 5-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-羟基苯甲酸甲酯
参照实施例1中步骤1.2-1.3的合成方式制得标题化合物0.15g。
3.2 5-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-(3-(甲磺酰基)丙氧基)苯甲醇
参照实施例2的步骤2.1-2.3制得标题化合物62mg(MS(ESI)m/z:508[M+H]+)。
1H NMR(400MHz,CDCl3)δ7.61(d,J=8.3Hz,1H),7.46(d,J=2.0Hz,1H),7.31(dd,J=8.6,2.2Hz,1H),7.04(d,J=7.0Hz,1H),6.82(s,1H),6.71(d,J=8.7Hz,1H),4.55(d,J=5.1Hz,2H),4.14(t,J=5.9Hz,2H),3.62(dt,J=8.3,5.6Hz,1H),3.25(t,J=7.4Hz,2H),2.96(s,3H),2.59(dd,J=15.2,7.6Hz,2H),2.56–2.48(m,2H),2.40–2.31(m,2H),1.96(dt,J=16.2,6.1Hz,1H),1.71(ddd,J=19.8,8.6,6.0Hz,1H),1.58(td,J=12.0,6.1Hz,1H),1.21(t,J=7.6Hz,3H),0.95–0.83(m,1H),0.52–0.42(m,3H),0.34(dd,J=10.6,5.2Hz,1H)。
实施例4:3-(4-(((R)-2,6-二乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-(羟甲基)苯氧基)四氢噻吩1,1-二氧化物的合成
参照实施例3的步骤制得标题化合物60mg(MS(ESI)m/z:494.0[M+H]+)。
1H NMR(400MHz,CDCl3)δ7.62(d,J=8.3Hz,1H),7.59–7.31(m,2H),7.05(d,J=8.3Hz,1H),6.80(s,1H),6.72(dd,J=10.2,8.7Hz,1H),4.64–4.50(m,2H),4.16(dd,J=6.5,4.0Hz,1H),3.43–3.30(m,3H),3.30–3.17(m,1H),2.71–2.36(m,6H),1.89–1.70(m,2H),1.58(d,J=6.4Hz,2H),1.50–1.37(m,2H),1.22(t,J=7.6Hz,3H),0.94(t,J=7.4Hz,3H)。
实施例5:3-((4-(((R)-2,6-二乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-(羟甲基)苯氧基)甲基)四氢噻吩1,1-二氧化物的合成
参照实施例3的步骤制得标题化合物40mg(MS(ESI)m/z:508.0[M+H]+)。
1H NMR(400MHz,CDCl3)δ7.64(d,J=8.3Hz,1H),7.49(t,J=2.1Hz,1H),7.42–7.37(m,1H),7.06(dd,J=8.3,2.0Hz,1H),6.82–6.71(m,2H),4.60(s,2H),4.17(dd,J=12.9,6.4Hz,1H),4.14–4.04(m,2H),3.29(ddd,J=12.6,10.6,6.3Hz,2H),3.10(ddd,J=21.4,13.1,9.1Hz,2H),3.03–2.93(m,1H),2.59(q,J=7.6Hz,2H),2.42(ddd,J=23.2,14.9,7.4Hz,2H),2.27–2.14(m,1H),1.94–1.68(m,2H),1.67–1.58(m,2H),1.43(ddd,J=24.4,13.6,7.0Hz,2H),1.22(t,J=7.6Hz,3H),0.94(t,J=7.4Hz,3H)。
实施例6:5-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((4-甲基-4H-1,2,4-三唑-3-基)甲氧基)苯甲醇的合成
/>
参照实施例1的步骤制得标题化合物33mg(MS(ESI)m/z:483.0[M+H]+)。
1H NMR(400MHz,CDCl3)δ8.05(s,1H),7.59(d,J=8.3Hz,1H),7.48(d,J=2.1Hz,1H),7.29–7.24(m,1H),7.03(dd,J=8.3,1.5Hz,1H),6.94(d,J=8.7Hz,1H),6.83(s,1H),5.25(s,2H),4.53(s,2H),3.75(s,3H),3.65–3.52(m,2H),2.59(dd,J=15.1,7.6Hz,2H),2.52(dd,J=8.7,7.0Hz,1H),1.96(dt,J=16.3,6.1Hz,1H),1.71(dq,J=8.6,5.9Hz,1H),1.58(td,J=12.0,6.1Hz,1H),1.21(t,J=7.6Hz,3H),0.94–0.83(m,1H),0.53–0.40(m,3H),0.37–0.29(m,1H)。
实施例7:5-(((S)-2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((嘧啶-4-基)甲氧基)苯甲醇的合成
参照实施例1的步骤制得标题化合物11mg(MS(ESI)m/z:480[M+H]+)。
1H NMR(400MHz,CDCl3)δ9.20(s,1H),8.77(d,J=5.1Hz,1H),7.64(d,J=8.3Hz,1H),7.53(d,J=2.0Hz,1H),7.47(d,J=5.0Hz,1H),7.39(dd,J=8.6,2.2Hz,1H),7.07–7.02(m,1H),6.80(d,J=8.9Hz,2H),5.23(s,2H),4.72(s,2H),3.65(dt,J=8.4,5.7Hz,1H),2.59(dd,J=15.1,7.6Hz,2H),2.56–2.50(m,1H),1.96(dt,J=16.2,6.1Hz,2H),1.74(ddd,J=19.8,8.5,5.9Hz,1H),1.65–1.57(m,1H),1.22(t,J=7.6Hz,3H),0.90(ddd,J=16.4,10.8,6.0Hz,1H),0.49(ddd,J=19.2,9.5,3.8Hz,3H),0.35(dd,J=10.3,5.5Hz,1H)。
实施例8:3-((4-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-(羟甲基)苯氧基)甲基)硫杂环丁烷1,1-二氧化物的合成
参照实施例3的步骤制得标题化合物32mg(MS(ESI)m/z:506[M+H]+)。
1H NMR(400MHz,CDCl3)δ7.62(d,J=8.3Hz,1H),7.45(d,J=2.1Hz,1H),7.31(dd,J=8.6,2.3Hz,1H),7.04(dd,J=8.3,1.5Hz,1H),6.83(s,1H),6.70(d,J=8.7Hz,1H),4.63–4.52(m,2H),4.34(dd,J=14.6,10.1Hz,2H),4.21(dd,J=5.6,2.8Hz,1H),4.18(d,J=5.1Hz,2H),3.63(dt,J=8.4,5.6Hz,1H),3.10–2.99(m,1H),2.74(s,1H),2.59(q,J=7.5Hz,2H),2.53(dd,J=8.7,6.9Hz,1H),1.97(dt,J=16.3,6.1Hz,1H),1.71(t,J=6.6Hz,2H),1.59(dt,J=19.5,6.1Hz,1H),1.22(t,J=7.6Hz,3H),0.89(ddd,J=13.2,8.8,6.7Hz,1H),0.54–0.42(m,3H),0.34(dd,J=10.8,5.2Hz,1H)。
实施例9:3-((4-((2,6-二乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-(羟甲基)苯氧基)硫杂环丁烷1,1-二氧化物的合成
参照实施例3的步骤制得标题化合物54mg(MS(ESI)m/z:480[M+H]+)。
1H NMR(400MHz,CDCl3)δ:7.63(d,J=8.3Hz,1H),7.55(d,J=2.0Hz,1H),7.40(dd,J=8.5,2.2Hz,1H),7.06(d,J=8.2Hz,1H),6.80(s,1H),6.57(d,J=8.6Hz,1H),5.16–5.09(m,1H),4.60(ddd,J=11.2,6.6,3.4Hz,4H),4.24(dd,J=15.4,2.6Hz,2H),4.20–4.10(m,1H),2.59(q,J=7.6Hz,2H),2.45–2.34(m,1H),2.19(dt,J=13.2,6.9Hz,1H),1.87–1.68(m,2H),1.63(d,J=7.2Hz,1H),1.51–1.36(m,2H),1.22(t,J=7.6Hz,3H),0.94(t,J=7.4Hz,3H)。
实施例10:5-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((1,5-二甲基-1H-1,2,3-三氮唑-4-基)甲氧基)苯甲醇的合成
实施例11:5-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((1,4-二甲基-1H-1,2,3-三氮唑-5-基)甲氧基)苯甲醇的合成
10.1 2-(丁-2-炔-1-基氧基)-5-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)苯甲酸甲酯
向50mL原底烧瓶中加入5-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-羟基苯甲酸甲酯(250mg),1-溴-2-丁炔(95.4mg),碘化钾(10mg)和N,N-二甲基甲酰胺(12mL),混合液在室温搅拌12小时。取样,送检LC-MS,检测到产物峰468.2[M+1]+。反应液冷却到室温,乙酸乙酯(100mL)稀释,有机相饱和食盐水(30mL×3)洗,无水硫酸钠干燥,过滤,减压旋蒸除去溶剂,硅胶柱层析得到标题化合物280mg(MS(ESI)m/z 468.2[M+1]+)。
10.2 5-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((5-甲基-1-((三甲硅基)甲基)-1H-1,2,3-三氮唑-4-基)甲氧基)苯甲酸甲酯和5-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((4-甲基-1-((三甲硅基)甲基)-1H-1,2,3-三氮唑-5-基)甲氧基)苯甲酸甲酯
向50mL圆底烧瓶中投入2-(丁-2-炔-1-基氧基)-5-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)苯甲酸甲酯(150mg),用N,N-二甲基甲酰胺(4.5mL)和甲醇(0.5mL)溶解,向其中加入碘化亚铜(4.5mL)和三甲基硅基叠氮甲烷(249mg),所得反应混合物在氮气氛围下加热搅拌三天。取样,送检LC-MS,检测到产物峰597.2[M+1]+。反应液冷却到室温,乙酸乙酯(120mL)稀释,有机相用饱和食盐水(30mL×3)洗,无水硫酸钠干燥,过滤,减压旋蒸除去溶剂,经Prep-HPLC纯化得到的120mg粗品(MS(ESI)m/z 596.8[M+1]+)后,再经过制备TLC板分离分别得到5-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((5-甲基-1-((三甲硅基)甲基)-1H-1,2,3-三氮唑-4-基)甲氧基)苯甲酸甲酯(72mg)和5-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((4-甲基-1-((三甲硅基)甲基)-1H-1,2,3-三氮唑-5-基)甲氧基)苯甲酸甲酯(49.6mg)。
10.3 5-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((1,5-二甲基-1H-1,2,3-三氮唑-4-基)甲氧基)苯甲酸甲酯
向25mL圆底烧瓶中投入5-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((5-甲基-1-((三甲硅基)甲基)-1H-1,2,3-三氮唑-4-基)甲氧基)苯甲酸甲酯(89mg)和四氢呋喃(2mL),向其中加入四丁基氟化铵(58.4mg),所得混合液室温搅拌3小时。取样,送检LC-MS,检测到产物峰525.1[M+1]+。将反应液用乙酸乙酯(60mL)稀释,有机相用水(20mL×2)洗,饱和食盐水(20mL)洗,无水硫酸钠干燥,过滤,减压旋蒸除去溶剂得到标题化合物(90mg),粗品直接投入下一步。
10.4 5-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((1,5-二甲基-1H-1,2,3-三氮唑-4-基)甲氧基)苯甲醇
向25mL圆底烧瓶中投入5-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((1,5-二甲基-1H-1,2,3-三氮唑-4-基)甲氧基)苯甲酸甲酯(80mg)和四氢呋喃(2mL),于0℃冷却,向其中加入四氢铝锂(17.4mg),所得混合液于0℃搅拌30分钟。取样,送检LC-MS,检测到产物峰497.1[M+1]+。将反应液用水(20μL)淬灭,反应液用四氢呋喃(30mL)稀释,加入10%的氢氧化钠溶液(20μL),搅拌5分钟,加入水(60μL),加入无水硫酸镁搅拌10分钟,硅藻土过滤,滤液减压旋干,经Prep-HPLC纯化得标题化合物27mg(HPLC纯度99.28%,MS(ESI)m/z 497.1[M+1]+)。
1H NMR(400MHz,CDCl3):δ7.66(d,J=8.4Hz,1H),7.48(d,J=2.4Hz,1H),7.40(dd,J=8.4,2.4Hz,1H),7.06(dd,J=8.4,1.6Hz,1H),7.01(d,J=8.8Hz,1H),6.85(s,1H),5.18(s,2H),4.55(d,J=5.6Hz,2H),3.98(s,3H),3.66(dt,J=8.4,5.6Hz,1H),2.65–2.59(m,2H),2.58–2.51(m,1H),2.40(br.s,1H),2.34(s,3H),2.06–1.97(m,1H),1.80–1.72(m,1H),1.66–1.56(m,1H),1.24(t,J=7.6Hz,3H),0.98–0.88(m,1H),0.56–0.45(m,3H),0.40–0.34(m,1H).
实施例11:5-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((1,4-二甲基-1H-1,2,3-三氮唑-5-基)甲氧基)苯甲醇
参照实施例10的步骤10.3和10.4以同样的方式合成标题化合物9mg(HPLC纯度99.02%,MS(ESI)m/z 497.1[M+1]+).
1H NMR(400MHz,CDCl3):δ7.65(d,J=8.4Hz,1H),7.53(d,J=2.0Hz,1H),7.41(d,J=8.4Hz,1H),7.07(dd,J=8.4,1.6Hz,1H),6.89(d,J=8.8Hz,1H),6.86(s,1H),5.10(s,2H),4.56(d,J=5.2Hz,2H),4.07(s,3H),3.72–3.60(m,1H),2.65–2.54(m,3H),2.36(s,3H),2.05–1.96(m,1H),1.80–1.73(m,1H),1.67–1.59(m,1H),1.24(t,J=7.6Hz,3H),0.97–0.88(m,1H),0.57–0.43(m,3H),0.40–0.33(m,1H).
实施例12:5-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((3,5-二甲基异恶唑-4-基)甲氧基)苯甲醇的合成
参照实施例1中步骤1.4-1.5的合成方式制得标题化合物82.21mg(HPLC纯度98.46%,MS(ESI)m/z:497.1[M+1]+)。
1H NMR(400MHz,CDCl3)δ7.64(d,J=8.3Hz,1H),7.51(d,J=2.3Hz,1H),7.39(dd,J=8.6,2.4Hz,1H),7.04(dd,J=8.3,1.9Hz,1H),6.86(d,J=8.7Hz,1H),6.84(s,1H),4.84(s,2H),4.55(d,J=5.6Hz,2H),3.65(dt,J=8.5,5.6Hz,1H),2.60(dd,J=9.4,5.7Hz,2H),2.55(dd,J=8.0,5.8Hz,1H),2.40(s,3H),2.27(s,3H),2.21(t,J=5.7Hz,1H),2.00(dt,J=16.3,6.1Hz,1H),1.76–1.69(m,1H),1.67–1.56(m,1H),1.22(t,J=7.6Hz,3H),0.91(dt,J=8.2,5.2Hz,1H),0.55–0.41(m,3H),0.39–0.29(m,1H).
实施例13:5-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((嘧啶-5-基)甲氧基)苯甲醇的合成
参照实施例1中步骤1.4-1.5的合成方式制得标题化合物43mg(MS(ESI)m/z:480.0[M+H]+)。
1H NMR(400MHz,CDCl3)δ9.23(s,1H),8.82(s,2H),7.64(d,J=8.3Hz,1H),7.55(d,J=1.8Hz,1H),7.39(dd,J=8.6,2.1Hz,1H),7.05(d,J=8.2Hz,1H),6.86(d,J=8.6Hz,1H),6.83(s,1H),5.14(s,2H),4.63(s,2H),3.65(dt,J=8.3,5.7Hz,1H),2.63–2.50(m,3H),2.21(s,1H),1.97(dt,J=16.3,6.1Hz,1H),1.76(dd,J=8.4,5.7Hz,1H),1.60(td,J=12.3,6.1Hz,1H),1.22(t,J=7.6Hz,3H),0.96–0.85(m,1H),0.55–0.42(m,3H),0.35(dd,J=10.5,5.6Hz,1H).
实施例14:5-((6-(环戊-1-烯-1-基)-2-环丙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲醇的合成
14.1 5-((2-环丙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-羟基苯甲酸甲酯
参照实施例1中步骤1.2-1.3的合成方式制得标题化合物720mg。
14.2 5-((2-环丙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯
向50mL单口瓶中投入5-((2-环丙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-羟基苯甲酸甲酯(720mg),加15ml N,N-二甲基甲酰胺溶解,加入对甲苯磺酸-4-吡喃甲酯(650mg),碳酸钾(514mg),加入碘化钾(15mg),油浴70℃反应16小时,取样,TLC检测,原料点消失。后处理:加水100ml,用乙酸乙酯(30ml×3)萃取三次,合并有机相,用50mL饱和食盐水洗涤,无水硫酸钠干燥,减压旋蒸除去溶剂得标题化合物1.1g(粗品)。
14.3 5-((2-环丙基-6-碘-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯
向50mL单口瓶中投入5-((2-环丙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯(600mg),加5ml三氟乙酸溶解,冰浴降温,分批加入N-碘代丁二酰亚胺(292mg),加料毕升至室温搅拌过夜,取样,TLC检测,原料点消失,送检LC-MS,无MS信号。后处理:加水50ml,用乙酸乙酯(20ml×3)萃取三次,合并有机相,用亚硫酸钠水溶液洗,碳酸钠水溶液洗,饱和食盐水洗涤,无水硫酸钠干燥,减压旋蒸除去溶剂得标题化合物660mg。
14.4 5-((6-(环戊-1-烯-1-基)-2-环丙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯
向单口瓶中投入5-((2-环丙基-6-碘-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯(140mg)、1-环戊烯硼酸频哪醇酯(67mg),用1,4-二氧六环(4ml)溶解,加入150mg碳酸铯,水(31mL),四三苯基磷钯(13mg),氮气置换并保护,80℃搅拌过夜。TLC检测反应完全,LC-MS检测到产物峰552.1[M+1]+。加水(50ml),用乙酸乙酯(20ml×3)萃取三次,合并有机相,饱和食盐水洗涤,无水硫酸钠干燥,减压旋蒸除去溶剂得标题化合物220mg(粗品,MS(ESI)m/z 552.1[M+1]+)。
14.5 5-((6-(环戊-1-烯-1-基)-2-环丙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲醇
于100ml单口瓶中加入5-((6-(环戊-1-烯-1-基)-2-环丙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯(220mg),加无水THF 5ml溶解,冰浴降温,分批加入四氢铝锂(44mg),加料完毕,冰浴下搅拌30min,TLC检测反应完全,LC-MS:524.0[M+1]+。加1ml水淬灭,补加10ml乙酸乙酯,无水硫酸钠干燥。过滤,减压浓缩得220mg粗品。分析制备得12.63mg(HPLC纯度:99.3%,MS(ESI)m/z:524.0[M+1]+)。
1H NMR(400MHz,CDCl3)δ7.71(d,J=8.5Hz,1H),7.55(d,J=2.2Hz,1H),7.37(dd,J=8.6,2.3Hz,1H),7.30(dd,J=8.5,1.7Hz,1H),7.06(s,1H),6.75(d,J=8.7Hz,1H),6.14(s,1H),4.61(d,J=5.9Hz,2H),4.01(dd,J=11.3,3.7Hz,2H),3.85(d,J=6.3Hz,2H),3.68(dt,J=8.6,5.5Hz,1H),3.44(t,J=11.0Hz,2H),2.63(ddd,J=15.9,10.7,6.8Hz,3H),2.55–2.42(m,2H),2.22–1.95(m,5H),1.68(dd,J=12.2,3.1Hz,2H),1.62(dd,J=13.3,5.7Hz,1H),1.47(qd,J=12.4,4.4Hz,2H),0.96–0.84(m,1H),0.49(qd,J=12.4,5.6Hz,3H),0.35(dd,J=9.1,4.1Hz,1H).
实施例15:5-((2-环丙基-6-(2,3-二氢呋喃-2-基)-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲醇的合成
15.1 5-((2-环丙基-6-(2,3-二氢呋喃-2-基)-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯
向单口瓶中投入5-((2-环丙基-6-碘-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯(实施例26.3,270mg)、2,3-二氢呋喃(310mg),用N,N-二甲基甲酰胺(2ml)溶解,加入110mg醋酸钾,354mg四丁基溴化胺,5mg醋酸钯,氮气置换并保护,35℃搅拌过夜。TLC检测反应完全,LC-MS检测到产物峰,554.1[M+1]+。体系加水和乙酸乙酯萃取,有机层干燥浓缩得标题化合物450mg(粗品,MS(ESI)m/z 554.1[M+1]+)。
15.2 5-((2-环丙基-6-(2,3-二氢呋喃-2-基)-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲醇
于100ml单口瓶中加入原料12(450mg),加重蒸THF 10ml溶解,冰浴降温,分批加入四氢铝锂(93mg),加料完毕,冰浴下搅拌30min,TLC检测反应完全,LC-MS,526.3[M+1]+。加1ml水淬灭,补加10ml乙酸乙酯,无水硫酸钠干燥。过滤,减压浓缩得300mg油状物。分析制备得标题化合物92.12mg(HPLC纯度:96.7%,MS(ESI)m/z:526.3[M+1]+)。
1H NMR(400MHz,CDCl3)δ7.76(d,J=8.5Hz,1H),7.45(d,J=8.8Hz,1H),7.41(dd,J=8.0,4.4Hz,1H),7.19(dd,J=11.1,4.2Hz,1H),7.03(d,J=6.3Hz,1H),6.76(d,J=8.5Hz,1H),6.42(d,J=1.8Hz,1H),5.45(ddd,J=10.5,8.8,4.9Hz,1H),5.03–4.94(m,1H),4.59(d,J=5.9Hz,2H),4.02(dd,J=11.3,3.9Hz,2H),3.85(d,J=6.3Hz,2H),3.69(dt,J=8.6,5.5Hz,1H),3.44(t,J=11.1Hz,2H),3.05(ddd,J=15.2,10.7,2.3Hz,1H),2.69–2.51(m,2H),2.18–1.98(m,3H),1.74(t,J=6.6Hz,2H),1.68–1.57(m,2H),1.47(qd,J=12.4,4.5Hz,2H),0.97–0.83(m,1H),0.59–0.42(m,3H),0.34(dd,J=7.4,5.3Hz,1H)。
实施例16:5-((2-环丙基-6-(氧杂环丁-3-基)-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲醇的合成
/>
16.1 N-(4-溴苯基)-2,2,2-三氟乙酰胺
向100mL单口瓶中投入对溴苯胺(5.0g)和二氯甲烷(25mL),向其中加入三乙胺(2.96g),混合液于0℃冷却,滴入三氟乙酸酐(6.14g),所得反应液逐渐升至室温搅拌5小时。取样,TLC检测,原料点消失。将反应液用二氯甲烷(100mL)稀释,饱和食盐水(30mLx2)洗,有机相减压旋干,硅胶柱层析分离得N-(4-溴苯基)-2,2,2-三氟乙酰胺7.42g。
16.2 N-(4-(3-羟基氧杂环丁-3-基)苯基)三氟乙酰胺
将N-(4-溴苯基)-2,2,2-三氟乙酰胺(7.42g)投入250mL三口瓶中,加入无水四氢呋喃(80mL)溶解,氮气保护。将反应体系冷却到-78℃,向其中滴加入正丁基锂(24.5mL),并于该温度下搅拌30分钟。向其中滴加入3-氧杂环丁酮(4.4g)。所得混合物液在-78℃搅拌2小时后,逐渐升至室温搅拌1小时。取样,TLC检测,原料点消失。用饱和氯化铵溶液(50mL)淬灭反应,乙酸乙酯(80mLx3)萃取,合并有机相,无水硫酸钠干燥,过滤,减压旋蒸除去溶剂,硅胶柱层析分离得N-(4-(3-羟基氧杂环丁-3-基)苯基)三氟乙酰胺(6.56g)。
16.3 N-(4-(3-氟氧杂环丁-3-基)苯基)三氟乙酰胺
向250mL单口瓶中投入N-(4-(3-羟基氧杂环丁-3-基)苯基)三氟乙酰胺(2.0g),四氢呋喃(7mL)和二氯甲烷(70mL)。将反应体系冷却到-78℃,向其中滴加入二乙胺基三氟化硫(1.85g),并于该温度下搅拌30分钟。取样,送检LC-MS,检测到产物峰261.9[M-1]-。将反应液用饱和氯化铵溶液(15mL)淬灭,用二氯甲烷(300mL)稀释,饱和食盐水(100mL)洗,无水硫酸钠干燥,过滤,减压旋蒸除去溶剂,硅胶柱层析分离得N-(4-(3-氟氧杂环丁-3-基)苯基)三氟乙酰胺625mg(MS(ESI)m/z 261.9[M-1]-)。
16.4 N-(4-(氧杂环丁-3-基)苯基)三氟乙酰胺
向50mL单口瓶中投入N-(4-(3-氟氧杂环丁-3-基)苯基)三氟乙酰胺(400mg),加入氢氧化钯碳(192mg)和乙醇(14mL),加上氢气球,氢气置换三次,室温反应3小时。取样,送检LC-MS,检测到产物峰243.9[M-1]-。硅藻土过滤,浓缩得N-(4-(氧杂环丁-3-基)苯基)三氟乙酰胺(400mg,粗品),直接投入下一步。
16.5 4-(氧杂环丁-3-基)苯胺
将N-(4-(氧杂环丁-3-基)苯基)三氟乙酰胺(400mg)溶于乙醇(14mL)中,向其中加入氢氧化钠的水溶液(3.3mL,1N),所得混合液于80℃加热搅拌3小时。取样,送检LC-MS,检测到产物峰150.1[M+1]+。减压旋除乙醇,用水(15mL)稀释,乙酸乙酯(40mLx3)萃取,合并有机相,无水硫酸钠干燥,过滤,减压旋蒸除去溶剂,硅胶柱层析(PE:EA=10:0至1:1洗脱),得黄色固体4-(氧杂环丁-3-基)苯胺140mg
16.6 5-((2-环丙基-6-(氧杂环丁-3-基)-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-羟基苯甲酸甲酯
参照中间体1中步骤1.1-1.3以及实施例1中步骤1.2-1.3的合成方式制得标题化合物239mg(MS(ESI)m/z 444.2[M+1]+)。
16.7 5-((2-环丙基-6-(氧杂环丁-3-基)-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯
向25mL单口瓶中投入5-((2-环丙基-6-(氧杂环丁-3-基)-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-羟基苯甲酸甲酯(209mg),对甲苯磺酸-4-吡喃甲酯(255mg),碳酸钾(130mg),碘化钾(7.8mg)和N,N-二甲基甲酰胺(14mL),70℃反应24小时。取样,送检LC-MS,检测到产物峰542.2[M+1]+。反应液冷却到室温,乙酸乙酯(100mL)稀释,有机相饱和食盐水(30mL×3)洗,无水硫酸钠干燥,过滤,减压旋蒸除去溶剂,硅胶柱层析分离得到标题化合物90mg(MS(ESI)m/z 542.3[M+1]+)。
16.8 5-((2-环丙基-6-(氧杂环丁-3-基)-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲醇
向25mL三口瓶中投入5-((2-环丙基-6-(氧杂环丁-3-基)-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯(60mg),无水四氢呋喃(4mL),氮气置换3次,冰浴冷却至0℃。分批将氢化铝锂(8.4mg)加入到反应液中,保持0℃反应1小时。取样,送检LC-MS,检测到产物峰514.2[M+1]+。在冰浴下用水(0.02mL)淬灭反应,再滴入10%的氢氧化钠水溶液(0.01mL),继续滴入水(0.06mL),室温搅拌5分钟。反应液用四氢呋喃(30mL)稀释,加入适量无水硫酸镁,搅拌15分钟。硅藻土过滤,滤液减压浓缩,粗品经PREP-HPLC纯化得标题化合物18.73mg(HPLC纯度99.95%,MS(ESI)m/z 514.2[M+1]+.
1H NMR(400MHz,CDCl3):δ7.76(d,J=8.4Hz,1H),7.55(d,J=2.4Hz,1H),7.42(dd,J=8.4,2.4Hz,1H),7.22(dd,J=8.4,2.0Hz,1H),7.08(s,1H),6.79(d,J=8.4Hz,1H),5.11-5.02(m,2H),4.75(dd,J=12.0,6.0Hz,2H),4.63(d,J=6.0Hz,2H),4.23-4.11(m,1H),4.09-3.98(m,2H),3.88(d,J=6.4Hz,2H),3.74-3.63(m,1H),3.45(t,J=11.2Hz,2H),2.73-2.60(m,1H),2.26-2.04(m,3H),1.79-1.71m,3H),1.70-1.62(m,1H),1.58-1.38(m,2H),0.97-0.85(m,1H),0.59-0.42(m,3H),0.41-0.31(m,1H)。
实施例17:(S)-5-((2-环丙基-6-乙基-3,4-二氢-1,8-萘啶-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲醇的合成
17.1 5-乙基-3-碘-2-吡啶胺
向100mL单口瓶中投入5-乙基-2-吡啶胺(1.1g),加10ml三氟乙酸溶解,冰浴降温,分批加入碘代丁二酰亚胺(2.1g)加料毕升至室温搅拌过夜,取样,TLC检测,原料消失。LC-MS检测到产物峰248.8[M+1]+.后处理:加水50ml,用乙酸乙酯萃取(30mL×3),合并有机相,用碳酸钠水溶液调PH至中性,用50mL饱和食盐水洗涤,无水硫酸钠干燥,过滤减压旋蒸除去溶剂得5-乙基-3-碘-2-吡啶胺1.4g。
17.2(S)-3-(2-氨基-5-乙基吡啶-3-基)-1-环丙基-2-丙炔-1-醇
向单口瓶中投入5-乙基-3-碘-2-吡啶胺(680mg),加10ml三乙胺溶解,加入(S)-1-环丙基-2-丙炔-1-醇(394mg),加入碘化亚铜(26mg),95mg二-三苯基膦二氯化钯,氮气置换三次,室温搅拌过夜,取样,TLC检测,原料反应完全。LC-MS检测217.1[M+1]+,后处理:加水100ml,用乙酸乙酯(50mlx3)萃取三次,合并有机相,用饱和氯化钠水溶液洗,无水硫酸钠干燥,过滤,滤液减压浓缩得油状物,过柱纯化,收集产物点减压浓缩,得(S)-3-(2-氨基-5-乙基吡啶-3-基)-1-环丙基-2-丙炔-1-醇(630mg)。
17.3(R)-3-(2-氨基-5-乙基吡啶-3-基)-1-环丙基-1-丙醇
于单口瓶中加入(S)-3-(2-氨基-5-乙基吡啶-3-基)-1-环丙基-2-丙炔-1-醇(630mg),15ml甲醇,5ml乙酸乙酯溶解,加入120mg氢氧化钯碳,氢气置换三次,加氢气,油浴45℃搅拌过夜。LC-MS检测221.1[M+1]+。原料反应完全,过滤减压浓缩得标题化合物(510mg)。
17.4(R)-1-环丙基-3-(5-乙基-2-碘吡啶-3-基)-1-丙醇
向单口瓶中加入(R)-3-(2-氨基-5-乙基吡啶-3-基)-1-环丙基-1-丙醇(470mg),加亚硝酸钠(295mg),加二甲亚砜(3ml)溶解搅拌,滴加二甲亚砜(2ml)溶解的碘化钾(1.77g),氢碘酸(1.1g)溶液,滴加毕,氮气置换三次,油浴55℃搅拌过夜。取样,TLC检测,原料点消失,LC-MS检测331.6[M+1]+。后处理:将反应液倒入50ml饱和碳酸钾冰水溶液中,用乙酸乙酯30mlx3萃取三次,合并有机相,食盐水洗,无水硫酸钠干燥,过滤,减压浓缩,得油状物,柱层析分离,收集产物点,减压浓缩得标题化合物(140mg).
17.5(R)-5-(N-(3-(3-环丙基-3-羟基丙基)-5-乙基吡啶-2-基)氨基磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯
向50mL单口瓶中投入(R)-1-环丙基-3-(5-乙基-2-碘吡啶-3-基)-1-丙醇(140mg),加5-胺磺酰基-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯(210mg,其合成详见专利CN201710913429.3),加1,4-二氧六环(2ml)溶解,加入碘化亚铜(16mg),N,N’-二甲基乙二胺(8mg),室温搅拌过夜,取样,TLC检测,原料点少量剩余,送检LC-MS,检测到产物峰,532.9[M+1]+。后处理:加水50ml,用乙酸乙酯(20ml×3)萃取三次,合并有机相,用50mL饱和食盐水洗涤,无水硫酸钠干燥,减压旋蒸除去溶剂得油状物,柱层析分离,收集产物点,减压浓缩得标题化合物(120mg).
17.6(S)-5-((2-环丙基-6-乙基-3,4-二氢-1,8-萘啶-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯
向250mL三口瓶中加入三苯基膦(180mg),加3ml重蒸四氢呋喃溶解,氮气置换三次,冰浴降温至0℃,滴加116mg偶氮二甲酸二异丙酯,滴加完毕,冰浴下搅拌30分钟,滴加(R)-5-(N-(3-(3-环丙基-3-羟基丙基)-5-乙基吡啶-2-基)氨基磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯(120mg)的四氢呋喃(2ml)溶液,滴加完毕升至室温搅拌过夜。取样,TLC检测,原料点少量剩余。硅胶拌样,柱层析分离,收集产物点,减压浓缩得标题化合物(粗品,140mg)。
17.7(S)-5-((2-环丙基-6-乙基-3,4-二氢-1,8-萘啶-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲醇
于100ml单口瓶中加入(S)-5-((2-环丙基-6-乙基-3,4-二氢-1,8-萘啶-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯(140mg),加甲醇5ml溶解,加热回流,分批加入硼氢化钠(56mg),加料完毕,回流30min,TLC检测反应完全,LC-MS,487.3[M+1]+。加水50ml,用乙酸乙酯(20ml×3)萃取三次,合并有机相,用50mL饱和食盐水洗涤,无水硫酸钠干燥。过滤,减压浓缩得200mg油状物。Prep-HPLC制备得标题化合物2.1mg(HPLC纯度:98.57%,MS(ESI)m/z:487.3[M+1]+)。
1H NMR(400MHz,CDCl3)δ8.15–8.07(m,2H),7.92(d,J=2.0Hz,1H),7.20(s,1H),6.88(d,J=8.4Hz,1H),4.70(d,J=6.1Hz,2H),4.16(dt,J=9.5,3.5Hz,1H),4.02(dd,J=11.1,3.7Hz,2H),3.90(d,J=6.4Hz,2H),3.44(td,J=11.9,1.8Hz,2H),3.02(ddd,J=30.4,15.6,9.1Hz,1H),2.74(dd,J=17.0,4.8Hz,1H),2.50(q,J=7.6Hz,2H),2.12(dd,J=15.8,3.9Hz,2H),2.08–2.03(m,1H),1.98(dd,J=13.3,5.7Hz,1H),1.73(d,J=13.1Hz,2H),1.47(ddd,J=25.4,12.3,4.6Hz,2H),1.16(t,J=7.6Hz,3H),1.00–0.85(m,2H),0.75(dt,J=9.2,4.6Hz,1H),0.55(q,J=5.8Hz,2H),0.35–0.25(m,1H).
实施例18:5-((6-(氮杂环丁烷-1-基)-2-环丙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲醇的合成
18.1 5-((6-(氮杂环丁烷-1-基)-2-环丙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯
向闷罐中投入5-((2-环丙基-6-碘-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯(实施例26.3,160mg)、氮杂环丁烷盐酸盐(254mg),N,N-二甲基甲酰胺(5ml),碳酸铯(678mg),碘化亚铜(2.5mg),,2-异丁酰基环己酮(13mg),80℃搅拌过夜。TLC检测少量原料剩余,LC-MS检测到产物峰:541.1[M+1]+。后处理:加水50ml,用乙酸乙酯(20ml×3)萃取三次,合并有机相,饱和食盐水洗涤,无水硫酸钠干燥,过滤减压浓缩得标题化合物(粗品,390mg,MS(ESI)m/z 541.1)。
18.2 5-((6-(氮杂环丁烷-1-基)-2-环丙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲醇
于100ml单口瓶中加入5-((6-(氮杂环丁烷-1-基)-2-环丙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯(390mg),加无水四氢呋喃10ml溶解,冰浴降温,分批加入四氢铝锂(82mg),加料完毕,冰浴下搅拌30min,TLC检测反应完全,LC-MS,513.3[M+1]+。加1ml水淬灭,补加10ml乙酸乙酯,无水硫酸钠干燥。过滤,减压浓缩得370mg油状物。HPLC分析制备得标题化合物(9.87mg,HPLC纯度99.2%,MS(ESI)m/z:513.3[M+1]+)。
1H NMR(400MHz,CDCl3)δ7.52(d,J=8.7Hz,1H),7.37(d,J=2.3Hz,1H),7.28(dd,J=8.6,2.4Hz,1H),6.72(d,J=8.7Hz,1H),6.31(dd,J=8.7,2.7Hz,1H),6.00(d,J=2.6Hz,1H),4.57(s,2H),4.00(dd,J=11.3,3.6Hz,2H),3.86–3.76(m,6H),3.60(dd,J=14.4,6.4Hz,1H),3.41(td,J=11.9,1.8Hz,2H),2.39–2.28(m,3H),2.06(td,J=11.5,5.7Hz,1H),1.80–1.60(m,5H),1.44(qd,J=12.2,4.4Hz,3H),0.86(ddt,J=10.7,8.1,3.9Hz,1H),0.45(dddd,J=12.8,10.6,8.2,3.0Hz,3H),0.37–0.28(m,1H).
实施例19:5-((2-环丙基-6-二氟甲基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲醇的合成
19.1 5-((2-环丙基-6-甲酰基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯
向50mL单口瓶中投入5-((2-环丙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯(实施例26.2,370mg),加二氯甲烷(9ml)溶解,氮气保护,降温至-20℃,滴加四氯化钛(434mg),滴加毕,-20℃搅拌1小时,滴加二氯甲基甲醚(263mg),滴加毕-20℃下搅拌16小时,取样,TLC检测,原料点消失。后处理:加氯化铵水溶液50ml淬灭,用乙酸乙酯(20ml×3)萃取三次,合并有机相,饱和食盐水洗涤,无水硫酸钠干燥,减压旋蒸除去溶剂得标题化合物500mg。
19.2 5-((2-环丙基-6-二氟甲基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯
向单口瓶中投入5-((2-环丙基-6-甲酰基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯(500mg),用6ml二氯甲烷溶解,冰浴降温,滴加二乙胺基三氟化硫,滴加毕室温搅拌过夜。TLC检测少量原料剩余,LC-MS检测到产物峰,536.1[M+1]+。后处理:加水溶液50ml淬灭,用二氯甲烷(20ml×3)萃取三次,合并有机相,饱和食盐水洗涤,无水硫酸钠干燥,过滤减压浓缩得标题化合物(粗品,500mg,MS(ESI)m/z536.1[M+1]+)。
19.3 5-((2-环丙基-6-二氟甲基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲醇
于100ml单口瓶中加入5-((2-环丙基-6-二氟甲基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯甲酸甲酯(500mg),加无水四氢呋喃10ml溶解,冰浴降温,分批加入四氢铝锂(75mg),加料完毕,冰浴下搅拌30分钟,TLC检测反应完全,LC-MS,508.2[M+1]+。加1ml水淬灭,补加10ml乙酸乙酯,无水硫酸钠干燥。过滤,减压浓缩得470mg油状物,经HPLC分析制备得标题化合物(17.7mg,HPLC纯度97.8%,MS(ESI)m/z:508.2[M+1]+)。
1H NMR(400MHz,CDCl3)δ7.88(d,J=8.5Hz,1H),7.58(d,J=2.4Hz,1H),7.42(dd,J=8.6,2.4Hz,1H),7.33(d,J=8.5Hz,1H),7.19(s,1H),6.79(d,J=8.7Hz,1H),6.60(t,J=56.6Hz,1H),4.64(d,J=4.7Hz,2H),4.03(dd,J=11.2,3.5Hz,2H),3.87(d,J=6.4Hz,2H),3.80–3.66(m,1H),3.44(td,J=11.9,1.9Hz,2H),2.74(dt,J=16.6,8.2Hz,1H),2.26(dt,J=16.6,5.5Hz,1H),2.16–2.03(m,1H),1.94(s,1H),1.71(dt,J=7.6,5.2Hz,4H),1.48(ddd,J=25.0,12.4,4.5Hz,2H),0.97–0.82(m,1H),0.51(tdd,J=16.5,7.5,3.9Hz,3H),0.40–0.30(m,1H).
实施例20:3-((4-(((S)-2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-(羟甲基)苯氧基)甲基)四氢噻吩1,1-二氧化物的合成
参照实施例3的步骤得到标题化合物36mg(M S(ESI)m/z:520.2[M+H]+)。
1H NMR(400MHz,CDCl3)δ7.64(d,J=8.3Hz,1H),7.49(d,J=2.1Hz,1H),7.37(dd,J=8.6,2.4Hz,1H),7.05(dd,J=8.3,1.9Hz,1H),6.83(s,1H),6.72(d,J=8.7Hz,1H),4.65–4.52(m,2H),4.13–4.03(m,2H),3.69–3.60(m,1H),3.28(ddd,J=12.8,10.5,6.2Hz,2H),3.16–3.02(m,2H),3.01–2.92(m,1H),2.63–2.51(m,3H),2.49–2.38(m,1H),2.26–2.12(m,2H),1.99(dt,J=16.3,6.1Hz,1H),1.73(ddt,J=8.8,6.0,4.4Hz,1H),1.65–1.60(m,1H),1.22(t,J=7.6Hz,3H),0.96–0.84(m,1H),0.57–0.41(m,3H),0.40–0.30(m,1H)。
实施例21:4-((4-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-(羟甲基)苯氧基)甲基)二氢呋喃-2(3H)-酮的合成
/>
参照实施例3的步骤得到标题化合物14.3mg(M S(ESI)m/z:486.2[M+H]+)。
1H NMR(400MHz,CDCl3)δ7.64(d,J=8.3Hz,1H),7.49(dd,J=6.3,2.3Hz,1H),7.39–7.31(m,1H),7.05(dd,J=8.3,1.9Hz,1H),6.83(s,1H),6.72(d,J=8.7Hz,1H),4.55(d,J=3.6Hz,2H),4.53–4.48(m,1H),4.32(ddd,J=9.5,4.0,2.1Hz,1H),4.07(qd,J=9.3,5.7Hz,2H),3.64(dt,J=8.5,5.6Hz,1H),3.05(ddq,J=13.8,9.3,4.7Hz,1H),2.78(dd,J=17.6,9.1Hz,1H),2.59(q,J=7.7Hz,2H),2.50(ddd,J=17.6,4.5,1.7Hz,1H),2.11–1.92(m,2H),1.78–1.66(m,1H),1.66–1.55(m,2H),1.22(t,J=7.6Hz,3H),0.95–0.82(m,1H),0.56–0.42(m,3H),0.38–0.30(m,1H)。
实施例22:4-((4-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-(羟甲基)苯氧基)甲基)-1-甲基吡咯烷-2-酮的合成
参照实施例3的步骤得到标题化合物15.3mg(M S(ESI)m/z:499.3[M+H]+)。
1H NMR(400MHz,CDCl3)δ7.64(d,J=8.3Hz,1H),7.52(d,J=1.3Hz,1H),7.34(d,J=8.6Hz,1H),7.05(dd,J=8.3,1.5Hz,1H),6.84(s,1H),6.72(d,J=8.7Hz,1H),4.64–4.46(m,2H),4.09–3.91(m,2H),3.64(td,J=8.5,4.2Hz,2H),3.31(ddd,J=10.1,4.3,1.5Hz,1H),2.87(s,4H),2.69–2.45(m,5H),2.30(dd,J=17.0,5.2Hz,1H),2.00(dt,J=16.4,6.0Hz,1H),1.72(dt,J=14.3,7.0Hz,1H),1.60(td,J=11.9,6.1Hz,1H),1.22(t,J=7.6Hz,3H),0.90(ddd,J=16.1,8.2,5.2Hz,1H),0.56–0.40(m,3H),0.40–0.26(m,1H)。
实施例23:(5-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-(哒嗪-4-基甲氧基)苯基)甲醇的合成
参照实施例3的步骤得到标题化合物15.9mg(M S(ESI)m/z:480.0[M+H]+)。
1H NMR(400MHz,CDCl3)δ9.25(s,1H),9.21(dd,J=5.3,1.0Hz,1H),7.63(d,J=8.3Hz,1H),7.58(d,J=2.3Hz,1H),7.56(dd,J=5.3,2.3Hz,1H),7.36(dd,J=8.6,2.3Hz,1H),7.05(dd,J=8.3,1.9Hz,1H),6.83(s,1H),6.78(d,J=8.7Hz,1H),5.18(s,2H),4.71(s,2H),3.65(dt,J=8.5,5.7Hz,1H),2.59(q,J=7.5Hz,2H),2.55–2.51(m,1H),1.96(dt,J=16.3,6.2Hz,1H),1.82–1.69(m,2H),1.60(td,J=12.0,6.2Hz,1H),1.22(t,J=7.6Hz,3H),0.96–0.84(m,1H),0.57–0.40(m,3H),0.40–0.28(m,1H)。
实施例24:(5-((2-环丙基-6-乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((5-甲基-1,3,4-恶二唑-2-基)甲氧基)苯基)甲醇的合成
参照实施例3的步骤得到标题化合物6.5mg(M S(ESI)m/z:484.2[M+H]+)。
1H NMR(400MHz,CDCl3)δ7.64(d,J=8.3Hz,1H),7.53(d,J=2.2Hz,1H),7.39(dd,J=8.6,2.3Hz,1H),7.05(dd,J=8.3,1.6Hz,1H),6.93(d,J=8.7Hz,1H),6.83(s,1H),5.28(s,2H),4.62(s,2H),3.64(dt,J=8.5,5.6Hz,1H),2.63–2.58(m,2H),2.56(s,3H),2.56–2.50(m,1H),2.35(s,1H),1.97(dt,J=16.3,6.1Hz,1H),1.77–1.68(m,1H),1.64–1.56(m,1H),1.22(t,J=7.6Hz,3H),0.95–0.85(m,1H),0.55–0.41(m,3H),0.34(dd,J=10.3,5.5Hz,1H).
实施例25:(5-((2-环丙基-6-(吡咯烷-1-基)-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-(((四氢-2H-吡喃-4-基)甲氧基)苯基)甲醇的合成
参照实施例18的步骤得到标题化合物7.0mg(M S(ESI)m/z:527.1[M+H]+)。
1H NMR(400MHz,CDCl3)δ7.57(d,J=8.8Hz,1H),7.43(d,J=2.2Hz,1H),7.37(dd,J=8.6,2.3Hz,1H),6.78(d,J=8.6Hz,1H),6.49(dd,J=8.8,2.7Hz,1H),6.16(d,J=2.6Hz,1H),4.68–4.57(m,2H),4.04(dd,J=11.2,3.6Hz,2H),3.88(d,J=6.4Hz,2H),3.66(dd,J=14.3,6.5Hz,1H),3.51–3.42(m,2H),3.28(dd,J=9.7,6.5Hz,4H),2.40(dt,J=15.4,6.3Hz,1H),2.11(dd,J=9.6,5.8Hz,1H),2.02(dd,J=7.9,5.1Hz,4H),1.85(ddd,J=25.7,13.1,6.5Hz,2H),1.78–1.67(m,3H),1.56–1.43(m,3H),0.93–0.89(m,1H),0.60–0.36(m,4H)。
实施例26:1-(2-环丙基-1-((3-(羟甲基)-4-((四氢-2H-吡喃-4-基)甲氧基)苯基)磺酰基)-1,2,3,4-四氢喹啉-6-基)吡咯烷-2-酮的合成
参照实施例18的步骤得到标题化合物7.0mg(MS(ESI)m/z:541.2[M+H]+)。
1H NMR(400MHz,CDCl3)δ7.77(d,J=8.8Hz,1H),7.46–7.39(m,2H),7.32(d,J=1.8Hz,1H),7.19(dd,J=8.8,2.4Hz,1H),6.77(d,J=8.7Hz,1H),4.59(dd,J=40.7,14.4Hz,2H),4.01(dd,J=11.3,3.6Hz,2H),3.95–3.76(m,4H),3.69(dd,J=14.0,5.9Hz,1H),3.44(t,J=11.0Hz,2H),2.74(s,1H),2.60(t,J=8.1Hz,2H),2.56–2.44(m,1H),2.16(dt,J=16.9,5.6Hz,2H),2.12–2.04(m,1H),1.89(dt,J=12.8,6.2Hz,2H),1.78–1.68(m,3H),1.61–1.53(m,1H),1.47(ddd,J=25.0,12.4,4.5Hz,2H),0.94–0.85(m,1H),0.57–0.43(m,3H),0.42–0.34(m,1H)。
实施例27:(5-((2-环丙基-6-(恶唑-5-基)-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-(((四氢-2H-吡喃-4-基)甲氧基)苯基)甲醇的合成
参照实施例14的步骤得到标题化合物20.5mg(MS(ESI)m/z:525.1[M+H]+)。
1H NMR(400MHz,CDCl3)δ7.89(s,1H),7.86(d,J=8.6Hz,1H),7.61(d,J=2.3Hz,1H),7.49(dd,J=8.6,2.1Hz,1H),7.42(dd,J=8.6,2.4Hz,1H),7.32(d,J=1.8Hz,1H),7.30(s,1H),6.78(d,J=8.7Hz,1H),4.63(s,2H),4.01(dd,J=11.4,3.4Hz,2H),3.86(d,J=6.3Hz,2H),3.73(dt,J=8.8,5.2Hz,1H),3.43(td,J=11.8,1.8Hz,2H),2.79–2.66(m,1H),2.29–2.17(m,1H),2.13–1.93(m,2H),1.71(dd,J=13.2,4.3Hz,4H),1.47(ddd,J=16.7,12.4,4.8Hz,2H),0.94–0.86(m,1H),0.60–0.44(m,3H),0.36(td,J=6.6,2.3Hz,1H)。
实施例28:(5-((2-环丙基-6-吗啉代-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-((四氢-2H-吡喃-4-基)甲氧基)苯基)甲醇的合成
参照实施例18的步骤得到标题化合物3.2mg(M S(ESI)m/z:543.1[M+H]+)。
1H NMR(400MHz,CDCl3)δ7.67(d,J=8.8Hz,1H),7.48(d,J=2.4Hz,1H),7.39(dd,J=8.4,2.4Hz,1H),6.82(dd,J=8.8,2.8Hz,1H),6.78(d,J=8.8Hz,1H),6.54(d,J=2.8Hz,1H),4.63(s,2H),4.04(dd,J=11.4,3.6Hz,2H),3.95-3.80(m,6H),3.69-3.62(m,1H),3.52-3.40(m,2H),3.20–3.09(m,4H),2.56–2.46(m,1H),2.16–2.05(m,1H),2.00–1.88(m,2H),1.79-1.69(m,3H),1.60–1.44(m,3H),0.93–0.88(m,1H),0.57–0.41(m,3H),0.40-0.33(m,1H)。
实施例29:(5-((2,6-二乙基-3,4-二氢喹啉-1(2H)-基)磺酰基)-2-(2-(吡嗪-2-基)乙氧基)苯基)甲醇的合成
参照实施例1的步骤得到标题化合物36mg(MS(ESI)m/z:481.9[M+H]+)。
1H NMR(400MHz,CDCl3)δ8.56(d,J=0.9Hz,1H),8.53–8.49(m,1H),8.47(d,J=2.5Hz,1H),7.62(d,J=8.3Hz,1H),7.44(d,J=2.1Hz,1H),7.34(dd,J=8.6,2.3Hz,1H),7.03(dd,J=8.3,1.5Hz,1H),6.79(s,1H),6.76(s,1H),4.54–4.44(m,2H),4.40(t,J=5.9Hz,2H),4.18–4.09(m,1H),3.36(s,1H),3.31(t,J=5.9Hz,2H),2.58(q,J=7.6Hz,2H),2.42–2.32(m,1H),1.86(dt,J=16.0,6.4Hz,1H),1.75–1.65(m,1H),1.58(td,J=14.4,7.4Hz,1H),1.49–1.33(m,2H),1.21(t,J=7.6Hz,3H),0.92(t,J=7.4Hz,3H)。
实施例30:N-((R)-1-(4-(乙基磺酰基)苯基)-2-羟乙基)-4-(2-甲基-1-(((反式-4-(三氟甲基)环己基)甲基)氨基)丙基)苯甲酰胺的合成
30.1 4-(1-羟基-2-甲基丙基)苯甲酸甲酯
向150mL圆底烧瓶中投入4-甲酰基苯甲酸甲酯(3.0g)和四氢呋喃(60mL),混合物在0℃搅拌。向其中加入异丙基溴化镁(18.3mL),反应混合物在0℃搅拌1小时。将反应液逐渐升至室温搅拌3小时。取样,送检LC-MS,检测到产物分子量209.0[M+1]+。将反应用饱和氯化铵(20mL)淬灭,将反应液减压旋干,加入水(50mL),用乙酸乙酯(50mLx3)萃取,合并有机相,无水硫酸钠干燥,过滤,滤液减压旋干,硅胶柱层析(PE:EA=10:0至10:3洗脱)得4-(1-羟基-2-甲基丙基)苯甲酸甲酯1.4g(MS(ESI)m/z 209.0[M+1]+)。
30.2 4-异丁酰基苯甲酸甲酯
将4-(1-羟基-2-甲基丙基)苯甲酸甲酯(445mg)溶于二氯甲烷(10mL)中,向其中加入氯铬酸吡啶盐(507mg),所得混合物液在室温搅拌10小时。取样,送检LC-MS,检测到产物分子量207.0[M+1]+。将反应用硅藻土过滤,滤液减压旋干,粗品硅胶柱层析得4-异丁酰基苯甲酸甲酯356mg(MS(ESI)m/z 207.0[M+1]+)。
30.3 4-异丁酰基苯甲酸
将4-异丁酰基苯甲酸甲酯(350mg)溶于甲醇(2mL)和水(1mL)中,向其中加入一水合氢氧化锂(214mg),所得混合物于室温搅拌3小时。取样,送检LC-MS,检测到产物分子量193.0[M+1]+。将反应液减压旋干,加入水(10mL),用1N盐酸调节PH至3,用乙酸乙酯(20mLx3)萃取,合并有机相,无水硫酸钠干燥,过滤,滤液减压旋干,得4-异丁酰基苯甲酸330mg。
30.4(R)-N-(1-(4-(乙基磺酰基)苯基)-2-羟乙基)-4-异丁酰基苯甲酰胺
将4-异丁酰基苯甲酸(52mg)溶于N,N-二甲基甲酰胺(2mL)中,加入1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(150mg)和1-羟基苯并三唑(84.5mg),所得混合物室温搅拌30分钟,加入(R)-2-氨基-2-(4-(乙基磺酰基)苯基)乙醇(119.3mg),搅拌5分钟,加入N-甲基吗啡啉(158mg),所得混合物室温搅拌20.5小时。取样,送检LC-MS,检测到产物分子量403.9[M+1]+。将反应液用乙酸乙酯(100mL)稀释,用饱和食盐水(30mLx3)洗,有机相用无水硫酸钠干燥,过滤,滤液减压旋干,硅胶柱层析得标题化合物75mg(MS(ESI)m/z 403.8[M+1]+)。
30.5N-((R)-1-(4-(乙基磺酰基)苯基)-2-羟乙基)-4-(2-甲基-1-(((反式-4-(三氟甲基)环己基)甲基)氨基)丙基)苯甲酰胺
向10mL圆底烧瓶中投入(R)-N-(1-(4-(乙基磺酰基)苯基)-2-羟乙基)-4-异丁酰基苯甲酰胺(25mg),反式-4-(三氟甲基)环己基)甲氨(13.5mg)和异丙醇(2mL),向其中加入钛酸异丙酯(52.9mg),所得混合物回流搅拌4小时,后冷却至室温。向其中加入硼氢化钠(2.4mg),室温搅拌1小时。取样,送检LC-MS,检测到产物分子量568.9[M+1]+。将反应用水(0.1mL)淬灭,将反应液用硅藻土过滤,滤液减压旋干,粗品送pre-HPLC制备,得标题化合物9mg(MS(ESI)m/z 568.9[M+1]+)。
1H NMR(400MHz,CDCl3):δ7.89(d,J=8.4Hz,2H),7.80(d,J=8.0Hz,2H),7.61(d,J=8.4Hz,2H),7.37(d,J=8.0Hz,2H),7.13(d,J=6.4Hz,1H),5.36-5.27(m,1H),4.12-3.97(m,2H),3.37(d,J=6.4Hz,1H),3.11(q,J=7.6Hz,2H),2.34-2.26(m,1H),2.19-2.12(m,1H),2.01-1.91(m,4H),1.89-1.80(m,2H),1.43-1.24(m,7H),0.97(d,J=6.8Hz,3H),0.93-0.83(m,2H),0.77(d,J=6.8Hz,3H)。
实施例31:N-((5-(乙基磺酰基)吡啶-2-基)甲基)-4-(2-甲基-1-(((反式-4-(三氟甲基)环己基)甲基)氨基)丙基)苯甲酰胺的合成
参照实施例30中步骤30.4-30.5的合成方式制得标题化合物22mg(MS(ESI)m/z539.8[M+1]+)。
1H NMR(400MHz,CDCl3):δ9.04(s,1H),8.15(d,J=8.0Hz,1H),7.82(d,J=8.0Hz,2H),7.56(d,J=8.0Hz,1H),7.48(s,1H),7.36(d,J=8.0Hz,2H),4.87(d,J=5.2Hz,2H),3.35(d,J=6.8Hz,1H),3.16(q,J=7.2Hz,2H),2.28(dd,J=11.6,6.0Hz,1H),2.15(dd,J=11.6,7.2Hz,1H),1.98-187(m,4H),1.87-1.75(m,2H),1.40-1.23(m,7H),0.95(d,J=6.8Hz,3H),0.92-0.82(m,2H),0.75(d,J=6.8Hz,3H).。
实施例32:6-(1-乙基-2-((反式-4-(三氟甲基)环己基)甲基)肼基)-N-((5-(乙基磺酰基)吡啶-2-基)甲基)烟酰胺的合成
32.1 6-肼基烟酸叔丁酯
向250mL圆底烧瓶中投入6-氯烟酸叔丁酯(3.0g)和叔丁醇(60mL),混合物回流搅拌至物料完全溶解。向其中加入水合肼(7.05g),继续加热搅拌5小时。取样,送检LC-MS,检测到产物峰210.0[M+1]+。将反应液减压旋干,用甲基叔丁基醚(200mL)稀释,水(60mLx3)洗,饱和食盐水(60mL)洗。有机相无水硫酸钠干燥,过滤,滤液减压旋干,得6-肼基烟酸叔丁酯2.6g。
32.2 6-(2-((反式-4-(三氟甲基)环己烷羰基)肼基)烟酸叔丁酯
将反式-4-(三氟甲基)环己烷甲酸(2.25g)溶于N,N-二甲基甲酰胺(50mL)中,加入1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(2.75g)和1-羟基苯并三唑(1.55g),所得混合物室温搅拌30分钟,加入6-肼基烟酸叔丁酯(2.0g),搅拌5分钟,加入N-甲基吗啡啉(2.90g),所得混合物室温搅拌22.5小时。取样,送检LC-MS,检测到产物分子量387.9[M+1]+。将反应液用乙酸乙酯(200mL)稀释,用饱和食盐水(50mLx3)洗,有机相用无水硫酸钠干燥,过滤,滤液减压旋干,硅胶柱层析得标题化合物2.6g(MS(ESI)m/z 388.0[M+1]+)。
32.3 6-(2-((反式-4-(三氟甲基)环己基)甲基)肼基)烟酸叔丁酯
向50mL圆底烧瓶中投入6-(2-((反式-4-(三氟甲基)环己烷羰基)肼基)烟酸叔丁酯(200mg)和四氢呋喃(15mL),混合物在0℃搅拌。向其中加入1M硼烷四氢呋喃溶液(2mL),所得反应液于室温搅拌24小时。取样,送检LC-MS,检测到产物分子量373.9[M+1]+。将反应液用甲醇(15mL)淬灭,所得反应液减压旋干,硅胶柱层析得标题化合物80mg(收率41.5%,MS(ESI)m/z374.0[M+1]+)。
32.4 6-(2-(叔丁氧羰基)-2-((反式-4-(三氟甲基)环己基)甲基)肼基)烟酸叔丁酯
将6-(2-((反式-4-(三氟甲基)环己基)甲基)肼基)烟酸叔丁酯(66mg)溶于二氯甲烷(1.5mL)中,向其中加入二碳酸二叔丁酯(38.6mg),所得反应混合液室温搅拌4小时。取样,送检LC-MS,检测到产物分子量474.0[M+1]+。将反应液减压旋干,粗品经硅胶柱层析得标题化合物80mg。
32.5 6-(1-乙基-2-(叔丁氧羰基)-2-((反式-4-(三氟甲基)环己基)甲基)肼基)烟酸叔丁酯
将6-(2-(叔丁氧羰基)-2-((反式-4-(三氟甲基)环己基)甲基)肼基)烟酸叔丁酯(200mg)溶于N,N-二甲基甲酰胺(2.5mL)中,置于冰浴中冷却,向其中加入钠氢(17mg)搅拌30分钟。滴入碘乙烷(66mg),所得混合液逐渐升至室温搅拌4小时。取样,送检LC-MS,检测到产物分子量502.0[M+1]+。将反应液用乙酸乙酯(100mL)稀释,用饱和食盐水(30mLx3)洗,有机相用无水硫酸钠干燥,过滤,滤液减压旋干,硅胶柱层析得标题化合物200mg(MS(ESI)m/z502.1[M+1]+)。
32.6 6-(1-乙基-2-(叔丁氧羰基)-2-((反式-4-(三氟甲基)环己基)甲基)肼基)烟酸
将6-(1-乙基-2-(叔丁氧羰基)-2-((反式-4-(三氟甲基)环己基)甲基)肼基)烟酸叔丁酯200mg)溶于乙醇(10mL)和水(3mL)中,向其中加入氢氧化钠(48mg),所得混合液加热搅拌24小时。取样,送检LC-MS,检测到产物分子量445.9[M+1]+。将反应液用水(30mL)稀释,减压旋去乙醇,用1N盐酸调节pH=3,水层用乙酸乙酯(50mLx3)萃取,合并有机相,饱和食盐水(50mL)洗。有机相用无水硫酸钠干燥,过滤,滤液减压旋干,得标题化合物174mg(MS(ESI)m/z 445.9[M+1]+)。
32.7 6-(1-乙基-2-(叔丁氧羰基)-2-((反式-4-(三氟甲基)环己基)甲基)肼基)-N-((5-(乙基磺酰基)吡啶-2-基)甲基)烟酰胺
将6-(1-乙基-2-(叔丁氧羰基)-2-((反式-4-(三氟甲基)环己基)甲基)肼基)烟酸(60mg)溶于N,N-二甲基甲酰胺(2mL)中,加入2-(7-氧化苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(56.5mg),搅拌5分钟,加入5-(乙基磺酰基)吡啶-2-基)甲胺(27mg),搅拌5分钟,加入N,N-二异丙基乙胺(34.9mg),所得反应液室温搅拌4小时。取样,送检LC-MS,检测到产物分子量627.8[M+1]+。将反应液用乙酸乙酯(80mL)稀释,用水(30mLx3)洗,饱和食盐水(30mL)洗,有机相用无水硫酸钠干燥,过滤,滤液减压旋干,得标题化合物100mg(MS(ESI)m/z 627.8[M+1]+)。
32.8 6-(1-乙基-2-((反式-4-(三氟甲基)环己基)甲基)肼基)-N-((5-(乙基磺酰基)吡啶-2-基)甲基)烟酰胺
向25mL圆底烧瓶中投入6-(1-乙基-2-(叔丁氧羰基)-2-((反式-4-(三氟甲基)环己基)甲基)肼基)-N-((5-(乙基磺酰基)吡啶-2-基)甲基)烟酰胺(51mg),二氯甲烷(5mL)溶解,向其中加入三氟乙酸(463.5mg),所得反应液室温搅拌5小时。取样,送检LC-MS,检测到产物分子量527.9[M+1]+。将反应液用二氯甲烷(60mL)稀释,用饱和碳酸氢钠(10mLx3)洗,饱和食盐水(20mL)洗,有机相用无水硫酸钠干燥,过滤,滤液减压旋干,送pre-HPLC制备,得标题化合物9.19mg(MS(ESI)m/z 527.8[M+1]+。
1H NMR(400MHz,MeOD):δ9.03(d,J=1.6Hz,1H),8.58(s,1H),8.48(d,J=9.2Hz,1H),8.38(d,J=6.4Hz,1H),7.79(d,J=8.2Hz,1H),7.39(d,J=8.0Hz,1H),4.85(s,2H),3.93(q,J=6.8Hz,2H),3.33-3.30(m,2H),2.87(d,J=6.4Hz,2H),2.22-2.10(m,1H),2.09-1.95(m,4H),1.68-1.55(m,1H),1.43-1.32(m,5H),1.28(t,J=7.2Hz,3H),1.21-1.07(m,2H).。
实施例33:N-((5-(乙基磺酰基)吡啶-2-基)甲基)-6-(2-甲基-1-(((反式-4-(三氟甲基)环己基)甲基)氨基)丙基)烟酰胺的合成
33.1 6-二溴甲基烟酸甲酯
向100mL单口瓶中加入6-甲基烟酸甲酯(3.0g),N-溴代丁二酰亚胺(7.42g)和偶氮二异丁腈(391mg),混合物用二氯乙烷(45mL)溶解。所得反应液在氮气保护下回流搅拌反应8小时。取样,送检LC-MS,检测到产物峰309.7[M+1]+。将反应液用硅藻土过滤,滤液减压旋干,硅胶柱层析得6-二溴甲基烟酸甲酯2.1g。
33.2 6-甲酰基烟酸甲酯
向50mL圆底烧瓶中投入6-二溴甲基烟酸甲酯(1.88g)和乙腈(8mL),于室温搅拌,向其中加入硝酸银(4.14g)的水(8mL)溶液,所得混合物液于50℃加热搅拌24小时。取样,送检LC-MS,检测到产物峰165.9[M+1]+。将反应液冷却到室温,硅藻土过滤,滤液减压旋干,硅胶柱层析得6-甲酰基烟酸甲酯527mg。
33.3 N-((5-(乙基磺酰基)吡啶-2-基)甲基)-6-(2-甲基-1-(((反式-4-(三氟甲基)环己基)甲基)氨基)丙基)烟酰胺单甲酸盐
其余合成步骤参照实施例30所述的方式制得标题化合物3.5mg。
(MS(ESI)m/z 541.0[M+1]+。
1H NMR(400MHz,CDCl3):δ9.18(s,1H),9.06(d,J=2.0Hz,1H),8.29(d,J=7.2Hz,1H),8.20(dd,J=8.0,2.0Hz,1H),7.97(s,1H),7.60(d,J=8.0Hz,1H),7.45(d,J=7.6Hz,1H),4.90(d,J=4.0Hz,2H),4.72(brs,3H),4.11(s,1H),3.17(q,J=7.2Hz,2H),2.91(d,J=7.2Hz,1H),2.72-2.54(m,1H),2.41-2.27(m,1H),2.14-2.03(m,1H),2.00-1.75(m,5H),1.33(t,J=7.2Hz,3H),1.30-1.22(m,2H),1.02(d,J=3.6Hz,3H),0.95-0.85(m,2H),0.82(d,J=3.6Hz,3H).
实施例34:N-((5-(乙基磺酰基)吡啶-2-基)甲基)-3-氟-4-(2-甲基-1-(((反式-4-(三氟甲基)环己基)甲基)氨基)丙基)苯甲酰胺的合成
34.1 4-二溴甲基-3-氟苯甲酸
向100mL单口瓶中加入4-甲基-3-氟苯甲酸(3.0g),N-溴代丁二酰亚胺(8.32g)和过氧化苯甲酰(236mg),混合物用二氯乙烷(40mL)溶解。所得反应液在氮气保护下回流搅拌反应12小时。取样,送检LC-MS,检测到产物峰310.8[M+1]+。将反应液用硅藻土过滤,滤液减压旋干得4-二溴甲基-3-氟苯甲酸6.04g。
34.2 3-氟-4-甲酰苯甲酸
向50mL圆底烧瓶中投入4-二溴甲基-3-氟苯甲酸(6.04g)和乙醇(50mL),于50℃搅拌,向其中加入硝酸银(6.04g)的水(10mL)溶液,所得混合物液于50℃加热搅拌5小时。取样,送检LC-MS,检测到产物峰166.9[M-1]-。将反应液冷却到室温,硅藻土过滤,滤液减压旋干,用水(50mL)稀释,混合液用1N的盐酸调节PH至3,用乙酸乙酯(60mLx3)萃取,合并有机相,无水硫酸钠干燥,过滤,滤液减压旋干得3-氟-4-甲酰苯甲酸5.0g(收率>100%,MS(ESI)m/z 166.9[M-1]-)。
34.3 3-氟-4-甲酰苯甲酸甲酯
向50mL圆底烧瓶中投入3-氟-4-甲酰苯甲酸(2.5g),碳酸氢钾(1.79g)和N,N-二甲基甲酰胺(20mL),向其中加入碘甲烷(3.17g),所得反应混合物室温搅拌24小时。取样,送检LC-MS,检测到产物分子量183.0[M+1]+。将反应液用乙酸乙酯(150mL)稀释,用饱和食盐水(40mLx4)洗,有机相用无水硫酸钠干燥,过滤,滤液减压旋干,硅胶柱层析得3-氟-4-甲酰苯甲酸甲酯600mg。
34.4 N-((5-(乙基磺酰基)吡啶-2-基)甲基)-3-氟-4-(2-甲基-1-(((反式-4-(三氟甲基)环己基)甲基)氨基)丙基)苯甲酰胺
其余合成步骤参照实施例30所述的方式制得标题化合物15.63mg(MS(ESI)m/z557.9[M+1]+)。
1H NMR(400MHz,CDCl3):δ9.05(d,J=2.0Hz,1H),8.17(dd,J=8.0,2.4Hz,1H),7.61(d,J=8.0Hz,1H),7.58-7.52(m,2H),7.49-7.42(m,2H),4.87(d,J=5.2Hz,2H),3.70(d,J=7.2Hz,1H),3.16(q,J=7.2Hz,2H),2.32-2.24(m,1H),2.20-2.12(m,1H),2.00-1.87(m,5H),1.87-1.79(m,1H),1.40-1.22(m,7H),0.99(d,J=6.8Hz,3H),0.94-0.84(m,2H),0.80(d,J=6.8Hz,3H)。
实施例35:N-((5-(乙基磺酰基)吡啶-2-基)甲基)-N-甲基-6-(2-甲基-1-(((反式-4-(三氟甲基)环己基)甲基)氨基)丙基)烟酰胺的合成
35.1((5-(乙基磺酰基)吡啶-2-基)甲基)氨基甲酸叔丁酯
向100mL单口瓶中加入(5-(乙基磺酰基)吡啶-2-基)甲胺盐酸盐(1.57g),二氯甲烷(15mL)和三乙胺(1.726g),向所得反应液中加入二碳酸二叔丁酯(1.24g),混合液室温搅拌5小时。取样,送检LC-MS,检测到产物峰300.9[M+1]+。将反应液旋干,硅胶柱层析得((5-(乙基磺酰基)吡啶-2-基)甲基)氨基甲酸叔丁酯1.24g(MS(ESI)m/z 300.9[M+1]+)。
35.2((5-(乙基磺酰基)吡啶-2-基)甲基)(甲基)氨基甲酸叔丁酯
向25mL圆底烧瓶中投入((5-(乙基磺酰基)吡啶-2-基)甲基)氨基甲酸叔丁酯(400mg)和N,N-二甲基甲酰胺(4mL),于冰浴中冷却,向其中加入钠氢(59mg),所得混合物液于0℃搅拌0.5小时。向其中加入硫酸二甲酯(252.2mg),反应液逐渐升至室温,搅拌3小时。取样,送检LC-MS,检测到产物峰314.9[M+1]+。将反应液用饱和氯化铵溶液(0.1mL)萃取,将反应液用乙酸乙酯(150mL)稀释,饱和氯化钠(40mLx3)洗,有机相无水硫酸钠干燥,过滤,滤液减压旋干,粗品硅胶柱层析(PE:EA=10:0至5:1洗脱)得无色油状液体((5-(乙基磺酰基)吡啶-2-基)甲基)(甲基)氨基甲酸叔丁酯179mg(MS(ESI)m/z 314.9[M+1]+)。
35.3 1-(5-(乙基磺酰基)吡啶-2-基)N-甲基)甲氨盐酸盐
向25mL圆底烧瓶中投入((5-(乙基磺酰基)吡啶-2-基)甲基)(甲基)氨基甲酸叔丁酯(179mg),溶于二氯甲烷(5mL)中,向其中加入盐酸二氧六环溶液(4M,2.8mL),所得混合物室温搅拌4小时。取样,送检LC-MS,检测到产物分子量214.9[M+1]+。将反应液减压旋干,得1-(5-(乙基磺酰基)吡啶-2-基)N-甲基)甲氨盐酸盐164mg。
35.4N-((5-(乙基磺酰基)吡啶-2-基)甲基)-N-甲基-6-(2-甲基-1-(((反式-4-(三氟甲基)环己基)甲基)氨基)丙基)烟酰胺
其余合成步骤以实施例33中的中间体为原料参照实施例30中步骤30.4-30.5的合成方式制得标题化合物42.1mg(MS(ESI)m/z 554.9[M+1]+)。
1H NMR(400MHz,CDCl3):δ9.06(s,1H),8.78-8.62(m,1H),8.19(d,J=7.6Hz,1H),7.79(dd,J=8.0,2.0Hz,1H),7.65-7.40(m,1H),7.39-7.29(m,1H),5.05-4.66(m,2H),3.24-3.05(m,1H),3.24-3.07(m,5H),2.33-2.20(m,1H),2.21-2.11(m,1H),2.00-1.90(m,5H),1.86-1.81(m,1H),1.46-1.15(m,7H),0.95(d,J=5.6Hz,3H),0.91-0.81(m,2H),0.78(d,J=6.4Hz,3H)。
实施例36:N-((R)-1-(4-(乙基磺酰基)苯基)-2-羟乙基)-6-(2-甲基-1-(((反式-4-(三氟甲基)环己基)甲基)氨基)丙基)烟酰胺的合成
参照实施例33的合成方式制得标题化合物12.5mg(MS(ESI)m/z 570.3[M+1]+)。
1H NMR(400MHz,CDCl3):δ9.01(s,1H),8.09(dd,J=8.0,2.4Hz,1H),7.87(d,J=8.4Hz,2H),7.60(d,J=8.4Hz,2H),7.38(d,J=8.0Hz,1H),7.24(d,J=7.2Hz,1H),5.37-5.29(m,1H),4.13-3.97(m,2H),3.45(dd,J=6.4,2.4Hz,1H),3.10(q,J=7.2Hz,2H),2.31-2.25(m,1H),2.17-2.10(m,1H),1.99-1.91(m,4H),1.90-1.80(m,2H),1.41-1.20(m,7H),0.96(d,J=6.8Hz,3H),0.91-0.82(m,2H),0.78(d,J=6.8Hz,3H)。
实施例37:4-(1-((4-氯苯基)氨基)-2-甲基丙基)-N-((R)-1-(4-(乙基磺酰基)苯基)-2-羟乙基)-3-氟苯甲酰胺的合成
参照实施例34的合成方式制得标题化合物5.66mg(MS(ESI)m/z 547.2[M+1]+)。
1H NMR(400MHz,CDCl3):δ7.87(d,J=8.4Hz,2H),7.63(d,J=8.0Hz,1H),7.60(d,J=8.4Hz,2H),7.56(dd,J=10.8,1.6Hz,1H),7.49(t,J=7.6Hz,1H),7.31-7.27(m,2H),7.27-7.24(m,1H),7.21(d,J=8.4Hz,2H),5.34-5.26(m,1H),4.14-3.95(m,2H),3.75(d,J=7.2Hz,1H),3.60(d,J=13.4Hz,1H),3.47(d,J=13.4Hz,1H),3.11(q,J=7.2Hz,2H),1.99-1.90(m,2H),1.29(t,J=7.2Hz,3H),1.01(d,J=6.8Hz,3H),0.80(d,J=6.8Hz,3H)。
实施例38:N-((R)-1-(4-(乙基磺酰基)苯基)-2-羟乙基)-3-氟-4-(2-甲基-1-(((反式-4-(三氟甲基)环己基)甲基)氨基)丙基)苯甲酰胺的合成
参照实施例34的合成方式制得标题化合物9.77mg(MS(ESI)m/z 587.3[M+1]+)。
1H NMR(400MHz,CDCl3):δ7.86(d,J=8.4Hz,2H),7.62–7.56(t,J=6.4Hz,3H),7.52(dd,J=10.4,1.6Hz,1H),7.45(t,J=7.6Hz,1H),7.20(d,J=7.2Hz,1H),5.30–5.25(m,1H),4.09–3.96(m,2H),3.70(d,J=7.2Hz,1H),3.09(q,J=7.2Hz,2H),2.30–2.22(m,1H),2.17–2.11(m,1H),1.96–1.88(m,5H),1.84–1.80(m,1H),1.39–1.22(m,7H),0.98(d,J=6.8Hz,3H),0.94–0.83(m,2H),0.79(d,J=6.8Hz,3H).
实施例39:4-(1-((4-氯苯基)氨基)-2-甲基丙基)-N-((R)-1-(4-(乙基磺酰基)苯基)-2-羟乙基)-3-甲氧基苯甲酰胺的合成
以4-甲基-3-甲氧基苯甲酸为原料参照实施例34的合成方式制得标题化合物19.7mg(MS(ESI)m/z 559.0[M+1]+)。
1H NMR(400MHz,CDCl3):δ7.88(d,J=8.0Hz,2H),7.61(d,J=8.0Hz,2H),7.44(s,1H),7.40-7.33(m,2H),7.27(d,J=8.8Hz,2H),7.24-7.18(m,3H),5.34-5.26(m,1H),4.11-3.96(m,2H),3.85(s,3H),3.72(d,J=7.2Hz,1H),3.57(d,J=13.4Hz,1H),3.42(d,J=13.4Hz,1H),3.11(q,J=7.2Hz,2H),2.06-1.92(m,2H),1.29(t,J=7.2Hz,3H),1.00(d,J=6.8Hz,3H),0.76(d,J=6.8Hz,3H)。
实施例40:6-(1-乙基-2-(((1R,4R)-4-(三氟甲基)环己基)甲基)肼基)-N-((R)-1-(4-(乙基磺酰基)苯基)-2-羟乙基)烟酰胺的合成
40. 1叔丁基2-乙基-2-(5-((((R)-1-(4-(乙基磺酰基)苯基)-2-羟乙基)氨基甲酰基)吡啶-2-基)-1-(((1R,4R)-4-(三氟甲基)环己基)甲基)肼甲酸
将6-(2-(叔丁氧基羰基)-1-乙基-2-((((1R,4R)-4-(三氟甲基)环己基)甲基)肼基)烟酸(30mg)溶于N,N-二甲基甲酰胺(1.5mL)中,加入1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(19.4mg)和1-羟基苯并三唑(11.0mg),所得混合物室温搅拌30分钟,加入(R)-2-氨基-2-(4-(乙基磺酰基)苯基)乙醇(15.4g),搅拌5分钟,加入N-甲基吗啡啉(20.4mg),所得混合物室温搅拌23.5小时。取样,送检LC-MS,检测到产物分子量656.9[M+1]+。将反应液用乙酸乙酯(80mL)稀释,用水(30mLx2)洗,饱和食盐水(30mL)洗,有机相用无水硫酸钠干燥,过滤,滤液减压旋干,得淡黄色油状液体65mg(MS(ESI)m/z 656.9[M+1]+)。
40.2 6-(1-乙基-2-(((1R,4R)-4-(三氟甲基)环己基)甲基)肼基)-N-((R)-1-(4-(乙基磺酰基)苯基)-2-羟乙基)烟酰胺
向10mL圆底烧瓶中投入叔丁基2-乙基-2-(5-((((R)-1-(4-(乙基磺酰基)苯基)-2-羟乙基)氨基甲酰基)吡啶-2-基)-1-(((1R,4R)-4-(三氟甲基)环己基)甲基)肼甲酸(65mg),二氯甲烷(3mL)溶解,向其中加入三氟乙酸(565mg),所得反应液室温搅拌5小时。取样,送检LC-MS,检测到产物分子量556.9[M+1]+。将反应液用二氯甲烷(80mL)稀释,用饱和碳酸氢钠(30mLx2)洗,饱和食盐水(30mL)洗,有机相用无水硫酸钠干燥,过滤,滤液减压旋干,送pre.HPLC制备,得白色固体5mg(MS(ESI)m/z 556.9[M+1]+。
1H NMR(400MHz,CDCl3):δ8.63(s,1H),7.89(d,J=2.4Hz,1H),7.86(d,J=8.4Hz,2H),7.56(d,J=8.4Hz,2H),6.96(d,J=6.8Hz,1H),6.90(d,J=9.2Hz,1H),5.29(dd,J=9.2,6.4Hz,1H),4.08-3.95(m,2H),3.73(q,J=7.2Hz,2H),3.09(q,J=7.2Hz,2H),2.73(d,J=6.4Hz,2H),2.08-1.89(m,6H),1.50-1.41(m,1H),1.38-1.30(m,2H),1.28(t,J=7.2Hz,4H),1.19(t,J=7.2Hz,3H),1.09-0.98(m,2H)。
实施例41:N-((R)-1-(4-(乙基磺酰基)苯基)-2-羟乙基)-3-氟-4-(1-(((4-氟苄基)氨基)-2-甲基丙基)苯甲酰胺的合成
向10mL圆底烧瓶中投入(R)-N-(1-(4-(乙基磺酰基)苯基)-2-羟乙基)-3-氟-4-异丁酰基苯甲酰胺(45mg),(4-氟苯基)甲胺(16.0mg)和异丙醇(2.5mL),向其中加入钛酸异丙酯(91.1mg),所得混合物回流搅拌4小时,后冷却至室温。向其中加入硼氢化钠(4.0mg),室温搅拌1小时。取样,送检LC-MS,检测到产物分子量531.0[M+1]+。将反应用水(0.2mL)淬灭,将反应液用硅藻土过滤,滤液减压旋干,粗品送pre.HPLC制备,得白色固体20.55mg(MS(ESI)m/z 531.0[M+1]+。
1H NMR(400MHz,CDCl3):δ7.86(d,J=8.0Hz,2H),7.63(d,J=8.0Hz,1H),7.59(d,J=8.0Hz,2H),7.56(d,J=10.8Hz,1H),7.51(t,J=7.6Hz,1H),7.27-7.20(m,3H),7.00(t,J=8.8Hz,2H),5.32-5.26(m,1H),4.11-3.95(m,2H),3.76(d,J=7.2Hz,1H),3.59(d,J=13.2Hz,1H),3.46(d,J=13.2Hz,1H),3.11(q,J=7.2Hz,2H),1.99-1.92(m,1H),1.29(t,J=7.2Hz,3H),1.01(d,J=6.8Hz,3H),0.80(d,J=6.8Hz,3H)。
实施例42:6-((S)-1-(4-氯苯甲酰胺基)-2-甲基丙基)-N-((R)-1-(4-(乙基磺酰基)苯基)-2-羟乙基)-5-氟烟酰胺
42.1 2,6-二氯-5-氟烟酸甲酯
向100mL单口瓶中加入2,6-二氯-5-氟烟酸(5.0g)和二氯甲烷(20mL),滴入N,N-二甲基甲酰胺(1滴),所得混合物室温搅拌1小时。减压旋干,再用二氯甲烷(10mL)稀释。向上述溶液中滴入二氯甲烷(20mL)与甲醇(20mL)的混合物液,所得混合液于室温搅拌1小时。将反应液减压旋干,硅胶柱层析(PE:EA=10:0至10:1洗脱)得黄色油状液体5.516g(MS(ESI)m/z 223.9,225.9[M+1]+)。
42.2 2-氯-5-氟-6-甲基烟酸甲酯
向100mL圆底烧瓶中投入2,6-二氯-5-氟烟酸甲酯(2.8g),四三苯基膦钯(1.45g),碳酸钾(4.68g)和二氧六环(32mL),向其中加入三甲基环三硼氧烷(3.1mL),所得混合物于100℃加热搅拌12小时。将反应液冷却到室温,硅藻土过滤,滤液减压旋干,硅胶柱层析(PE:EA=10:0至10:1洗脱)得无色油状液体1.875g(MS(ESI)m/z 204.0[M+1]+)。
42.3 5-氟-6-甲基烟酸甲酯
向50mL圆底烧瓶中投入2-氯-5-氟-6-甲基烟酸甲酯(1.63g),氢氧化钯碳(0.33g),醋酸钠(2.63g)和乙酸乙酯(20mL),所得混合物液于氢气氛围下室温搅拌6小时。将反应液用硅藻土过滤,滤液减压旋干,硅胶柱层析(PE:EA=10:0至10:1洗脱)得白色固体653mg(MS(ESI)m/z 170.1[M+1]+)。
42.4 6-(二溴甲基)-5-氟烟酸甲酯
向50mL圆底烧瓶中投入5-氟-6-甲基烟酸甲酯(650mg),二氯乙烷(12mL),N-溴代琥珀酰亚胺(1.45g)和偶氮二异丁腈(76mg),所得混合物在氮气保护下回流搅拌2天。将反应液用硅藻土过滤,滤液减压旋干,粗品硅胶柱层析(PE:EA=10:0至5:1洗脱)得无色油状液体958mg(MS(ESI)m/z 325.8,327.8,329.7[M+1]+)。
42.5 5-氟-6-甲酰基烟酸甲酯
向25mL圆底烧瓶中投入6-(二溴甲基)-5-氟烟酸甲酯(500mg)和乙腈(3mL),于室温搅拌,向其中加入硝酸银(1.04g)的水(3mL)溶液,所得混合物液于50℃加热搅拌2天。将反应液冷却到室温,硅藻土过滤,滤液减压旋干,硅胶柱层析(PE:EA=10:0至3:1洗脱)得黄色固体135mg(MS(ESI)m/z 184.0[M+1]+)。
42.6(S,E)-6-((((叔丁基亚磺酰基)亚氨基)亚氨基)甲基)-5-氟烟酸甲酯
将5-氟-6-甲酰基烟酸甲酯(135mg)和(S)-2-甲基丙烷-2-亚磺酰胺(121.1mg)溶于二氯乙烷(3mL),向其中加入硫酸铜(352mg),所得混合物于60℃加热搅拌24消失。将反应液冷却到室温,硅藻土过滤,滤液减压旋干,得黄色油状液体200mg,粗品直接投入下一步。
42.7 6-((S)-1-((S)-1,1-二甲基乙基亚磺酰胺基)-2-甲基丙基)-5-氟烟酸甲酯
向25mL圆底烧瓶中投入(S,E)-6-((((叔丁基亚磺酰基)亚氨基)亚氨基)甲基)-5-氟烟酸甲酯(133mg),溶于四氢呋喃(5mL)中,混合物于-78°冷却,向其中滴加入底物异丙基溴化镁的四氢呋喃溶液(0.51mL,1M),反应液逐渐升至室温,共搅拌24小时。将反应液用饱和氯化铵(1mL)淬灭。反应液用水(20mL)稀释,乙酸乙酯(40mLx3)萃取,合并有机相,无水硫酸钠干燥,过滤,滤液减压旋干,粗品送pre.HPLC制备,得淡黄色油状液体42mg。
42.8(S)6-(1-氨基-2-甲基丙基)-5-氟烟酸甲酯二盐酸盐
向25mL圆底烧瓶中投入6-((S)-1-((S)-1,1-二甲基乙基亚磺酰胺基)-2-甲基丙基)-5-氟烟酸甲酯(42mg),溶于二氯甲烷(2.5mL)中,向其中加入盐酸二氧六环溶液(0.16mL),所得混合物室温搅拌24小时。将反应液减压旋干,得乳白色固体(42mg),粗品直接投入下一步。
42.9(S)-6-(1-(4-氯苯甲酰胺基)-2-甲基丙基)-5-氟烟酸甲酯
将(S)6-(1-氨基-2-甲基丙基)-5-氟烟酸甲酯二盐酸盐(42mg)溶于N,N-二甲基甲酰胺(2.5mL)中,加入2-(7-氧化苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(67mg),搅拌5分钟,加入4-氯苯甲酸(25mg),搅拌5分钟,加入N,N-二异丙基乙胺(62mg),所得反应液室温搅拌4小时。将反应液用乙酸乙酯(60mL)稀释,用水(20mLx3)洗,饱和食盐水(20mL)洗,有机相用无水硫酸钠干燥,过滤,滤液减压旋干,硅胶柱层析(PE:EA=10:0至2:1洗脱)得无色油状液体20mg(收率:34.3%)。
42.10(S)-6-(1-(4-氯苯甲酰胺基)-2-甲基丙基)-5-氟烟酸
将(S)-6-(1-(4-氯苯甲酰胺基)-2-甲基丙基)-5-氟烟酸甲酯(20mg)溶于甲醇(1mL)和水(0.5mL)中,向其中加入一水合氢氧化锂(7mg),所得混合物于室温搅拌5小时。将反应液减压旋干,加入水(10mL),用1N盐酸调节PH至3,用乙酸乙酯(30mLx3)萃取,合并有机相,饱和食盐水(10mL)洗,无水硫酸钠干燥,过滤,滤液减压旋干,得白色固体40mg,粗品直接投入下一步。
42.11 6-((S)-1-(4-氯苯甲酰胺基)-2-甲基丙基)-N-((R)-1-(4-(乙基磺酰基)苯基)-2-羟乙基)-5-氟烟酰胺
将(S)-6-(1-(4-氯苯甲酰胺基)-2-甲基丙基)-5-氟烟酸(40mg)溶于N,N-二甲基甲酰胺(2.5mL)中,加入1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(32.9mg)和1-羟基苯并三唑(18.5mg),所得混合物室温搅拌30分钟,加入(R)-2-氨基-2-(4-(乙基磺酰基)苯基)乙醇(26.2mg),搅拌5分钟,加入N-甲基吗啡啉(34.6mg),所得混合物室温搅拌5小时。将反应液用乙酸乙酯(60mL)稀释,用饱和食盐水(20mLx3)洗,有机相用无水硫酸钠干燥,过滤,滤液减压旋干,粗品送pre.HPLC制备,得白色固体10mg(收率15.6%,MS(ESI)m/z562.2[M+1]+,
1H NMR(400MHz,CDCl3):δ9.09(d,J=7.8Hz,1H),9.01(d,J=8.0Hz,1H),8.88(s,1H),8.15(d,J=10.2Hz,1H),7.90(d,J=8.4Hz,2H),7.84(d,J=8.4Hz,2H),7.68(d,J=8.4Hz,2H),7.53(d,J=8.4Hz,2H),5.22–5.03(m,3H),3.78–3.65(m,2H),3.27(q,J=7.2Hz,2H),2.39–2.29(m,1H),1.15–1.02(m,6H),0.76(d,J=6.8Hz,3H)。
实施例43:(R)-N-(1-(4-(乙基磺酰基)苯基)-2-羟乙基)-3-氟-4-(异丙基((6-(三氟甲基)吡啶-2-基)甲基)氨基)苯甲酰胺
43.1 6-(三氟甲基)吡啶甲酸甲酯
向100mL单口瓶中加入6-(三氟甲基)吡啶甲酸(2.0g)和甲醇(25mL),向其中滴入二氯亚砜(1.49g),所得混合物于70℃加热搅拌4小时。将反应液减压旋干,乙酸乙酯(100mL)稀释,饱和碳酸氢钠水溶液(30mL)洗,饱和食盐水(30mL)洗。有机相无水硫酸钠干燥,过滤,滤液减压旋干,得白色固体1.9g(MS(ESI)m/z 206.1[M+1]+)。
43.2(6-(三氟甲基)吡啶-2-基)甲醇
向150mL圆底烧瓶中加入6-(三氟甲基)吡啶甲酸甲酯(1.5g),硼氢化钠(835mg)和四氢呋喃(30mL),混合物于50℃加热搅拌。向反应液中滴加甲醇(6mL),所得反应液于该温度搅拌4小时。将反应液冷却到室温,加入饱和氯化铵溶液(20mL)淬灭反应,减压旋蒸,除去有机溶剂,残留物用水(20mL)稀释,乙酸乙酯(50mLx3)萃取,饱和食盐水(30mLx2)洗,有机相无水硫酸钠干燥,过滤,滤液减压旋干,得无色油状液体1.22g(MS(ESI)m/z204.0[M+1]+)。
43.3(6-(三氟甲基)吡啶-2-基)甲磺酸甲酯
向50mL圆底烧瓶中投入(6-(三氟甲基)吡啶-2-基)甲醇(1.216g),加入二氯甲烷(20mL)溶解。将反应液冷却至0℃,向其中依次滴加入三乙胺(0.834g)和甲烷磺酰氯(865mg)。所得混合物逐渐升至室搅拌24小时。将反应液用二氯甲烷(100mL)稀释,饱和食盐水(30mLx2)洗,有机相无水硫酸钠干燥,过滤,滤液减压旋干,得棕黄色油状液体2.82g(MS(ESI)m/z 256.1[M+1]+)。
43.4(6-(三氟甲基)吡啶-2-基)甲胺
向50mL圆底烧瓶中加入(6-(三氟甲基)吡啶-2-基)甲磺酸甲酯(1.0g)用1.4-二氧六环(10mL)溶解,向混合液中滴加氨水(10mL,28%wt),所得反应混合物室温搅拌24小时。将反应液减压旋干,硅胶柱层析(PE:EA=10:0至5:1洗脱)得白色固体245mg(MS(ESI)m/z177.1[M+1]+)。
43.5 3-氟-4-((((6-(三氟甲基)吡啶-2-基)甲基)氨基)苄腈
向25mL圆底烧瓶中投入(6-(三氟甲基)吡啶-2-基)甲胺(245mg)和3,4-二氟苄腈(193mg)用二甲亚砜(5mL)溶解。所得混合物在70℃加热搅拌9小时。将反应液用乙酸乙酯(100mL)稀释,饱和食盐水(30mLx3)洗,有机相无水硫酸钠干燥,过滤,滤液减压旋干,硅胶柱层析(PE:EA=10:0至3:1洗脱)得白色固体241mg(MS(ESI)m/z 296.1[M+1]+)。
43.6 3-氟-4-(异丙基((6-(三氟甲基)吡啶-2-基)甲基)氨基)苄腈
将3-氟-4-((((6-(三氟甲基)吡啶-2-基)甲基)氨基)苄腈(140mg)溶于N,N-二甲基甲酰胺(2.5mL)中,置于冰浴中冷却。向其中加入钠氢(19mg),所得混合物在0℃搅拌30分钟,向反应液中加入2-碘丙烷(242mg),所得反应液在室温搅拌3小时。将反应液用饱和氯化铵溶液(5mL)淬灭,用乙酸乙酯(120mL)稀释,饱和食盐水(30mLx3)洗,有机相无水硫酸钠干燥,过滤,滤液减压旋干,硅胶柱层析(PE:EA=10:0至2:1洗脱)得无色油状液体57mg(MS(ESI)m/z 338.1[M+1]+)。
43.7 3-氟-4-(异丙基((6-(三氟甲基)吡啶-2-基)甲基)氨基)苯甲酸甲酯
向25mL圆底烧瓶中投入3-氟-4-(异丙基((6-(三氟甲基)吡啶-2-基)甲基)氨基)苄腈(47mg),溶于甲醇(4mL)中。向反应液中加入浓硫酸(0.8mL),所得混合物回流搅拌3天。将反应液冷却至室温,用饱和碳酸氢钠溶液调节PH=7,减压旋除甲醇,残留液加入水(20mL)稀释,乙酸乙酯(40mLx3)萃取,合并有机相,无水硫酸钠干燥,过滤,滤液减压旋干,得无色油状液体50mg,粗品直接投入下一步。
43.8 3-氟-4-(异丙基((6-(三氟甲基)吡啶-2-基)甲基)氨基)苯甲酸
向25mL圆底烧瓶中投入3-氟-4-(异丙基((6-(三氟甲基)吡啶-2-基)甲基)氨基)苯甲酸甲酯(50mg),溶于二氯甲烷(4mL)和水(2mL)中,向其中加入氢氧化锂(17mg),所得混合物室温搅拌3小时。将反应液减压旋除甲醇,残留液用水(15mL)稀释,用1N盐酸调节PH=3,用乙酸乙酯(30mLx3)萃取,合并有机相,饱和食盐水(30mL)洗,无水硫酸钠干燥,过滤,滤液减压旋干,得淡黄色油状液体50mg,粗品直接投入下一步。
43.9(R)-N-(1-(4-(乙基磺酰基)苯基)-2-羟乙基)-3-氟-4-(异丙基((6-(三氟甲基)吡啶-2-基)甲基)氨基)苯甲酰胺
将3-氟-4-(异丙基((6-(三氟甲基)吡啶-2-基)甲基)氨基)苯甲酸(50mg)溶于N,N-二甲基甲酰胺(2.5mL)中,加入1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(40.3mg)和1-羟基苯并三唑(23mg),所得混合物室温搅拌30分钟,加入(R)-2-氨基-2-(4-(乙基磺酰基)苯基)乙醇(32mg),搅拌5分钟,加入N-甲基吗啡啉(42.4mg),所得混合物室温搅拌5小时。取样,送检LC-MS,检测到产物分子量568.3[M+1]+。将反应液用乙酸乙酯(100mL)稀释,用饱和食盐水(30mLx3)洗,有机相用无水硫酸钠干燥,过滤,滤液减压旋干,粗品送pre.HPLC制备,得白色固体12mg(MS(ESI)m/z 568.2[M+1]+,
1H NMR(400MHz,CDCl3):δ7.82–7.69(m,3H),7.57–7.42(m,5H),7.40–7.31(m,1H),7.21–7.05m,1H),6.90–6.39(m,1H),5.19–5.08(m,1.7H),4.54(s,0.7H),4.45(t,J=6.4Hz,0.7H),4.04–3.90(m,1H),3.89–3.83(m,1H),3.15–2.94(m,3H),2.39–1.94(m,1H),1.31–1.14(m,6H),1.02–0.92(m,3H))。
实施例44:(R)-4-(2-(4-氯苯基)-N-异丙基乙酰胺基)-N-(1-(4-(乙基磺酰基)苯基)-2-羟乙基)-3-氟苯甲酰胺
参照上述实施例43的步骤得到标题化合物13.2mg(MS(ESI)m/z:561.1[M+H]+)。
1H NMR(400MHz,CDCl3)δ7.91(d,J=8.1Hz,2H),7.74(d,J=9.7Hz,1H),7.66(d,J=8.1Hz,1H),7.62(d,J=8.1Hz,2H),7.22(d,J=8.3Hz,3H),7.15(td,J=7.8,2.7Hz,1H),6.97(d,J=8.3Hz,2H),5.40–5.32(m,1H),5.01(dt,J=13.6,6.8Hz,1H),4.17–3.97(m,2H),3.30(dd,J=44.1,16.1Hz,2H),3.13(q,J=7.4Hz,2H),2.29(s,1H),1.31(t,J=7.4Hz,3H),1.14(d,J=6.7Hz,3H),1.03(d,J=6.6Hz,3H)。
实施例45:(R)-N-(1-(4-(乙基磺酰基)苯基)-2-羟乙基)-3-氟-4-(异丙基(吡啶-2-基甲基)氨基)苯甲酰胺
参照上述实施例43的步骤得到标题化合物7.6mg(MS(ESI)m/z:500.2[M+H]+)。
1H NMR(400MHz,CDCl3)δ8.44(d,J=4.4Hz,1H),7.80(d,J=8.4Hz,2H),7.57–7.47(m,4H),7.37–7.28(m,2H),7.20–7.05(m,2H),6.84(t,J=8.4Hz,1H),5.24–5.17(m,1H),4.48(s,2H),4.08–3.86(m,3H),3.06(q,J=7.2Hz,2H),1.26–1.22(m,9H)。
实施例46:(R)-N-(1-(4-(乙基磺酰基)苯基)-2-羟乙基)-3-氟-4-(异丙基((6-(三氟甲基)吡啶-3-基)甲基)氨基)苯甲酰胺
参照上述实施例43的步骤得到标题化合物38.7mg(MS(ESI)m/z:568.2[M+H]+)。
1H NMR(400MHz,CDCl3)δ8.65(s,1H),7.86-7.76(m,3H),7.56(d,J=8.0Hz,1H),7.52(d,J=8.4Hz,2H),7.48(dd,J=13.4,2.0Hz,1H),7.40(dd,J=8.4,2.0Hz,1H),6.98(d,J=7.2Hz,1H),6.88(t,J=8.4Hz,1H),5.26–5.20(m,1H),4.46(s,2H),4.03–3.89(m,3H),3.07(q,J=7.2Hz,2H),2.45(s,1H),1.28–1.24(m,9H)。
实施例47:N-((R)-1-(4-(乙基磺酰基)苯基)-2-羟乙基)-3-氟-4-(2-甲基-1-(((6-(三氟甲基)吡啶-2-基)甲基)氨基)丙基)苯甲酰胺
参照上述实施例41的步骤得到标题化合物6.1mg(MS(ESI)m/z:582.1[M+H]+)。
1H NMR(400MHz,CDCl3)δ7.89(d,J=8.4Hz,2H),7.82(t,J=7.6Hz,1H),7.61(d,J=8.0Hz,3H),7.55(t,J=8.4Hz,3H),7.47(d,J=7.6Hz,1H),7.19(d,J=7.2Hz,1H),5.34-5.27(m,1H),4.13-3.97(m,2H),3.85-3.69(m,3H),3.12(q,J=7.2Hz,2H),2.43(br.s,1H),2.04-1.96(m,1H),1.29(t,J=7.2Hz,3H),1.06(d,J=6.8Hz,3H),0.83(d,J=6.8Hz,3H)。
实施例48:(R)-N-(1-(4-(乙基磺酰基)苯基)-2-羟乙基)-3-氟-4-(异丙基((2-(三氟甲基)吡啶-4-基)甲基)氨基)苯甲酰胺
/>
参照上述实施例43的步骤得到标题化合物7.0mg(M S(ESI)m/z:568.2[M+H]+)。
1H NMR(400MHz,CDCl3)δ8.68(d,J=4.4Hz,1H),7.87–7.74(m,2H),7.64(s,1H),7.59–7.47(m,3H),7.45(d,J=4.8Hz,1H),7.35(d,J=8.0Hz,1H),7.03(s,1H),6.24(t,J=8.3Hz,1H),5.20(s,1H),4.79(s,1H),4.32(t,J=5.7Hz,1H),3.93(dd,J=15.2,10.4Hz,2H),3.07(q,J=7.3Hz,2H),2.19(dt,J=13.1,6.6Hz,1H),1.29–1.22(m,4H),1.04(dd,J=8.7,7.1Hz,6H)。
实施例49:6-(1-((4-氯苄基)氨基)-2-甲基丙基)-N-((R)-1-(4-(乙基磺酰基)苯基)-2-羟乙基)-5-氟烟酰胺
参照实施例33的步骤得到标题化合物32.6mg(MS(ESI)m/z:548.3[M+H]+)。
1H NMR(400MHz,CDCl3)δ8.88(s,1H),7.86(d,J=8.4Hz,2H),7.80(dd,J=9.6,1.6Hz,1H),7.59(d,J=8.4Hz,2H),7.29(d,J=6.8Hz,1H),7.25-7.17(m,4H),5.35-5.30(m,1H),4.12-3.96(m,2H),3.77(d,J=7.2Hz,1H),3.57(dd,J=13.6,2.0Hz,1H),3.41(d,J=13.6Hz,1H),3.09(q,J=7.2Hz,2H),2.23(br.s,1H),1.98(dd,J=13.6,6.8Hz,1H),1.27(t,J=7.2Hz,3H),1.02(d,J=6.8Hz,3H),0.78(d,J=6.8Hz,3H)。
实施例50:(R)-N-(1-(4-(乙基磺酰基)苯基)-2-羟乙基)-3-氟-4-(异丙基((5-(三氟甲基)吡啶-2-基)甲基)氨基)苯甲酰胺
参照上述步骤得到标题化合物4.3mg(MS(ESI)m/z:568.1[M+H]+)。
1H NMR(400MHz,CDCl3)δ8.85(s,1H),8.05(dd,J=8.4,2.0Hz,1H),7.85(dd,J=8.4,2.4Hz,2H),7.69–7.59(m,3H),7.54(dt,J=12.8,1.6Hz,1H),7.48(d,J=8.4Hz,1H),6.64(t,J=8.4Hz,1H),5.19(t,J=6.4Hz,1H),4.56(s,1H),4.45(d,J=7.8Hz,1H),3.85(d,J=6.4Hz,2H),3.17(q,J=7.6Hz,2H),2.34-2.19(m,1H),1.19(t,J=7.6Hz,3H),1.12(d,J=6.8Hz,3H),0.85(d,J=6.8Hz,3H)。
生物活性试验
荧光素酶检测(Luciferase assay)
本检验方法使用荧光素酶作为报告基因来检测转染了基因重组质粒的细胞在基因转录水平上的表达,该重组质粒由目的基因的启动子和荧光素酶基因构建而成。实验主要是有关重组质粒hRORγt(“RORgt”)的转染。转染需要27.75微克的DNA,18毫升体积的细胞和培养液以及125毫升的摇瓶。
一.试剂及材料:
1.细胞:中国仓鼠卵巢细胞(CHO-S,Invitrogen,Cat#R80007),悬浮培养在CD-CHO培养液中,包含8mM L-glutamine(L-谷氨酰胺)和1×HT。
2.培养液:
a)CD-CHO(Invitrogen,Cat#10743029)培养液[添加1×的HT(Invitrogen,Cat#11067030),L-谷氨酰胺(Invitrogen,Cat#25030149)];
青霉素-链霉素100X(Invitrogen,Cat#10378016)仅在传代中使用,转染时不使用。
b)Opti-MEM(Invitrogen,Cat#51985034)是一种降低血清培养液即转染复合物的形成过程中使用。
3.DNA:
a)荧光素酶报告基因质粒pG5-luc:reporter plasmid(Promega)。
b)目的基因质粒pM-hRORγt:human RORgamma。
4.转染试剂:TransIT-CHO转染试剂盒(Mirus Bio公司),含有Trans-It试剂以及Mojo试剂(Mirus,MIR2170)。
5.培养板:白色细胞培养平板(VWR,Catalog#29444-041)。
6.化合物板:聚丙烯96孔圆底板(VWR,Catalog#29444-104)。
7.荧光素酶试剂盒:(Promega 1Glo,100毫升,Catalog#E6120):含有荧光素酶底物(辅酶A、ATP和荧光素)和反应缓冲液。
8.摇瓶。
二.实验具体步骤:
A细胞培养
1.细胞铺板:转染之前18-24小时,向125毫升摇瓶中加入浓度为0.5-0.6×10^6个细胞/毫升CHO-S细胞,加入CD-CHO培养液(培养液只含有L-谷氨酰胺和HT添加物)至最终体积为18毫升。摇瓶置于摇床上,在120转/分、37℃和8%二氧化碳条件下过夜传代。
2.细胞转染:此时上述溶液的细胞浓度应在1.2-1.5×10^6细胞/毫升。使用CD-CHO培养液(含有L-谷氨酰胺和HT添加物)将细胞浓度稀释到1×10^6细胞/毫升。
B转染试剂准备(TransIT-CHO:Mojo:DNA复合物),转染之前现配。
1.预热trans-IT试剂到室温,使用前震荡混匀。
2.准备DNA转染:在1.5毫升无菌离心管里,混合以下试剂:
27微克荧光素酶报告基因质粒pG5-luc:27微升、1毫克/毫升溶液,
0.75微克目的基因表达质粒(pM-hRORγt,7.5微升、0.1毫克/毫升溶液)。
3.将以下试剂加入15毫升无菌离心管:
2.8毫升Opti-MEM
83微升Tansit-CHO试剂
步骤2准备好的DNA复合物
4.混合均匀,室温放置5分钟.
5.加入13.9微升Mojo试剂到一个无菌离心管,微微混匀,室温放置20分钟形成转染复合物。
C转染细胞:
1.缓慢摇动125毫升摇瓶的同时逐滴加入步骤B准备的转染复合物。
2.37℃摇床、8%二氧化碳下,培养4小时。
3.四小时后转移细胞到50毫升无菌离心管,以1200rpm离心四分钟,吸走上清液体。
4.重新悬浮细胞至6毫升冷冻培养液(CD-CHO、L-谷氨酰胺、HT添加物和10%DMSO)中,此时细胞密度应在3x10^6细胞/毫升。
5.分装于12管,每管0.5毫升,置于零下80度冰箱缓慢冷冻过夜,然后转移到液氮长期储存。
D荧光素酶活性检测(96孔平板)
1.37℃解冻细胞。
2.2毫升现配培养液(CD-CHO、L-谷氨酰胺和HT添加物)稀释细胞(1.5×10^6细胞/0.5毫升)到2.5毫升体积。转移到15毫升无菌离心管。
3.细胞计数,如果细胞完全存活,应该得到6×10^5个细胞/毫升,一般情况下应该得到65%~70%存活率,细胞密度应为4×10^5个细胞/毫升,如有必要,使用培养液进行稀释。
4.细胞铺板,每孔加入100微升细胞(4×10^4个细胞)。
5.每孔加入1微升待测化合物(溶解于100%DMSO),使用预先准备好的100倍浓度待测化合物平板。
6.37℃,5%二氧化碳过夜培养。
7.第二天,培养液稀释现配1GLO荧光素酶(4:1),转移50微升到细胞平板,排枪混匀。
8.震荡混匀5分种。
9.荧光测定仪测定荧光素酶活性。
Wallac Trilux luminometer荧光测定仪设置:
Protocol:Luciferase luminescence
读取时间:1sec/well,6wells/read
96孔平板荧光素酶实验设计安排:
本实验使用白色不透明96孔平板,
B1是指空白对照组:无菌去离子水
S是指阳性对照组(100%抑制):2uM乌索酸的DMSO溶液
D是指阴性对照组(100%活性):DMSO
C1-C8是指待测试化合物组:不同稀释浓度的待测试化合物或者重复实验组。
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | |
A | Bl | Bl | Bl | Bl | Bl | Bl | Bl | Bl | Bl | Bl | Bl | Bl |
B | Bl | S | D | C1 | C2 | C3 | C4 | C5 | C6 | C7 | C8 | Bl |
C | Bl | S | D | C1 | C2 | C3 | C4 | C5 | C6 | C7 | C8 | Bl |
D | Bl | S | D | C1 | C2 | C3 | C4 | C5 | C6 | C7 | C8 | Bl |
E | Bl | S | D | C1 | C2 | C3 | C4 | C5 | C6 | C7 | C8 | Bl |
F | Bl | S | D | C1 | C2 | C3 | C4 | C5 | C6 | C7 | C8 | Bl |
G | Bl | S | D | C1 | C2 | C3 | C4 | C5 | C6 | C7 | C8 | Bl |
H | Bl | Bl | Bl | Bl | Bl | Bl | Bl | Bl | Bl | Bl | Bl | Bl |
本实验每个孔含有:1微升待测化合物(溶于DMSO),100微升细胞,50微升荧光素酶试剂。
荧光素酶检测结果如下表所示:
/>
/>
CytoStim刺激人PBMC细胞的抑制作用
本实验通过检测体外CytoStim刺激人PBMC后IL-17的变化,进而验证化合物的抑制作用。在100nM化合物作用4小时后,以10ul/ml CytoStim作用48小时,ELISA法检测上清中细胞因子IL-17的含量。
一、试剂及材料:
1.1实验试剂
1.2实验仪器
二、实验方法
2.1 PBMC培养、分组及上清收取
取冻存的PBMC(赛笠)共2支(5*107cells/支)复苏,混合后,加入适量1640(5%人血清)培养液,水平转子1500rpm离心5min,取细胞沉淀,再加入10ml培养基稀释,得到细胞悬液。调整细胞密度约为1.12*107个/ml,96孔培养板中每孔加入90μl细胞悬液(1*106cells/well),培养过夜。
设置对照组(不加化合物和CytoStim),CytoStim刺激组,实施例化合物(100nM)。纳升加样仪加样后培养4h,每孔再加入稀释后的10μl CytoStim刺激48h。每孔总液量为100μl,在48h取细胞上清液,2000g离心5min,收集上清。
2.2 ELISA法定量检测细胞上清中IL-17含量
使用Human IL-17Capture Antibody 4μg/mL蛋白作为包被抗体,每孔100μl,2~8℃包被过夜。弃去板中液体,PBST洗3次,每孔加入200μl含1%BSA的PBST,25±2℃封闭1h。PBST洗板3次。加入50μl标准曲线等样品,25±2℃振荡孵育2h,用Human IL-17 DetectionAntibody 60倍稀释作为检测二抗,每孔100μl,25±2℃孵育1h。Streptavidin-HRP 40倍稀释作为检测三抗,每孔100μl,25±2℃孵育30min;加入TMB显色,1M H2SO4终止反应。读板仪上在450/630nm波长处读吸光度值,曲线拟合采用4 parameter logistic fit,最终OD值为OD450nm-OD630nm。
三、实验结果
PBMC细胞IL-17分泌的抑制作用如下表:
化合物 | 剂量(nM) | 抑制率(%) |
实施例5 | 100 | 50-90 |
实施例19 | 100 | 50-90 |
实施例37 | 100 | 50-90 |
。
Claims (10)
1.式(V)化合物、其立体异构体或其药学上可接受的盐,
其中,
X、Y、Q、P各自独立地选自CH或N,其中所述X、Y、Q、P可任选地被R6取代;
U'、V'、W'、Z'各自独立地选自CH或N,其中所述U'、V'、W'、Z'可任选地被R7取代;
L1、L2、L3各自独立地选自单键、CH2、NH、C(O)或S(O)2,其中所述L1、L2、L3可任选地被一个或两个选自R4'的基团取代,且L1、L2、L3各不相同;
R1'选自任选地被一个或两个或三个选自卤素、羟基或C3-C6环烷基的取代基取代的C1-C6烷基;
R2'选自H、卤素、羟基、C1-C6烷基、卤代C1-C6烷基或羟基C1-C6烷基;
R3'选自H、C1-C6烷基或C1-C6烷基C(O)-;
R4'独立地选自卤素、羟基、氨基或C1-C6烷基,其中所述C1-C6烷基可任选地被一个或两个或三个选自卤素、羟基、氰基或氨基的取代基取代;
R5选自3-6元环烷基、3-6元杂环烷基、苯基或5-6元杂芳基,其中所述3-6元环烷基、3-6元杂环烷基、苯基或5-6元杂芳基可任选地被一个或两个或三个选自卤素、羟基、氰基、硝基、氨基、C1-C3烷基或卤代C1-C3烷基的取代基取代;
R6选自卤素、羟基、氨基、硝基或C1-C6烷基,其中所述C1-C6烷基可任选地被一个或两个或三个选自卤素、羟基、氰基或氨基的取代基取代;
R7选自卤素、羟基、氨基、硝基、C1-C6烷基或C1-C6烷氧基,其中所述C1-C6烷基或C1-C6烷氧基可任选地被一个或两个或三个选自卤素、羟基、氰基或氨基的取代基取代。
2.权利要求1所述的式(V)化合物、其立体异构体或其药学上可接受的盐,其中,X、Y、Q、P中至少有一个为CH,其中所述X、Y、Q、P可任选地被R6取代,或者,X、Y、Q、P中至多有一个为N,其中所述X、Y、Q、P可任选地被R6取代;优选的,X、Q、P选自CH,Y选自CH或N,其中所述X、Y、Q、P可任选地被R6取代;
其中,U'、V'、W'、Z'中至少有一个为CH,其中所述U'、V'、W'、Z'可任选地被R7取代,或者,U'、V'、W'、Z'中至多有一个为N,其中所述U'、V'、W'、Z'可任选地被R7取代;优选的,U'、V'、W'、Z'中至多有一个为N,其中所述U'、V'、W'、Z'可任选地被R7取代;更优选的,U'、V'、W'、Z'均为CH,其中所述U'、V'、W'、Z'可任选地被R7取代,或者,U'、W'、Z'为CH,V'为N,其中所述U'、W'、Z'可任选地被R7取代,或者U'、V'、Z'为CH,W'为N,其中所述U'、V'、Z'可任选地被R7取代;最优选的,U'、V'、W'、Z'均为CH,其中U'、V'、W'、Z'未被R7取代,或者,U'、W'、Z'选自CH,V选自C(F)或C(OCH3),其中U'、W'、Z'未被R7取代,或者,U'、W'、Z'选自CH,V'选自N,其中U'、W'、Z'未被R7取代,或者,U'、Z'选自CH,W'选自N,V'选自C(F),其中U'、Z'未被R7取代;
其中,R7选自-F、-Cl、-Br、甲氧基、乙氧基、异丙基氧基或叔丁基氧基;优选的,R7选自-F或甲氧基。
3.权利要求1所述的式(V)化合物、其立体异构体或其药学上可接受的盐,其中,R1'选自甲基、乙基、异丙基或叔丁基;优选的,R1'选自乙基。
4.权利要求1所述的式(V)化合物、其立体异构体或其药学上可接受的盐,其中,R2'选自H、甲基、乙基、异丙基或叔丁基,其中所述甲基、乙基、异丙基或叔丁基可任选地被一个羟基取代;优选的,R2'选自H或-CH2OH;更优选的,R2'选自-CH2OH,且与R2'连接的C原子的手性构型为R型。
5.权利要求1所述的式(V)化合物、其立体异构体或其药学上可接受的盐,其中,R3'选自H、甲基、乙基、异丙基或叔丁基;优选的,R3'选自H或甲基。
6.权利要求1所述的式(V)化合物、其立体异构体或其药学上可接受的盐,其中,L1选自CH2或NH,其中所述L1可任选地被一个或两个选自R4'的基团取代;优选的,L1选自CH2,其中L1被异丙基取代;或者优选的,L1选自NH,其中L1被异丙基或乙基取代;
其中,L2选自单键、NH或C(O),其中所述L2可任选地被一个或两个选自R4'的基团取代;
优选的,L2选自单键、NH或C(O);
其中,L3选自CH2或C(O),其中所述L3可任选地被一个或两个选自R4'的基团取代;优选的,L3选自CH2或C(O);
优选的,选自/>
其中,R4'选自甲基、乙基、异丙基或叔丁基;优选的,R4'选自乙基或异丙基。
7.权利要求1所述的式(V)化合物、其立体异构体或其药学上可接受的盐,其中,R5选自环丙基、环丁基、环戊基、环己基、苯基、呋喃基、噻吩基、吡咯基、吡唑基、咪唑基、吡啶基、嘧啶基、哒嗪基、吡嗪基、噻唑基、异噻唑基、噁唑基、异噁唑基、1,2,4-三氮唑基、1,2,3-三氮唑基、四唑基或三嗪基,其中所述环丙基、环丁基、环戊基、环己基、苯基、呋喃基、噻吩基、吡咯基、吡唑基、咪唑基、吡啶基、嘧啶基、哒嗪基、吡嗪基、噻唑基、异噻唑基、噁唑基、异噁唑基、1,2,4-三氮唑基、1,2,3-三氮唑基、四唑基或三嗪基可任选地被一个或两个或三个选自卤素、羟基、氰基、硝基、氨基、C1-C3烷基或卤代C1-C3烷基的取代基取代;优选的,R5选自环己基、苯基或吡啶基,其中所述环己基、苯基或吡啶基可任选地被一个或两个或三个选自卤素、羟基、氰基、硝基、氨基、C1-C3烷基或卤代C1-C3烷基的取代基取代;更优选的,R5选自环己基、苯基或吡啶基,所述环己基、苯基或吡啶基可任选地被一个或两个或三个选自F、Cl、三氟甲基的取代基取代;最优选的,R5选自
8.权利要求1所述的化合物、其立体异构体或其药学上可接受的盐,其中,式(V)化合物具有式(VII)所示的结构,
其中,U'、V'、W'、Z'、L1、L2、L3、R2'、R3'和R5如权利要求1中所定义;
或者,式(V)化合物具有式(VIII)所示的结构,
其中,U'、V'、W'、Z'、L1、L2、L3、R2'、R3'和R5如权利要求1中所定义。
9.下述化合物、其立体异构体或其药学上可接受的盐:
10.一种药物组合物,其包含治疗有效量的权利要求1-9所述的化合物、其立体异构体或其药学上可接受的盐;优选的,所述药物组合物还包含药学上可接受的辅料。
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811426060 | 2018-11-27 | ||
CN2018114260604 | 2018-11-27 | ||
CN2019102435551 | 2019-03-28 | ||
CN2019102435797 | 2019-03-28 | ||
CN201910243579 | 2019-03-28 | ||
CN201910243555 | 2019-03-28 | ||
PCT/CN2019/121306 WO2020108538A1 (zh) | 2018-11-27 | 2019-11-27 | 含有磺酰基结构的RORγ抑制剂 |
CN201980076661.3A CN113166061B (zh) | 2018-11-27 | 2019-11-27 | 含有磺酰基结构的RORγ抑制剂 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980076661.3A Division CN113166061B (zh) | 2018-11-27 | 2019-11-27 | 含有磺酰基结构的RORγ抑制剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117800904A true CN117800904A (zh) | 2024-04-02 |
Family
ID=70854038
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980076661.3A Active CN113166061B (zh) | 2018-11-27 | 2019-11-27 | 含有磺酰基结构的RORγ抑制剂 |
CN202311636222.8A Pending CN117800904A (zh) | 2018-11-27 | 2019-11-27 | 含有磺酰基结构的RORγ抑制剂 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980076661.3A Active CN113166061B (zh) | 2018-11-27 | 2019-11-27 | 含有磺酰基结构的RORγ抑制剂 |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN113166061B (zh) |
WO (1) | WO2020108538A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116710440A (zh) * | 2020-12-31 | 2023-09-05 | 赛诺哈勃药业(成都)有限公司 | 一种纤溶酶抑制剂、其制备方法及应用 |
CN115557913A (zh) * | 2021-07-02 | 2023-01-03 | 广东东阳光药业有限公司 | 苯并氮杂环类化合物及其在药物中的应用 |
CN113461608B (zh) * | 2021-07-12 | 2023-03-17 | 江苏弘和药物研发有限公司 | 一种6-甲酰基烟酸甲酯的合成方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012027965A1 (en) * | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
WO2013029338A1 (en) * | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel compounds |
AU2013254657B2 (en) * | 2012-04-27 | 2015-12-24 | Glaxo Group Limited | Novel compounds |
CA2872014A1 (en) * | 2012-05-08 | 2013-11-14 | Lycera Corporation | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease |
BR112014028017A2 (pt) * | 2012-05-08 | 2017-06-27 | Lycera Corp | composto, composição farmacêutica, método para tratar um distúrbio, método para reduzir a quantidade il-17 em um indivíduo e método para inibir a atividade de ror |
EP3145912A1 (en) * | 2014-05-23 | 2017-03-29 | F. Hoffmann-La Roche AG | Benzene sulfonamide derivatives and their use as rorc modulators |
EP3101009A1 (en) * | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
US11008340B2 (en) * | 2015-11-20 | 2021-05-18 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
WO2018116285A1 (en) * | 2016-12-23 | 2018-06-28 | Glenmark Pharmaceuticals S.A. | Substituted morpholine derivatives as ror gamma modulators |
US11396503B2 (en) * | 2017-09-30 | 2022-07-26 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Sulfonyl substituted bicyclic compound which acts as ROR inhibitor |
-
2019
- 2019-11-27 CN CN201980076661.3A patent/CN113166061B/zh active Active
- 2019-11-27 WO PCT/CN2019/121306 patent/WO2020108538A1/zh active Application Filing
- 2019-11-27 CN CN202311636222.8A patent/CN117800904A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CN113166061A (zh) | 2021-07-23 |
WO2020108538A1 (zh) | 2020-06-04 |
CN113166061B (zh) | 2023-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109195602B (zh) | 用作免疫调节剂的对称或半对称化合物 | |
JP7017521B2 (ja) | アクチビン受容体様キナーゼの阻害剤 | |
CN113272301B (zh) | 杂环类化合物、中间体、其制备方法及应用 | |
US10336762B2 (en) | Pyrrolo[1,2-b]pyridazine derivatives | |
US9145414B2 (en) | 1,2,4-triazine-6-carboxamide derivative | |
CN110678466A (zh) | 作为hpk1抑制剂的二氮杂萘类 | |
CN113166061B (zh) | 含有磺酰基结构的RORγ抑制剂 | |
JP2021193099A (ja) | 置換4−アザインドール及びglun2b受容体調節因子としてのそれらの使用 | |
EA027345B1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
US20220213112A1 (en) | Pyrrole tricyclic compounds as a2a / a2b inhibitors | |
US11471455B2 (en) | Compounds and compositions for treating conditions associated with APJ receptor activity | |
WO2019206069A1 (zh) | 一种二芳基巨环化合物、药物组合物以及其用途 | |
JP2021515773A (ja) | PI3K−γ阻害剤としてのアミノピラジンジオール化合物 | |
EA035739B1 (ru) | Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы | |
IL300289A (en) | Compounds, preparations and methods | |
JP7414827B2 (ja) | アクチビン受容体様キナーゼ-2の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物 | |
TWI804266B (zh) | Tyk2抑制劑及其用途 | |
WO2023134739A1 (zh) | 六元环并噻唑类化合物及其应用 | |
WO2020054657A1 (ja) | 新規ヘテロ芳香族アミド誘導体及びそれを含有する医薬 | |
JP5916719B2 (ja) | Jnkの阻害剤として有用な2−アミノ−ピリミジン誘導体 | |
US10961234B2 (en) | Oxazole derivatives for use in the treatment of cancer | |
WO2023237085A1 (zh) | Hpk1抑制剂及其在医药上的应用 | |
CN116745299A (zh) | 噻吩并嘧啶衍生物 | |
CN115873000A (zh) | 异喹啉酮类及喹唑啉酮类化合物及其组合物和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |